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The transient hyperaemic response (THR) is a novel way of assessing vascular reactivity 
that measures vasodilatory responses after 10-20 second periods of ischaemia. Previous 
studies have combined the THR test with measurements of microcirculatory perfusion 
using laser Doppler flowmetry in the of forearm skin of healthy volunteers. 
 
A database of over 1000 measurements in over 100 subjects was analysed to further 
establish the inter- and intra-individual variability of THR measurements. 
 
THR measurements of skin vascular reactivity were performed in laboratory experiments 
designed to explore the practicality of the test when investigating vascular reactivity in 
critical illness. Positive end-expiratory pressure caused fluctuations in skin perfusion but 
did not alter the THR. Both perfusion and THR could be manipulated by the iontophoresis 
of several drugs used in critical care, but the possibility of carrier solutions causing 
vasodilatory effects could not be ruled out. 
 
Norepinephrine was successfully iontophoresed into forearm skin and caused 
vasoconstriction which partially reversed the decreased THR caused by localised heating. 
 
A pilot study of cutaneous THR measurements in patients with evidence of systemic 
inflammation demonstrated decreases in vascular reactivity compared with the database 
of healthy volunteers, but the test was found to be less robust within intensive care than 
was anticipated. 
 
A retrospective analysis was performed of patients admitted to intensive care following a 
planned operation, or presumed to have sepsis, in order to evaluate the effects of prior 
administration of statins and other potentially vasoactive drugs. Previous research 
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demonstrated associations between statin usage and improved outcome in bacteraemic 
patients. This analysis identified no benefit from prior statin usage. One hypothesis 
generated by this research was that the pleiotropic effects of different statins were not 
class effects. Further research designed to evaluate the effects of different statins on skin 
microvascular reactivity using the transient hyperaemic response is planned. 
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Introduction and aims 
 
The transient hyperaemic response investigated within this thesis is a relatively novel 
method of assessing vascular reactivity. In health control of vascular blood flow is 
dynamic, increasing blood flow to areas of need in order to maintain: delivery of oxygen 
and nutrients; removal of carbon dioxide and metabolites; balance in tissue ion 
concentrations; delivery hormones and other mediators; and other specialist functions, for 
instance urine production within the kidney. Changes in tissue blood flow can be achieved 
by increasing blood flow throughout the large arteries and veins (the macrocirculation), or 
by directing it towards a specific vascular bed using neurohumoral control mechanisms. 
Alternatively local control mechanisms within smaller blood vessels (the microcirculation) 
can direct blood flow to specific areas of need within tissues. Local control may be 
maintained by increases in blood flow occurring when there is a build up of vasodilatory 
metabolites, a decrease in tissue oxygen tension, or a myogenic response whereby 
changes in vessel wall tension trigger reflex contraction or relaxation of smooth muscle 
within the microcirculation. These two mechanisms clearly overlap, and even where they 
do not the effects of one may impact on the other (Guyton AC, 2005). 
 
,Q WKH EURDGHVW VHQVH WKH WHUP ³YDVFXODU UHDFWLYLW\´ UHIHUV WR WKH DELOLW\ RI WKH ERG\ WR
achieve dynamic changes in tissue blood flow through acute changes (as opposed to 
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chronic adaptive mechanisms such as an increase in the number of overall blood 
vessels). 
 
Vascular reactivity of the cutaneous microcirculation in health and illness 
The microcirculation regulates blood flow to organs and is responsible for supplying them 
with oxygen and nutrients, as well as removing the waste products of metabolism. It is 
also involved in the delivery of inflammatory mediators to tissues, the maintenance of 
interstitial fluid balance, and body temperature regulation. The microcirculation is the 
largest contributor to systemic vascular resistance, and thus is involved in blood-pressure 
homeostasis. Its endothelium represents a large surface area of cells which are involved 
in processes ranging from inflammatory responses to coagulation homeostasis. It consists 
of capillaries, arterioles and venules, with blood flowing from the arterial macrocirculation 
to the capillaries, via arterioles and metarterioles, and exiting into the venous system via 
venules. The properties of the microcirculation differ according to which organ they belong 
to, but in general the different aspects have the characteristics found in table 1.1. 
 
6NLQEORRGIORZLVKLJKO\YDULDEOHGXHWRWKHVNLQ¶VUROHLQWHPSHUDWXUHUHJXODWLRQYDU\LQJ
between extremes of 50ml/min and greater than 2500 ml/min depending on the 
environmental temperature. At room temperature average skin blood flow is typically of 
the order of 400 ml/min, or 250ml/m2/min when body surface area is taken into account. 
Such a wide range of blood flow is possible because of the large venous plexus which is 
present within the subcutaneous tissue, and also because the cutaneous microcirculation 
is capable of shunting blood from the arterioles to venules through sections of larger 
arterioles and capillaries (figure 1.1). In some areas of skin which are more exposed to 
extremely cold contact, such as the hands or the lips, arterio-venous anastomoses also 
exist which can increase this shunting effect. The very small metabolic demands of skin 
also mean that in most circumstances blood perfusion is higher than, and thus 
independent of, nutritional demand (Guyton AC, 2005; Bliss M, 1998). 





It is well known that changes in the vascular reactivity of the cutaneous microcirculation 
are associated with a variety of diseases known to affect blood vessels, including 
diabetes, smoking, RaynauG¶V GLVHDVH DQG V\VWHPLF VFOHURVLV Morris SJ et al, 1995; 
Stansberry KB et al, 1996; Hilz MJ et al, 2000; Aso Y et al, 1997; Celermajor DS et al, 
1996 ; Noble M et al, 2003; Khan F et al, 1994; La Civita L et al, 1998; Goodfield MA et al, 
1989). Changes in cutaneous vascular reactivity have also been identified with systemic 
GLVHDVHV QRW WUDGLWLRQDOO\ DVVRFLDWHG ZLWK VNLQ SDWKRORJ\ LQFOXGLQJ $O]KHLPHU¶V GLVHDVH
(Algotsson A, Almkvist O et al, 1995), pre-eclampsia (Eneroth-Grimfors E, 1993), and 
sepsis (Young JD et al, 1995), raising the possibility that skin vascular reactivity might 
mirror changes occurring in other, less accessible, microcirculations. 
 
It is not clear what pathophysiological processes are at work within the microcirculation 
which might affect the vascular reactivity. Such processes are likely to be different for 
different disease states, resulting in changes such as the down-regulation of endothelial 
controlled vasodilatation, alteration of sympathetic tone or capillary oedema and 
disruption of cell-to-cell signalling (Caballero A et al, 1999; Consentino F et al, 1998; 
Oliviera RP et al, 2002). 
 
Changes in vascular reactivity within peripheral blood vessels and the cutaneous 
microcirculation have also been noted in subjects at risk of diseases such as non-insulin-
dependent diabetes, pre-eclampsia and atherosclerosis, suggesting that vascular 
reactivity may be altered before clinically apparent features develop (Caballero A et al, 
1999; Savvidou MD et al, 2003; Celemajor DS et al, 1992). 
 
The ability to measure change in vascular reactivity has prognostic and diagnostic 
implications, both in terms of progression of the disease itself and measuring its response 
to treatment. 










Surrounded by smooth muscle 
Well innervated 
Size = 10-ȝP 
 
A short vessel with muscle cells which act as a pre-capillary 














No smooth muscle 
No innervations 
Size = 5-ȝP 
 
This may have many tight junctions and transport vesicles 
(for example in skin and muscle), or very few (representing 
the blood-brain-barrier of the cerebral capillary bed) 
 
Where there are pores in the endothelium to allow fluid or 
small molecules to pass (found in the renal glomerulus, and 
also in endocrine glands) 
 
Found in liver, lymph glands and bone marrow allowing 





High endothelial venules 
Limited smooth muscle 
Limited innervations 
Size = 10-ȝP 
 
Lined with cuboidal cells allowing lymphocytes to enter 
 
Table 1.1 The characteristics of blood vessels within the microcirculation 







Figure 1.1 The circulation of the skin. Arterio-venous anastomoses are not found in 
all areas of skin (see text). 
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Investigating vascular reactivity 
Vascular reactivity within the microcirculation may be assessed in a number of ways. In 
order to assess vascular reactivity a means of imaging changes within the 
microcirculation is required. Alternatively surrogate markers of changes within the 
microcirculation may be measured. In both cases the microcirculation must also be 
stressed in order to trigger the changes which occur as a result of intact vascular reflexes. 
 
Several methods are available wKLFKFDQ ³LPDJH´ LQ-vivo vascular changes. Ultrasound 
imaging (either 2D or Doppler) of larger blood vessels such as the brachial, superficial-
femoral, and middle meningeal arteries has previously been investigated as a means of 
assessing vascular reactivity (Celermajor DS, 1992; Celermajor DS, 1996; Cavill G et al, 
1998). These measurements are not specifically of the microvasculature, and it is 
unknown how well any changes are mirrored between the two sites. Measurements of 
oxygen saturation, using near-infra red spectroscopy (NIRS), and carbon dioxide tension, 
using transcutaneous electrodes, have also been investigated in situations where the 
microcirculation might be altered (Crookes B et al, 2006; Haisjackl M et al, 1990). 
Compared with transcutaneous electrodes, NIRS is a much less invasive method and can 
be used to target muscle vasculature; work is underway to identify which muscle areas 
yield the most clinical useful information. Plethysmography has been used to measure 
changes in blood flow, but this also is not specific to tissue beds (Bird AD et al, 1967) 
 
Direct imaging of the microcirculation using orthogonal polarized spectral imaging has 
been used in conditions such as sepsis (De Backer D et al, 2002). This technique has the 
advantage that blood vessels within the microcirculation can actually be visualized and 
qualitatively assessed (delayed semi-quantitative imaging is also possible). One of the 
disadvantages is that it can only target the microvasculature near the surface of mucosal 
membranes, for example in the sublingual blood vessels. 
 





technique for measuring tissue perfusion. It has most commonly been used to monitor 
skin perfusion, although it can also been used to monitor the perfusion of mucosal 
surfaces (such as the intra-RUDOFDYLW\RUJDQVXUIDFHVGXULQJ³RSHQ´RSHUDWLRQVYLDERWK
surface and needle probes), and the choroidal surface of the eye. LDF is a non-invasive 
and readily portable method of measuring skin microcirculation perfusion, and for these 
reasons it was chosen as the technique of choice for the experiments within this thesis 
and will be covered in greater detail later in this chapter. 
 
In some cases simply monitoring the microvascular blood flow over time will deliver 
information about vascular reactivity, for example in conditions where the vasculature 
becomes stressed, such as developing illness or exercise. In other cases this may be as 
simple as instituting limited exercise (for example hand-grip exercises), localized heating, 
or pressure loading the skin (Kennedy WL et al, 1991; Kellogg DL et al, 1993; Agewall S 
et al, 1999; Hassan AA et al, 1988; Noble M, 2003).  
 
An alternative approach to measuring skin vascular reactivity is to evaluate the maximal 
dilatation the skin microcirculation can achieve in response to a stimulus. Such stimuli 
include the introduction of vasodilatory substances, such as acetylcholine and sodium 
nitroprusside, or a prolonged period of ischaemia (typically 3-10 minutes) ± the post-
occlusion hyperaemic response (Morris SJ et al, 1995; La Civita L et al, 1998; Goodfield 
M et al, 1989; Kvernebo K et al, 1989). 
 
Laser Doppler flowmetry 
Laser Doppler flowmetry uses light generated by light-emitting diodes or by helium/neon 
lasers of wavelengths between 540 and 850 nm (i.e. within the visible-red and near-infra-
red parts of the electromagnetic spectrum); the choice of wavelength being dictated by 
the absorption characteristics of skin and muscle, as well as that of erythrocytes. Using a 
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low power laser (typically less than 1mW at source) tissue penetration of 1 to 2 mm depth 
can be achieved without damaging or substantially heating the intervening structures. 
Upon entering the tissue light scattering occurs. The scattering effect prevents laser 
Dopplers from focusing upon either a specific depth or upon a specific point within any 
two-dimensional planes represented along that depth (i.e. they have neither focus nor 
resolution). Instead laser Dopplers measure the average Doppler-effect within a small 
volume of tissue. Since light will scatter multiple times whilst passing through tissue a 
range of Doppler shifts will be recorded according to the formula: 
 
Where  is the angular frequency shift (in rad/s);  is the velocity of the 
scattering particle;  is the light wavelength within the propagating medium; and 
, , and  represent the various scattering angles (  is the angle between the 
incoming and scattered light ,  is the angle between incoming light and the 
direction of the scattering particle within the plane of scattering, and  is the 
angle between the direction of the scattering particle and plane of scattering). 
 
Where tissue is not moving, erythrocytes will be the largest contributor to Doppler shifts, 
and when compared with ultrasound Doppler the effect of scattering will result in two 
important differences: firstly because most erythrocyte scattering is forward scattering 
with small scattering angles (  is close to zero) the largest Doppler shifts will occur when 
particles are moving across the path of laser light (rather than parallel to it as with 
ultrasound waves); and secondly because light will be scattered multiple times before 
encountering an erythrocyte each scattering event can be considered to be a random 
change in direction when all the events are summated. Thus laser Doppler is relatively 
insensitive to the direction of travel of erythrocytes and can represent an average picture 
of their velocities in all direction. Backscattered light can be analysed by a light-sensitive 




sensor resulting in an aggregate measurement of frequency distributions and phase 
changes (due to the varying distances travelled by individual photons at any given 
frequency) known as a Doppler power spectrum. The Doppler power spectrum is 
proportional to both the concentration of moving erythrocytes and the average velocity of 
erythrocytes. This in turns is proportional to tissue blood perfusion as: 
 
 
Where  is the concentration of moving erythrocytes (Red Blood Cells), and 
 is the average velocity of erythrocytes. 
 
The scattering effect also allows laser Doppler techniques to measure much slower 
objects, such as erythrocytes within the microcirculation of the skin and other organs 
(where average velocity can be of the order of 100-ȝPV 
 
The greatest single limitation of laser Doppler flowmetry is its inability to provide an 
absolute measurement of blood flow. Like most methods employed to investigate the 
microcirculation it may be affected by regional variations in blood flow. It is also 
susceptible to temperature changes, movement artefact, and external light interference 
(Vongsavan N et al, 1993; Obeid et al, 1990; Carpentier, 1999; Cooke et al, 1990). The 
practical application and limitations of LDF are discussed in greater detail in chapter 2. 
 
Hyperaemia and the transient hyperaemic response 
Hyperaemia is the vasodilatation of blood vessels occurring in response to local demand. 
It may be active, triggered by extra activity, or reactive, provoked by tissues deprived of 
blood supply and oxygen for any reason. Sustained ischaemia can be used to stimulate 
reactive hyperaemia to occur; this is typically achieved by inflating a pneumatic limb 
tourniquet to suprasystolic pressures, and is often referred to as post-occlusive reactive 
hyperaemia. Periods of occlusion as short as 5 seconds can provoke hyperaemia, but 
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prolonged periods (approximately 5 minutes) are often used as they result in a sustained, 
maximal response. Hyperaemic vasodilatation occurs in advance of the return of blood 
flow and is thought involve both vasodilator metabolites and myogenic reflexes. There 
may also be a sympathetic element, although hyperaemia is known to occur in 
denervated skin. Hypoxia, decreased pH, prostanoids and endothelial nitric oxide 
production have all been implicated to a greater or lesser degree in the metabolic triggers 
of reactive hyperaemia, but it is likely that there is more one than chemical responsible 
(Bliss M, 1998; Crawford DG et al, 1959;Khan F et al, 1991; Guyton AC et al, 1964; Larkin 
SW et al, 1993; Carlsson I et al, 1987; Engelke KA, 1996; Tagawa T et al, 1994; Nugent 
AG et al, 1999). 
 
The transient hyperaemic response (THR) occurs when arterial occlusion is only briefly 
applied. In this instance the vasodilatation which results is not sustained and the 
hyperaemic response is transitory in nature. It is thought that brief periods of arterial 
occlusion (typically between 5 and 30 seconds) do not allow for the build up of 
vasodilatory metabolites, and so any hyperaemic response is likely to be dominated by 
the myogenic response (Moppett IK, Davies JA, et al 2003). 
 
Using only a brief stimulus for hyperaemia offers certain advantages compared to 
classical means of inducing hyperaemia. Firstly it is unlikely that such a brief period of 
GHFUHDVHG EORRG IORZ LV OLNHO\ WR GDPDJH ³GRZQ-VWUHDP´ WLVVXHV DQG RUJDQV 7KLV LV
SDUWLFXODUO\ LPSRUWDQWZKHUHWKH³GRZQ-VWUHDP´RUJDQ LV OLNHO\ WREHSDUWLFXODUO\VHQVLWLYH
to periods of decreased perfusion, for example when the artery occluded is the common 
carotid artery the organ affected is the brain (and in clinical scenarios this may well be an 
already damaged brain with areas which are highly perfusion-dependent). Secondly THR 
can be used to target examination of the myogenic response, rather than the rate of build 
up of anoxic metabolites. And lastly tests involving THR can be repeated at short 
intervals, as they are unaffected by intervening periods of prolonged hyperaemia, which 




allows for dynamic testing to be performed before and after discrete events (Moppett IK, 
Davies JA, et al 2003; Brown H et al, 2003). 
 
The THR test involves inducing a transient hyperaemic response with some form of 
arterial compression and measuring the perfusion, or flow, immediately before and after. 
The transient hyperaemic response of the cerebral circulation has been investigated using 
transcranial Doppler ultrasound measurements of the middle cerebral artery (Cavill G et 
al, 1998; Sherman R, Bowie R, 2002; Sherman R, Armory P, 2003). Blood velocity within 
the middle cerebral artery can be estimated using a trans-cranial Doppler ultrasound 
probe which is placed against the temporal bone (figures 1.2 and 1.3). Although, as 
previously stated, trans-cranial Doppler differs from laser Doppler flowmetry, resulting in 
measurement of peaks of blood velocity as compared to a continuous measurement of 
tissue perfusion. Despite this the principles of the THR test remain the same, with the 
transient hyperaemic response ratio (THRR) being the ratio of perfusion/flow-flux (or flow 
velocity) immediately after release of arterial compression to the perfusion/flow-flux 
immediately before compression (figure 1.4). 
 
The cutaneous THR test can be performed on any area of skin where arterial occlusion is 
possible and a laser Doppler probe can be fixed to the surface of the skin via an adhesive 
dressing. In practice this means that limbs are favoured, particularly the forearm. Arterial 
occlusion and release must both be rapid, and there must be no collateral circulation, in 
order for a true hyperaemic response to be induced. A compressed gas pneumatic 
tourniquet can be used to achieve this in limbs (Marval PD et al, 2004), as can digital 
compression of the brachial artery for forearm measurements (Brown H et al, 2003). 
Arterial occlusion is applied for 20-30 seconds (as compared with typical occlusion 
periods of 5-10 seconds for trans-FUDQLDO'RSSOHU7+5PHDVXUHPHQWVZLWKD³UHFRYHU\´
period after each THR test to allow time for the dispersal of hypoxic metabolites which 
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might otherwise accumulate with repeated testing prolonging or increasing any 
hyperaemic response. 
 






Figure 1.2 Trans-cranial Doppler ultrasound measurements on a human volunteer. 
Reproduced with the permission of Professor R Mahajan. 
 
 
Figure 1.3 A sample trans-cranial Doppler trace of a transient hyperaemic response 
test, where A is the peak middle cerebral artery blood velocity prior to ipsilateral carotid 
artery occlusion, B is the peak blood velocity during arterial occlusion, and C is the 
increased peak blood velocity occurring after the occlusion is released, representing a 
hyperaemic response. The transient hyperaemic response ratio = C/A. Reproduced with 
permission from Dr R Sherman.





Figure 1.4 A sample trace of the transient hyperaemic response test using laser 
Doppler flowmetry, where F0 is the biological zero which occurs during arterial 
compression, F1 is the baseline flow-flux representing perfusion prior to arterial 
compression and F2 is the increased flow-flux occurring after the occlusion is released. 
The transient hyperaemic response ratio can be calculated as F2 / F1. 
 




What is known about the transient hyperaemic response 
Several small studies involving healthy volunteers have been performed using LDF 
measurement of the transient hyperaemic response in forearm skin in order to examine 
various aspects of the response. The THR test in volunteers has been demonstrated to 
be reproducible, well tolerated and simple to perform (Hancock et al, 2001). The effects of 
age (Abaza et al, 2004), and gender (not published) have been investigated, as have the 
effects of various physiological stresses on the THR, including: prolonged ischaemia, 
decreased skin perfusion, hypoxia, and hyper- and hypocapnia (Moppett IK, Jones LN et 
al, 2003; Hardman JG, et al 1997; Marval PD et al, 2004; Richardson JR et al, 2004). The 
results of these studies will be examined in greater detail later in this thesis, but taken as 
a whole they add support to this method of investigating vascular reactivity as being 
robust and reproducible, and minimally affected by minor physiological changes. 
 
THR has also been investigated in forearm skin which has been manipulated by external 
heating, and by exposure to exogenous vasodilators and vasoconstrictors delivered by 
LRQWRSKRUHVLV 2¶&RQQRU0%HWDO%URZQ+HWDO:HEVWHU9/HWDO
Iontophoresis is a method of transdermal drug delivery which utilizes electrical charge to 
promote the movement of chemicals across the skin (explained in greater detail in chapter 
2). Iontophoresis is a method of drug delivery which has been extensively investigated 
and allows localized manipulation of the cutaneous microcirculation whilst avoiding 
systemic changes (Coston AF et al, 2001; Korula M, 2004). Iontophoresis is easily 
combined with LDF and THR measurements. The results of the manipulation of THR by 
this method are discussed in more detail later in the thesis. 
 
The effects on cutaneous THR of topical and orally administered medications which are 
used clinically have also been studied. The medications involved include non-steroidal 
anti-inflammatory drugs, NSAIDs, (ibuprofen and rofecoxib) and local anaesthetic creams 
(EMLA, Rapyda, and Ametop) (Moppett IK, Davies JA et al, 2003; Wiles MD et al, 2010). 
P a g e  | 34        Chapter one 
 
 
The study involving NSAIDs demonstrated that LDF measured flowflux increases can be 
detected after the oral administration of medications predicted to have a vasoactive effect. 
Despite the increase in flowflux there was no demonstrable change in the THRR after 
administration of NSAIDs, suggesting that THRR and flowflux may to some extent be 
considered independently of each other. 
 
Vascular reactivity in critical illness 
The studies described above were performed in healthy volunteers. Although THR 
measurements of the cerebral circulation performed using transcranial Doppler ultrasound 
have been performed in patients, to date no studies have been published which have 
investigated the cutaneous transient hyperaemic response in patients with concurrent 
disease.  
 
One of the diseases known to have an extreme effect on vasculature reactivity is the 
inflammatory response to infection, sepsis. Sepsis is a multi-system inflammatory 
response associated with profound cardiovascular alterations which can result in shock 
and a loss of tissue perfusion. The exact mechanisms by which these occur remain 
unclear, and may even depend upon the specific cause. What is clear is that sepsis and 
septic shock can alter endothelial and local tissue responses, and that current methods of 
optimising tissue blood perfusion rely on global, systemic measurements of 
cardiovascular status, such as blood pressure, central venous pressure and cardiac 
output, or non-specific markers of organ perfusion such as urine output, serum lactate 
measurement, and level of consciousness (De Backer, Vincent J-L et al, 2002; Snowden 
C et al, 2002; Crowley SR et al, 1996; Sheehan M et al, 2002). 
 
Ideally critically ill and septic patients should be evaluated and resuscitated in response to 
non-invasive measurements of organ perfusion, but as yet there are no reliable methods 
of performing this, and in any case perfusion is likely to be different in different organs, 




necessitating multiple different modes of measurement. Attempts have been made to 
measure the perfusion of specific organs and monitor their response to resuscitation, 
assuming it to be a surrogate marker of organ perfusion in other organs, or, if not that, 
then at least a useful goal in its own right. The most notable example of this is gastric 
tonometry where the hydrogen ion concentration within the stomach is used as an 
indicator of regional oxygenation and perfusion within the stomach wall (Russell JA, 
1996). To date no organ-specific perfusion monitors exist that have gained wide-spread 
clinical acceptance. 
 
Although the skin can occasionally be the originating site of inflammation and sepsis in 
critically ill patients, for example in cellulitis or toxic-epidermal-necrolysis, for the most part 
it can be considered a peripheral end-organ affected by inflammation originating 
elsewhere. And due to its low nutritive requirements it does not usually fail (i.e. become 
ischaemic to the point of dying), even in profoundly shocked individuals in whom the 
perfusion of other organs has failed to such an extent that multiple organ failure has 
occurred. The skin, however, is a very large organ, with a great deal of vascular 
endothelium and microcirculatory reserve. Given that the endothelium is known to be 
intimately involved in the processes which occur in sepsis (Vallet B, 2002; Reinhart K et 
al, 2002), it is reasonable to assume that the vascular reactivity of the skin 
microcirculation might be affected in sepsis, even when there are no outward signs of this 
occurring. Thus measurement of vascular reactivity in skin, which is readily accessible in 
all but the most extreme cases, might act as a surrogate marker for impaired vascular 
reactivity, and hence impaired perfusion, elsewhere in the body. Evidence that skin 
vascular reactivity is altered in septic patients already exists, though its clinical 
significance has yet to be proven (Hartl WH et al, 1988; Haisjackl M et al, 1990). The 
transient hyperaemic response, being non-invasive, readily repeatable and primarily being 
affected by the myogenic response offers the opportunity of exploring a new aspect of the 
changes affecting the vascular reactivity in the cutaneous microcirculation in critically ill or 
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septic patients. It also offers the possibility, when combined with iontophoresis of different 
agents, of exploring the dynamic changes which may occur in response to different 
agents associated with critical illness, both in patients and healthy volunteers. With the 
exception of vasopressors (epinephrine, phenylephrine, and vasopressin) and NSAIDs, 
very few agents which have been used as treatments for critical illness, or as part of the 
general management of critical illness, have been investigated in this way before (Brown 




The aim of the research within this thesis was to further explore the cutaneous transient 
hyperaemic response with a view to investigating the changes which occur in skin 
vascular reactivity in critically ill patients. Many of the investigations presented here are 
pilot or proof-of-concept studies aimed at answering the following questions: 
1. Can a large enough dataset of THR measurements be obtained such that 
YDULDELOLW\ FDQ EH TXDQWLILHG DQG D ³QRUPDO´ UDQJH RI 7+5 UDWLRV EH PDGH
available for comparison? 
2. Is it possible to model some of the effects on THR that might occur in critical 
illness by, for example, artificially causing microcirculatory vasodilataion and 
attempting to modify it with various treatments? 
3. Can cutaneous THR be successfully measured in critically ill patients; and can it 
be manipulated in this same group? 
 
The effects of statins on critically ill patients 
There are many immuno-modulatory and vaso-active agents that have been investigated 
in order to ascertain whether or not they can improve the outcome of critically ill patients. 
Of those agents investigated many have poorly understood mechanisms of action and 
appear to have actions which overlap many different areas of physiological function, for 




example they might appear to downgrade the immune response and/or alter micro-
vascular blood flow, capillary permeability or interfere with the blood coagulation pathway. 
Examples of drugs which are thought to have multiple mechanisms of action include 
steroids, anti-thrombin III, activated protein-C, and L-NAME (Briegel J, 2000; Ilias W et al. 
2000; Bernard GR et al, 2001; Avontuur JAM et al, 1998). 
 
In the time period over which research into the transient hyperaemic response in skin was 
being carried out for inclusion in this thesis, new evidence was published which 
suggested a link between HMG CoA reductase inhibitors (statins) and improved outcome 
in patients with bacteraemia (Liappis AP et al, 2001; Almog Y et al, 2004). These 
improved outcomes included a lower incidence of severe sepsis, with patients being less 
likely to require ICU admission. There was also a trend towards improved survival in 
bacteraemic patients. Although these results were retrospective and observational in 
nature, they resulted in speculation that statins might have effects that were separate in 
nature to their well-known cholesterol-lowering properties ± pleiotropic effects. It was 
hypothesised the pleiotropic effects might be immuno-modulatory and/or vaso-active in 
nature (Almog Y, 2003). 
 
Further aims 
In response to this new evidence concerning statins two further questions were proposed:  
 
4. Is it possible to evaluate the effects of factors known to be associated with critical 
illness, in particular the prior usage of vaso-active or immuno-modulating agents, 
such as statins? 
5. Can the micro-circulatory effects of potentially vaso-active or immuno-modulating 
agents, such as statins, be investigated in volunteers using the cutaneous 
measurement of THR? 
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In order to achieve these aims it was thought necessary to first confirm the finding of an 
association between improved outcome and the premorbid prescribing of statins. For the 
most part previous retrospective studies have investigated the outcomes of patients who 
were not critically ill. For these reasons a retrospective study was designed to examine 
the effects of the prior administration of statins and cardiovascular medications in critically 
ill patients, the results of this study can be found in chapter six of this thesis. 
 
Following on from this, a study involving healthy volunteers has been designed with the 
aim of investigating whether or not statins have any effect on the vascular reactivity of the 
cutaneous microcirculation as measured by the transient hyperaemic response. At the 
time of writing this thesis, the aforementioned study has yet to be started. As a result the 
data from the retrospective study alone is included in chapter six, in the expectation that 
data from complementary volunteer studies will be available at some point in the future. 
 
 







Materials and methods 
 
In this chapter the materials and methods common to the studies performed will be 
outlined and justified. The refinement and adjustment of techniques used in individual 
experimental protocols will be further explained in the relevant chapters. The relevant 
volunteer information leaflet and consent forms for each study (or patient / relative 
information and consent / assent forms where appropriate) can be found within the 
appendices of the thesis. 
 
Laser Doppler flowmetry 
Two distinct techniques of laser Doppler flowmetry exist, laser Doppler perfusion 
monitoring (LDPM) and laser Doppler perfusion imaging (LDPI). LDPM utilises fibreoptic 
technology to sample a small volume of tissue and measure changes in perfusion over 
time. By contrast LDPI uses a scanning laser light generated at a distance from the 
subject tissue and can be used to build up a map, or image, of tissue perfusion over a 
broad area of tissue, but with an inevitable time lag from one end of the imaged area to 
the other, which is proportional to the area scanned. 
 
LDPM laser light can be delivered to, and measured from, the surface of tissue via a 
surface probe. All of the investigations within this thesis which involve laser Doppler 
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flowmetry are of the LDPM type using surface probes. Both the probes and the laser 
Doppler flowmeter used were designed by Moor instruments (Moor Instruments, 
Axminster, Devon). This equipment was used because it is designed to monitor the 
Doppler signal of the cutaneous microcirculation and communicate acquired data directly 
to a computer; it is also non-invasive and is compatible with equipment designed to alter 
the microcirculation by iontophoresis and cutaneous heating.  
 
The DRT4 is a microprocessor-controlled laser Doppler monitor which generates laser 
light at a wavelength of 785nm (±10nm) and an operating power of 0.5-1.5mW (figure 
2.1). This typically allows tissue penetration of 1-2mm without damaging or substantially 
heating the intervening structures. Laser light is transmitted from the DRT4 module via 2m 
fibre-optic cables to skin probes. Two different laser Doppler probes were used in the 
experiments within this thesis. The DP1T/7 laser Doppler probe (figure 2.2) consists of a 
central delivery fibre surrounded by 8 collecting fibres in a 2mm ring. The DP12-V2 
needle laser Doppler probe (figure 2.3) is a 2 fibre delivery and collecting system with 
0.5mm fibre separation which can be inserted through the middle of a heating probe 
(figure 2.6). Flux values as measured by the DRT4 module are recorded in arbitrary units 
(AU) and have an accuracy of ±10% and a precision of ±3%, the coefficients of variation 
EHLQJ ORZHU IRU WKH '37 SUREH EHFDXVH RI WKH ODUJHU ³FROOHFWLQJ´ DUHD '57 XVHU
manual, 2006). All of the experiments performed were done in ambient conditions which 
were within the operating temperature range of the DRT4 module (15-30°C). 
 
/DVHU SUREHV ZHUH FDOLEUDWHG DFFRUGLQJ WR WKH PDQXIDFWXUHU¶V LQVWUXFWLRQV '57 XVHU
manual, 2006). Since the DP1T/7 probe is capable of laser Doppler flowmetry and 
temperature measurement, both optical and temperature calibration were required. 
Probes were cleaned between subjects with running water and allowed to air dry, as per 
PDQXIDFWXUHU¶VLQVWUXFWLRQVH[FHSWZKHUHWKHSUREe was involved in iontophoresis where 




cleaning was similar to that used for iontophoresis chambers as described later in this 
chapter. 
 
Laser probes were fixed to skin using adhesive dressings and good skin contact was 
ensured, although this was more important for temperature measurement than for 
flowmetry measurements. The forearm was chosen as the site for flowmetry because it 
had been previously used for measurements (Brown et al, 2003; Webster et al, 2002, 
Moppett IK & Davies JA et al, 2003, Moppett IK & Jones LN et al, 2003) and because it 
has advantages when performing the THR test.  
 
As discussed in the introduction laser Doppler flowmetry is qualitatively different from 
other familiar forms of medical Doppler. The greatest single limitation of laser Doppler 
flowmetry is its inability to provide an absolute measurement of blood flow. Any movement 
of interstitial tissues, vascular smooth muscle, and even the residual Brownian motion of 
intracellular particles leads to a background reading of Doppler flux. This background 
UHDGLQJ LVRIWHQUHIHUUHGWRDVD³ELRORJLFDO]HUR´DQG LW LVFRPSDUHGZLWK WKLVELRORJLFDO
zero that changes in flux which represent perfusion are measured. Such measurements 
often have arbitrary units assigned to them, but are in reality merely a ratio of change 
compared with biological zero. Ideally the area of tissue being sampled should remain as 
stationary as possible during the period of sampling. In practice the biological zero is 
taken to mean the baseline flux which will be a combination of both true biological zero 
and baseline perfusion. 
 
It is not only movement that can increase the background level of flux that is measured. 
Relatively minor increases in temperature can cause an increase in the scattering due to 
increased residual Brownian motion. This results in an increase in the true biological zero 
which is proportional to temperature between the ranges of 15°C to 37°C. Also because 
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back-scattered light is used to calculate flowflux it is susceptible to interference from 
extraneous light sources. 
 
Laser Doppler flowmetry (as LDPM) has excellent temporal resolution but only limited 
potential for spatial resolution, and so the sampled area may be unrepresentative of 
overall tissue perfusion, and areas of regional variation may be missed. An extreme 
example of this can occur when the area of tissue being sampled involves all or part of a 
major blood vessel. In this case the much greater velocities of the erythrocytes within the 
major vessel will dominate the Doppler power spectrum analysis of perfusion, and the 
motion of the blood vessel wall will also lead to increased fluctuations in the biological 
zero. 
 
In order to avoid artefacts in blood flowflux measurement the following precautions were 
taken*: 
x Where possible the surroundings where LDF measurements were taken were 
kept at 19-23°C, and high levels of ambient light were avoided. 
x Subjects were allowed to acclimatize to ambient conditions for a period of 20 
minutes prior to any measurements being taken. During this time subjects were 
allowed to rest in a semi-reclining supine position with the forearm supported. 
x Prior to probe placement skin was prepared by cleaning with an alcohol wipe and 
allowing to air dry. Where excessive hair was present which may have obstructed 
the fibreoptic channels it was shaved off beforehand.  
x The probe was placed at 90° to the skin, at least 8cm from the ante-cubital fossa 
to decrease the likelihood of measurements involving flowflux from major vessels. 
After placement the baseline was examined for evidence of marked baseline 
pulsatile blood flow, and in cases where this was found to occur then the probe 
was re-sited in a different position. 
x The flowflux cable was secured to the forearm to prevent artefact within the cable 




x Subjects with damaged or broken skin, or who had a known allergy to adhesive 
dressings were excluded from taking part in any studies. 
x Subjects were discouraged from moving during measurements, were encouraged 
to breathe as normally as possible, and were discouraged from talking 
x Although the DRT4 module is capable of sampling at 40Hz measurements of 
flowflux variation were done using a time constant of 0.5seconds to avoid 
excessive artefact interference  
*Where subjects were intensive care unit (ICU) patients it was not always possible to 
tightly control environmental conditions or avoid patient movement 
 
These aspects of the protocol are consistent with existing recommendations (DRT4 User 
Manual, 2006; Nilsson et al, 1980). 
 
All recordings of measurements were made and analysed using the software Moorsoft for 
Windows/DRT4 v1.2 (Moor Instruments, Axminster, Devon, UK). 
 
Cutaneous temperature measurement 
Where a heating probe was used temperature measurement was done via that probe and 
is described later in this chapter. Where there was no heating probe skin temperature was 
measured using the DP1T/7 probe in conjunction with the DRT4 module which has a 
measurement range of 5-50°C, a resolution of 0.1°C and an accuracy of ±0.3°C (DRT4 
user manual, 2006). 






Figure 2.1 DRT4 laser Doppler flowmeter and screenshot of Moorsoft DRT4 
computer program (Moor Instruments) 
 
 




Figure 2.3 DP12-V2 blunt needle end laser Doppler probe (Moor Instruments) 




Flowflux measurements and the transient hyperaemic response 
Baseline flowflux (F1) was measured only after a 60 second period of recording in order to 
ensure that a steady state had been arrived at. 
 
The choice of forearm skin for measuring flowflux allowed the measurement of the 
hyperaemic response after digital compression of the brachial artery at the ACF (ante-
cubital fossa) ± an end artery with no collateral flow. Positioning the LDF probes at least 
8cm distal to the ACF minimized the movement artefact caused by digital compression. In 
previous studies adequate digital compression was confirmed by the presence of a 
sudden drop in flowflux to biological zero (F0). As an added measure digital pulse 
oximetry was used in the experiments presented within this thesis as a means of 
confirming that digital brachial artery pressure was sufficient to abolish distal pulsatile 
blood flow. 
 
An acceptable THR manoeuvre was defined as one in which a sudden drop in flowflux 
from baseline to biological zero which was maintained for 20 seconds with no 
demonstrable distal pulsatile flow; and was followed by a sudden rise after the release of 
digital compression back to baseline or higher levels of flowflux. Peak flowflux after 
release was defined as the hyperaemic peak (F2). As demonstrated previously (in figure 
1.4) THRR was defined as (F2- F0)/(F1 ± F0). All of the above is consistent with the 
manner in which cutaneous THRR has previously been measured in other similar studies 
(Brown et al, 2003; Webster et al, 2002, Moppett IK & Davies JA et al, 2003, Moppett IK & 
Jones LN et al, 2003). 
 
Apart from the choice of a compression period of 20 seconds which has been previously 
discussed, there is no clear-cut consensus on how F0, F1 and F2 are defined. For instance 
should F0 be the lowest biological zero point? Should F1 be the point measurement 
immediately before digital compression (and therefore more susceptible to movement 
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artefact from the application of digital pressure)? And at what point after the release of 
digital pressure should a rise in flowflux be no longer attributable to the THR, and 
therefore not be defined as F2? In all of the THR measurements made in the following 
experiments the following definitions were used: 
x F1 was a 20 second average of flowflux recording immediately prior to the THR 
manoeuvre 
x F0 was a 15 second average of biological zero during the period of arterial 
compression during which no distal pulsatile blood flow was demonstrable using a 
digital oxygen saturation probe 
x F2 was the peak hyperaemic response recorded using a 0.5 second time constant 
occurring within 20 seconds of the release of brachial artery compression 
x A minimum of 90 seconds was required between completion of a THR and the 
start of the F1 20 second averaging time of the next THR 
 
Where the subjects of experiments were intended to be healthy volunteers the following 
exclusion criteria were applied: 
x Under 18 (there was no upper age limit) 
x Pregnancy 
x Smokers 
x Evidence of pre-existing circulating disorders, including, but not limited to: 
peripheral and central vascular disease (e.g. known claudication, cerebrovascular 
disease, ischaemic heart disease); vasculitis (e.g. systemic sclerosis, systemic 
lupus erythematosus, arteritis, :HJHQHU¶V GLVHDVH DQG %HKçHW¶V GLVHDVH
5D\QDXG¶V GLVHDVH GLDEHWHV Fhronic kidney disease; hypertension; 
hypercholesterolaemia 
x The use of any regular prescribed medication, including aspirin 
x The recent use of any over-the-counter remedies including paracetamol, non-
steroidal anti-inflammatory drugs, and cold remedies 




x The recent use (within the past 24 hours) of any herbal remedies 
 
With the exception of the lower age limit (which was done to facilitate consent issues) all 
of the above criteria were consistent with other studies involving THR measurements 
(Brown et al, 2003; Webster et al, 2002, Moppett IK & Davies JA et al, 2003, Moppett IK & 
Jones LN et al, 2003). In each case this was because underlying conditions or medication 
use might reasonably be expected to interfere with the hyperaemic response (Celermajor 
DS et al, 1996; Noble M et al, 2003; Morris SJ et al, 1995; Stansberry KB et al, 1996; La 
Civita et al, 1998; Khan et al, 1994; Celermajor DS et al, 1992). Other issues suspected of 
affecting vascular reactivity, including age and gender, are addressed with the appropriate 
experiments discussed later in this thesis. 
 
All subjects were advised to avoid strenuous exercise, and avoid consuming food and 
alcohol or caffeine-containing substances for at least 6 hours before the duration of the 
study. Although it is standard practice in the field of microvascular research to 
recommend abstinence from exercise, food and caffeine in the preceding period there is 
very little evidence concerning how much of an effect may occur in healthy volunteers, 
and how long the period of abstinence should be in order to avoid any confounding effects 
(Duffy et al, 2001; Williams MJ et al, 1999; Perrin ME et al, 2004; Kvernmo HD et al 
1998). 
 
Within the clinical study involving ICU patients similar exclusion criteria were applied, 
except that the only circulatory disorders within the exclusion criteria were peripheral 
YDVFXODUGLVHDVH5D\QDXG¶VGLVHDVHLQVXOLQ-dependent diabetes and vasculitis. Smokers 
and patients with cardiac or renal disease were not excluded. Concurrent medication use 
was also allowed. 
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In all subjects heart rate and arterial oxygen saturations were recorded using a pulse 
oximeter before and during THR measurements, as was non-invasive blood pressure 
(using a blood pressure cuff attached to the contralateral arm). 
 
Transcutaneous iontophoresis 
Iontophoresis is a method of transdermal chemical delivery which utilizes a small electric 
current to actively transport chemicals into subcutaneous tissues via the processes of 
electromigration and electroosmosis. 
 
The epidermis provides the greatest barrier to transcutaneous chemical movement, and is 
traversed using a number of routes, which include paracellular gaps, transcellular 
movement, and via appendageal pathways (e.g. sweat ducts and hair follicles). 
Appendageal pathways are thought to account for the majority of chemical movement of 
water soluble chemicals, whilst lipophilic chemicals may involve proportionally more trans- 
and paracellular transport.  
 
The quantity of chemical displaced transdermally depends upon a number of different 
factors (Rawat et al 2008, Coston et al 2001): 
x Electric field intensity, current amplitude, current duration 
x Chemical solution pH and concentration 
x Molecular size and degree of ionization (and to a lesser extent 
polarization) 
x Epidermal (and in particular keratin) thickness and continuity; 
epidermal charge and pH 
 
One of the major drawbacks of transdermal iontophoresis is that there is only limited 
control over the quantity of chemical delivered, and no simple way of confirming that 
quantity. This drawback, and the fact that current duration is proportionally more important 




than current amplitude (i.e. prolonged iontophoresis may be required to deliver relatively 
small chemical concentrations), has resulted in there being only a limited number of 
clinical applications for iontophoretic drug-delivery. These include iontophoretic fentanyl 
delivery for analgesia, and the iotnophoresis of tap water delivery as a treatment for 
hyperhidrosis (Power I 2007; Midtgaard 1985). Reverse iontophoresis, the use of 
electrical current to attract chemicals through the skin, has been used to measure glucose 
concentrations in diabetes, and chloride concentrations in cystic fibrosis (Seig et al 2003). 
 
Compared with its clinical applications iontophoretic drug delivery has been widely used 
as a research tool for a wide variety of reasons: it can provide needle-free transdermal 
drug introduction and a large enough area of skin is normally readily accessible in both 
volunteers and patients; where systemic effects are desired it can avoid first-pass hepatic 
metabolism; and although the exact amount delivered cannot be calculated, where local 
effects are required it can be tailored to deliver just enough drug to provoke a local 
response, whilst avoiding a systemic response. 
 
In the context of both volunteer and patient studies within this thesis iontophoresis was 
considered the most appropriate way to alter the vascular reactivity of the cutaneous 
micro-circulation in a relatively non-invasive way. 
 
A custom-designed Perspex iontophoresis chamber (the ION1 iontophoresis chamber, 
Moor Instruments) was used which allowed both iontophoresis and LDF, temperature 
measurement and cutaneous heating to take place simultaneously (figure 2.4). The 
chamber was attached to the volar aspect of the forearm using an adhesive dressing 
similar to that used to attach standard LDF probes. As with LDF probes skin was cleaned 
with alcohol wipes and allowed to dry prior to chamber placement. Excess hair at the site 
was lightly shaved off where necessary. 
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Iontophoresis current was applied between the inert platinum wire within the iontophoresis 
chamber and a 4x4cm dispersive return electrode (MIC1-CP, Moor Instruments) placed 
approximately 10-15cm from the chamber (figure 2.5). Good electrical contact was 
maintained by placing a conductive gel hydro pad (MIC1-GP, Moor Instruments) between 
the return electrode and skin. Iontophoresis was controlled using a MIC1-e iontophoresis 
controller (Moor Instruments) and involved a pulsed pattern of current with fourteen 45 
second periods alternating between 75PA and no current. THR measurements were not 
recorded until at least 150 seconds had passed since the final period of iontophoresis. 
$OWKRXJK D ³WLQJOLQJ´ VHQVDWLRQ FDQ EH REVHUYHG E\ VXEMHFWV D FXUUHQW RI PA is not 
uncomfortable or painful. During prolonged periods of applied charge the skin surface 
may become polarized resulting in decreased efficiency of iontophoresis. In order to avoid 
this a pulsed pattern may be used (Rawat et al, 2008). 
  
As has been previously mentioned the main adjustable determinants of iontophoresis are 
the current amplitude and duration. The current flux of the ION1 chamber can deliver a 
current flux of 1mC/cm2 when a 71PA current is delivered over 10 seconds.  
 
Cumulative dose response curves have been demonstrated with various chemicals using 
a series of low currents (i.e. less than 100PA) of increasing duration (up to 40 seconds) 
separated by increasingly longer response periods (MIC1-e user manual, 1998). Although 
in the drugs being studied the dose response to iontophoresis had not previously been 
tested, it seemed likely that, should they behave in a manner similar to other chemicals 
the protocol chosen here would result in a maximal local effect and avoid electrical or 
thermal induction of the axon reflex, a neurological vasodilatory effect which can occur 
with currents exceeding 250PA (Westerman et al, 1988). The Mic1-e iontophoresis 
controller delivers current with an accuracy of r 1PA when the controller is kept within an 
ambient temperature range of 15-30qC, as was the case in all experiments. The MIC1-e 
controller was in turn controlled by the DRT4 module described earlier. 




The choice of polarity for the iontophoresis chamber depended upon the charge of the 
active ion. For example where the active ion was positive the electrode within the 
iontophoresis chamber was anodal and the return electrode cathodal. 
 
When performing iontophoresis the choice of drug concentration was dependent upon 
several factors which included stability in solution, ease of dilution and efficacy of 
iontophoresis. As previously stated the total dose of drug delivered by iontophoresis is 
predominantly dependent upon current amplitude and duration. Low drug concentrations 
may affect this by limiting the amount of active drug available for iontophoresis. 
Conversely high drug concentrations may result in decreased electrical conductivity and 
reduce iontophoresis (Rawat et al, 2008; MIC1-e user manual, 1998). 
 
Since there is no way of knowing the absolute drug concentration at the site of 
iontophoresis, each study involving iontophoresis, where there was no previous 
experimental work to suggest a dose, was designed to evaluate the maximal effect on 
local skin vascular reactivity at drug concentrations approximating standard drug 
concentrations used in clinical settings.  
 
Non-specific vasodilatation associated with iontophoresis has previously been reported in 
several studies. Suggested mechanisms by which this can be minimized have included: 
minimizing maximal voltage and current settings, pre-treatment with aspirin, avoidance of 
local skin heating, and the use of hypertonic saline (5 moles/L) as a dilutional agent 
(Westerman et al, 1988; Droog et al, 2003; Åsberg et al, 1999; Durand et al, 2002). A 
study by Brandrivskyy et al (2004) using a pulsed current protocol, similar to the one 
described above, provided little evidence of vasodilatation when deionised water or 5 
molar saline were iontophoresed into skin, which is in keeping with previously 
unpublished work from our centre using the above protocol to iontophorese 0.9% saline 
(0.308 molar saline). The only study which previously has examined the relationship 
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between 0.9% saline and THR (Brown et al, 2003) demonstrated that 0.9% saline did not 
cause a significant effect on baseline flowflux, but did decrease the THR ratio. Because 
the effects of 0.9% saline on flowflux and THRR were already established, it was chosen 
over 5 molar saline as the carrier diluent where one was necessary (for the drugs 
midazolam and norepinephrine). 
 
When filling the iontophoresis chamber with fluid, care was taken to avoid trapping air 
bubbles within the chamber and thus ensure contact between the chamber fluid and skin. 
Fluid was continuously monitored and topped up as required using the secondary filling 
well present on the chamber (figure 2.5). The presence of fluid between the LDF probe 
and skin was predicted to reduce the strength of the flux signal, and so where required, 
control probes were sited within inactive iontophoresis chambers containing 0.9% saline. 
 
Following each period of iontophoresis the iontophoresis chamber was cleaned as per the 
PDQXIDFWXUHU¶VLQVWUXFWLRQVXVLQJGH-ionised water for 2 minutes to prevent contamination 
between patients and avoid the build up of accretions on the electrode. After passive 
drying the chamber was cleaned with an alcohol wipe and allowed to passively dry a 
second time 
.

















Figure 2.5 Iontophoresis, cutaneous heating and laser Doppler flowmetry apparatus 
LQ VLWX RQ D YROXQWHHU¶V IRUHDUP $ ± Perspex iontophoresis chamber; B ± cutaneous 
heating probe with needle LDF probe; C ± standard LDF probe; D ± return iontophoresis 
electrode. In this example there are two LDF probes with the standard probe being a 
control probe used to confirm that a transient hyperaemic response had taken place.




Localized cutaneous heating was performed using an SHP2 heating probe controlled by 
an SH02 heating controller unit (both by Moor Instruments). The SHP2 probe has a 6mm 
heating element which is placed in contact with skin. The probe can be placed within the 
iontophoresis chamber or attached directly to skin. Unlike the laser Doppler probes no 
user calibration is required. The SH02 controller is a dual channel heater unit which has a 
heating range of 20-45°C, a resolution of 0.1°C, and an accuracy of ± 0.3°C. The 
environmental operating temperature of the controller unit is 15-30°C which encompassed 
the operating conditions in which all studies were performed (SH02 user manual, 1998). 
 
Where localized cutaneous heating was required the temperature of skin was monitored 
to ensure a constant temperature for at least 30 seconds before LDF measurements were 
performed. The choice of temperatures is discussed in the relevant chapters. 
 
The techniques for decontamination and cleaning of temperature probes which were used 
in combined heating and iontophoresis experiments were similar to those described 
earlier for iontophoresis chambers. 
 
Epidemiological studies 
In those studies which required the collection of epidemiological data the principles of 
data collection and reporting advocated by the STROBE guidelines (Strengthening the 
Reporting of Observational Studies in Epidemiology) were adhered to as far as was 
possible (von Elm et al, 2008). The exact details surrounding data collection and analysis 
can be found within the appropriate chapters. 
 
Data analysis 
All data collection and analysis was performed using SPSS statistics package version 17 
(SPSS incorporated, Chicago, Illinois, US). 






Figure 2.6 SHP2 cutaneous heating probe and SH02 heating module (Moor 
Instruments) 
  












Characterisation of the THR test 
 
Introduction 
All of the previous volunteer studies which have been undertaken in order to estimate the 
variability of THRR within individual subgroups have been small in nature, typically 
involving 8-15 volunteers, each providing 3-5 measurements. One of the earliest studies, 
by Hancock et al, 2001, demonstrated the THR to be reproducible with a moderate 
degree of within- and between-subject variability. Other studies have reported differing 
degrees of variability using laser Doppler flowflux measurements which can be improved 
by the application of extreme measures of vasodilatation such as the iontophoresis of 
acetylcholine (Kubli S et al, 2000). 
 
Attempts have been made to classify the individual-related variables of cutaneous blood 
flow measured by laser Doppler flowmetry using larger volunteer samples or by 
undertaking confirmatory measurements in separate groups. A review by Bircher et al, 
1994, identified variables considered important in assessing the variability associated with 
laser Doppler flowmetry; these included: age, sex, race, anatomical sites, intra- and inter-
individual variation, temporal variation, physical and mental activity, food, drugs and 
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nicotine, and menstrual cycle. Crucially these studies have not involved the transient 
hyperaemic response. 
 
Variables which might affect the THRR and have been studied in small volunteer groups 
include: 
x Age: 
Flowflux was decreased; THRR was unaffected (Abaza et al, 2004) 
x Gender: 
No differences in flowflux or THRR (not published, personal communication) 
x Inter-, intra-individual variation: 
33% within-and 66% between- subject variation, overall coefficient of variation 
0.38 (Hancock et al, 2001) 
x Menstrual cycle: 
Equivocal results (not published, personal communication) 
x Exercise: 
No differences in flowflux or THRR (Perrin ME et al, 2004) 
 
In order to confirm the findings of these earlier studies it was decided that a large dataset 
of THR responses from healthy volunteers be collated, using both new data and 
previously collected data which was reanalysed including over 1000 individual 
measurements in over 100 subjects. This is over ten times the numbers and 
measurements used in the original experiments designed to evaluate the variability of the 
THR test. It was decided to focus on age, gender and individual variation, and data from 
previous studies which specifically attempted to evaluate these areas was not included 
within the new dataset. It was hoped that by combining the data in this way variability 
could be better TXDQWLILHG DQG D ³QRUPDO´ UDQJH RI 7+5 UDWLRV EH PDGH Dvailable for 
comparison in situations where the subject could not act as their own control. 
 




In addition, since all of the previous data relates to standard LDF probes, a dataset was 
FRPSLOHGRIIORZIOX[DQG7+55PHDVXUHPHQWVIURP³QHHGOH´SUREHV 
 
Lastly, since some studies have suggested that the transient hyperaemic response might 
EHEHWWHUPHDVXUHGE\H[DPLQLQJ WKH ³DUHDXQGHU WKHFXUYH´ LH WDNLQJ LQWR WRDFFRXQW
both the magnitude and the length of the THR ± Marval et al, 2004), the time taken for the 
hyperaemic response to return to baseline values was also measured and analysed. 
 
P a g e  | 60       Chapter three 
 
Methods 
All previously performed THR studies which allowed specific consent for the anonymous 
use of recorded THR traces were identified and permission sought from the lead-
investigator to re-analyse data for suitability for inclusion in an aggregate database. Only 
those studies which involved control recordings were considered (i.e. those in which the 
study protocol specified flowflux and THR measurements made in the absence of any 
intervention). In total 5 studies were identified as being suitable for re-analysis; this 
included studies in which the subjects, whilst remaining anonymous, were known not to 
have been involved in any of the other 4 studies (i.e. there was no dupliction of subjects 
between studies). Other than confirming that reference was made to it in the study 
protocol associated with an individual recording, no attempt was made to confirm the 
ambient temperature conditions or that a pre-recording acclimatization period was 
enforced. The same is true of the pre-recording abstinence requirements in chapter 2. 
The results of 4 of these 5 studies have since been published (Moppett IK & Davies JA et 
al, 2003, Moppett IK & Jones LN et al, 2003; Perrin ME et al 20042¶&RQQRU0%HWDO
2003). 
 
The control recordings from each of the studies included within the volunteer experiments 
documented within chapter four of this thesis were also re-analysed. 
 
In addition a further 14 volunteers were recruited who underwent a series of 9 THR 
manoeuvres each which were recorded and analysed specifically for this research. 
Despite the use of old data within this investigation, the majority of data was acquired by 
the author of this thesis. 
 
In total flowflux and THR recordings from 126 subjects involving 6 observers were 
included. All of the data recordings, whether from new or old studies, were individually re-
analysed by me. Where traces were not adequately clear, were not accompanied by skin 




temperature measurements, or did not have sufficient gaps between THR manoeuvres or 
a sufficient lead-in time to allow for steady state (as defined in chapter 2) they were 
excluded.  
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Results 
1175 separate THR traces were analysed and THRRs calculated. Five THR traces were 
found not to demonstrate transient hyperaemic responses and were not included in 
further analysis. The dataset was made up of THR traces taken from 101 volunteers and 
with THR tests being performed by six different observers. A summary of the THRR data 
can be found in table 3.1. The number of measurements from a single subject made by a 
single observer varied from 3 to 50. The majority of single-subject, single-observer 
subgroups contained 10 or more measurements, with 5 groups containing 30 or more 
measurements (figure 3.1). 
 
Distribution and normality 
THRR data frequency histograms were compiled in order to assess the distribution (figure 
3.2) and Q-Q plots were calculated which demonstrated marked deviation from an 
expected normal distribution (figure 3.3). THRR data is a ratio of two numbers, and in 
common with other similar data its distribution is substantially right-skewed. This is true 
for both the large aggregate dataset and also of the measurement from single-subject, 
single-observer subgroups comprising 10 or more measurements.  
 
Evidence with similar ratio data suggests that a normal distribution may be achieved using 
a logarithmic transformation (Bland M, 1987; Altman DG, 1991). Box-Cox analysis was 
performed to confirm this and demonstrated a root-mean-square-error nadir 
corresponding to a lambda value of near zero (figure 3.4), which identifies a natural 
logarithmic transformation as being most likely to approximate normal distribution (Box 
GEP et al, 1964). Even after applying a natural logarithmic (Ln) transformation a 
Kolmogorov-Smirnov test for normality identified that complete normal distribution had not 
been achieved for the aggregate dataset (p=0.002), but had been for all subgroups with 
QS S S S S  
 




Data frequency histograms and Q-Q plots for the entire dataset indicated a near-normal 
distribution had been achieved (figures 3.5 and 3.6) for the majority of the range. 
Approximation with normal distribution improved still further after the aggregate dataset 
was corrected for extremes of skin temperature (see next section), with a Kolmogorov-
Smirnov test significance of p=0.040. 
 
Variation with skin temperature 
Skin temperature ranged from a minimum of 26.4°C to a maximum 37.1°C (mean 30.6°C, 
standard deviation 1.36). The correlation between resting skin temperature and LnTHRR 
was confirmed using Pearson correlation testing (r= -0.096, p=0.001); and, since 
homoscedasticity could not be assumed, also by Spearman rank correlation (r= -0.084, 
p=0.004). As r was less than 0.1 the correlation can be considered to be small (Cohen J, 
1988) but significant (figure 3.7) 
 
By limiting the dataset to avoid extremes of temperature it was hoped to minimise still 
further any correlation. After arbitrarily excluding all THR traces measured on skin with a 
temperature of >< 1.5 standard deviations of the mean temperature (i.e. 28.5°C to 
32.6°C) no statistically significant correlation was identifiable (Pearson: r= -0.013, 
p=0.682; Spearman: r= -0.015, p=0.638). Limiting the aggregate dataset in this way 
decreased the number of measurements to 1010 and improved the approximation of 
normal distribution as previously stated. 
 




THRR, (arbitrary units) 
n=1175 
Mean 3.490 
Standard deviation 1.812 









Figure 3.1 The number of THRR measurements made in each single-subject, 
single-observer subgroup making up the aggregate dataset.









Figure 3.3 Q-Q plot demonstrating deviation from normal distribution for THRR data




Figure 3.4 Box-Cox transformation equation graph of root-mean-square-error 
(RMSE) versus lambda of THRR measurements. The RMSE nadir occurs at a lambda of 
approximately 0.000





Figure 3.5 Histogram of the frequency distribution of natural logarithm transformed 




Figure 3.6 Q-Q plot demonstrating approximation of normal distribution of LnTHRR 
measurements




Figure 3.7 Scatter plot graph of LnTHRR variation with skin temperature. The dotted 
line represents the overall mean whilst the unbroken line represents an interpolated line 
assuming a linear relationship between temperature and LnTHRR. 




Variation within and between groups 
Heteroskedasticity was demonstrated between all groups of measurements within the 
temperature-limited aggregate dataset when examined using the Levene statistic. 
Because small or uneven sample sizes are predicted to affect variance the Levene 
statistic was also separately applied to comparisons limited to subgroups with equal 
measurement numbers; and also to comparisons between the largest 10 subgroups (with 
 20 measurement per subgroup). Variance was unequal between all subgroups, even 
where comparisons were limited to the same observer, subject, or both (in all cases 
p<0.001). This was true of both untransformed THRR measurements and log transformed 
data. 
 
The differences in variances made it difficult to identify the range of within-subject and 
between-subject variation. The same differences also interfered with attempts to measure 
point at which the mean of repeated measures might be expected to approximate the 
mean. 
 
The co-efficients of variation were calculated for THRR measurements from the largest 10 
subgroups revealing a range of co-efficients from 0.23 to 0.43.  
 
Using the entire temperature-limited aggregate dataset (i.e. combining the total within and 
between subject variability) the coefficient of variation for LnTHRR was 0.38. Error 
appears to be dependent upon the absolute value of the measurement with a correlation 
coefficient of 0.296 (p=<0.004), as demonstrated by the graph of absolute differences 
plotted against mean values for each subgroup (figure 3.8). 
 
Where the mean LnTHRR values from each individual were compared the overall mean 
did not change but the standard deviation was 0.31. 




Figure 3.8 Scatter plot graph of the absolute differences in LnTHRR measurements 
plotted against mean LnTHRR values for each subgroup 




THRR measurements made using needle-probes 
A smaller dataset was collated of THRR measurements made using laser Doppler needle 
probes (see chapter two). 215 measurements were made, involving 50 volunteers. There 
were far fewer needle-probe readings per volunteer, with only 18 volunteers contributing 
more than 5 measurements. Limiting the skin temperature range of samples eligible for 
inclusion and log-transformation of the resulting THRR measurements resulted in a 
dataset of 192 measurements, which were normally distributed (Kolgorov-Smirnov test, 
p=0.200). 
 
The average skin temperature measured by needle probes was 29.5°C (SD 0.61) which 
consistently lower than that recorded by normal laser Doppler probes (mean 30.4°C, SD 
0.82). This finding was confirmed by taking paired samples from the same subject, at the 
same time with the same observer, using a paired t-test (p<0.001). 
 
The overall mean of LnTHRR was smaller than was measured using the larger probes 
(mean 1.052, SD 0.471). Using single-volunteer subgroups where more than 5 
measurements had been taken coefficients of variation ranged from 0.16 to 0.54 (table 
3.2). 
 
Using paired samples (as described above) revealed no significant differences between 
LnTHRR measurements taken using needle probes when compared with standard probes 
(standard probe mean: 1.14, SD 0.33; needle probe mean 1.09, SD 0.41; unequal 
variance t-test p=0.363). 
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Mean LnTHRR  1.152  1.052 
Standard deviation  0.439  0.471 
Standard error of the mean  0.138  0.331 
Coefficient of variation  0.381  0.432 
 
Table 3.2 Comparison of mean LnTHRR readings, and associated variation, using 
both standard laser Doppler probes and needle laser Doppler probes. 




Other factors measured by laser Doppler flowmetry 
x Baseline flowflux variability 
The mean baseline flow-flux for standard probes was 20.40 (minimum 7.5, maximum 
126.7, SD 11.84); and for needle probes was 10.25 (minimum 3.7, maximum 46.9, SD 
6.60). The difference in flow-flux between standard and needle probes was significantly 
different (independent t-test assuming unequal variances, p<0.001). Baseline flowflux 
also exhibited heteroskedasticity between volunteers. 
 
There was no clear correlation between skin temperature and baseline flowflux, although 
there was a suggestion of increased flowflux variability as skin temperature increased 
(figure 3.9). Increasing flow-flux was also associated with a reduction in range and 
absolute value of the THRR response (figure 3.10). 
 
x THR shape 
Four differently shaped THR responses were identified. The most common response 
(figure 3.11 Trace A) involved a sudden increase in flow-flux in less than 5 seconds with a 
gradual decline to baseline values over 15-20 seconds. Occasionally a more gradual 
increase in flowflux was seen where both the increase and decline in flow-flux occurred 
over a number of seconds (figure 3.11B). The time taken for flow-flux values to return to 
baseline values also varied, and in some cases there appeared to be second, smaller 
peak (figure 3.11C) or inflection point (figure 3.11D). 
 
The average time taken to return to baseline flow-flux levels following a THR test (THR 
time) was 16.1 seconds (minimum 4, maximum 70, SD 7.2). Although the time taken to 
return to baseline appeared to be related to the size of the THRR, relatively small 
hyperaemic responses could also be prolonged. 
 




Figure 3.9 Scatter plot graph of baseline flowflux versus skin temperature within the 
temperature-limited dataset 
 
Figure 3.10 Scatter plot graph of LnTHRR versus baseline flowflux within the 
temperature-limited dataset






Figure 3.11 Sample THR traces. Trace A is the most commonly seen THR response. 
Trace B demonstrates a slowly rising hyperaemic response to transient ischaemia. Traces 
C and D demonstrate slow resolution of hyperaemia with a longer time taken to return to 
baseline flow-flux levels, and with a possible inflection point or secondary, lesser 
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Age and gender 
Using average values from the temperature-limited dataset gender did not appear to 
make any difference in terms of recorded skin temperature, baseline flow-flux, LnTHRR, 
or THR time (table 3.3). Subjects¶ ages ranged between 18 and 51 years, and over this 
range there was a correlation between increasing age and increased skin temperature 
using Spearman rank correlation test (r= -0.370, p<0.001); and an increase of half a 
degree was found in older subjects (35 years and over) compared with younger subjects 
25 years and under (unequal variance independent t-test, p=0.006). There were no 
statistically significant correlations between age and baseline flow-flux, LnTHRR, or THR 


















Mean skin temperature, °C (SD) 30.66 (0.82) 30.67 (0.79) 30.64 (0.89) 0.885 
Mean baseline flowflux (SD) 20.40 (11.84) 22.23 (9.10) 22.46 (19.11) 0.951 
Mean LnTHRR (SD) 1.15 (0.44) 1.11 (0.34) 1.03 (0.48) 0.216 
Mean THR time, seconds (SD) 16.1 (0.72) 15.8 (0.42) 15.4 (0.38) 0.656 
 
Table 3.3 Mean skin temperature, flowflux, LnTHRR, and THR time in male and 
female subjects taken from the temperature-limited dataset 






Figure 3.12 Scatter plot graphs of average flow flux and LnTHRR versus age of 
subjects 





These results confirm that THRR data is not normally distributed. Given the nature of the 
data this is not unexpected. Previous studies involving THRR data have compared results 
using both parametric and non-parametric statistical tests (Webster VL et al, 2002; Brown 
H et al, 2003; Moppett IK and Davies J et al, 2003; Moppett IK and Jones LN et al, 2003). 
Tests such as ANOVA and Mann-Whitney U are often considered to be relatively robust 
and able to cope with deviations from normality distribution (Bland M, 1987); unfortunately 
the finding of heteroskedasticity may be more of a problem as it may undermine some of 
the basic assumptions of such tests. Heteroskedasticity commonly occurs when 
combining data from groups which are small or have unequal sample sizes, but in this 
analysis it persisted even when data was limited to groups of the same size. Differences 
in variance occurred between data from different subjects, and to a lesser extent also 
between data taken from the same subject at different time points (with no change in 
observer or change of measurement site). 
 
It was hoped that a natural logarithmic transformation could convert the data to near-
normal distribution, as was the case; and in doing so might decrease the variance 
between groups of measurements. This did not happen and it seems likely that 
heteroskedasticity is an intrinsic property of the THR test, and these results would 
suggest that it is, at least in part, related to an increase in variability with larger 
measurements (figure 3.8). 
 
Given that THR measurements are ratios of change in flowflux, which is measured in 
arbitrary units, a logarithmic scale is an appropriate method of representation (Bland M, 
1987). Although a further variance-stabilising data-transformation (for example taking the 
square-route of the natural logarithm of the THRR data) could also be applied, standard 
deviations calculated from the transformed data could not be back-transformed (Bland M, 
Altman DG, 1996). 
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It is unclear how much the finding of heteroskedasticity could have interfered with the 
statistical analysis of results from previous studies, although it could be predicted that 
where ANOVA is used the power of the F-test would decrease (Weerhandi S, 1995). 
 
A previous study by Hancock et al, 2001, using a single observer and 10 subjects on 
whom 10 THR measurements revealed a cumulate mean THRR of 1.86 (standard 
deviation 0.7) with the proportion of within-subject variance being 33% (total mean square 
3.707). This would mean the overall coefficient of variation was 0.38 and the within 
subjects coefficient of variation was 0.23.  
 
In contrast the overall coefficient of variation of THRR measurements within the 
temperature limited aggregate dataset was 0.55. ANOVA testing was not performed, but 
of the 10 largest single-subject, single-observer groups, all but two groups had an 
individual coefficient of variation of greater than 0.3. This would suggest that the data by 
Hancock et al might have underestimated the between- and within-subject variability. 
 
It is unclear how this finding might affect previous studies with negative results, and it is 
possible these may need to be interpreted with caution. 
 
LnTHRR measurements and power calculations 
Previous studies used a measurement sample size of 3 in order to approximate the mean 
that would be achieved with larger repetitions of measurement. Using LnTHRR 
measurements derived from large single-subject, single-observer subgroups within the 
temperature-corrected aggregate dataset a worst-case-scenario can be estimated (i.e. 
applying the highest coefficient of variation to the smallest mean ± a scenario which would 
be unlikely to occur if variability increases with larger measurement averages). In such a 
scenario the lowest mean is 0.90 and the largest standard error of the mean was 0.30 
delivering a 95% probability that the mean of three measurements sample from an 




individual will be with within r RIWKH³WUXH´PHDQ,QSUDFWLFHWKHODUJHVWGHYLDWLRQWKDW
could be generated using real data, rather than worst-case scenario, was r 20%. 
 
Previous studies have involved between ten and twenty volunteers (Webster VL et al, 
2002; Brown H et al, 2003; Moppett IK and Davies J et al, 2003; Moppett IK and Jones LN 
et al, 2003). Assuming that the mean LnTHRR values from single-subjects within the 
DJJUHJDWHGDWDVHWGLGDSSUR[LPDWHWKHLU³WUXH´PHDQVDSRZHUFDOFXODWLRQGRQHXVLQJWKH
standard deviation between subjects (0.31) suggests that using 15 subjects would identify 
a >28% change in LnTHRR (Į 0.05; ȕ 0.8). 
 
Decreasing variability 
There are many reasons why the THR test may have such a degree of variability, from 
subtle variations in skin blood flow or ambient light interference, to the difficulty in 
ensuring a true biological zero during arterial compression. 
 
One of the advantages of the THR test is that, compared with other measurements of 
post-ischaemic reactive hyperaemia, it does not require prolonged periods of ischaemia 
(Kvernebo K, 1989; Patterson GC, 1955). It is possible that using digital compression to 
perform the THR test failure to achieve rapid arterial occlusion and release, or failure to 
maintain complete occlusion might increase the variability of results. In a previous study 
by Marval et al, 2004, digital compression was replaced by a pneumatic tourniquet driven 
by carbon dioxide, of the type used to facilitate orthopaedic procedures. This enabled very 
rapid inflation / deflation but had the disadvantage of requiring extra equipment and being 
very uncomfortable. In this study the overall coefficient of variation remained >0.3. For 
these reasons it was considered that digital arterial compression was likely to remain the 
least invasive and potentially more clinically useful method. 
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The relationship between temperature and THRR is not obvious. Biological zero is known 
to be related to skin temperature, in part due to the increase in residual Brownian motion 
(DRT4 manual, 2006; Fredriksson I et al, 2007), and flowflux itself has previously been 
shown to increase with skin temperatXUHV RYHU & 2¶&RQQRU 0% HW DO 
2¶&RQQRU¶VUHVHDUFKDOVRUHYHDOHGWKat THRR decreased as skin temperatures increased 
with active heating from 33-43°C. In our data only a very weak correlation between 
temperature and THRR was found at ambient skin temperatures.  
 
In order to minimize or mitigate the effects of these differences in variability it would seem 
appropriate to design studies which use paired measurements from one subject and 
ensure that minimal skin temperature changes occur where paired data is used. Where 
this is not possible measurements could be compared with the aggregate dataset 
represented here, in which case it may be appropriate to limit LnTHRR readings to 
subjects with initial skin temperatures within the ranges of 28.5°C to 32.6°C. For the 
research involved in this thesis the above suggestions were observed where possible and 
only statistical tests that do not assume equal variance were used. 
 
The use of needle probes 
Although measurements made using needle probes appear to correlate well with 
measurements made using standard probes when paired readings are taken at the same 
time, when this is not possible it would seem prudent to limit comparisons to 
measurements with other needle probes where possible. 
 
The relationship between flowflux and THR 
One would expect that higher flowflux values might result in lower THR measurements 
resulting from there being less latent vasodilatation available in an already vasodilated 
system. This was found to be the case in this study (figure 3.10), but the relationship was 
not linear in nature and transient periods of ischaemia provoked a range of hyperaemic 




responses for a given range of flowflux values. Low levels of skin perfusion have also 
been reported as lowering the THR (Hardman JG et al, 1997). 
 
The vascular tree is known to be in a constant state of vasomotion (Bliss M, 1998) and 
factors which promote or inhibit the myogenic response to ischaemia may be present at 
all levels of baseline flow. It can be hypothesized that the duration of the THR response 
might be altered even where high levels of baseline flowflux diminish the magnitude of the 
hyperaemic response. Whilst this supports the idea that the THR test is a measure of 
autoregulation it means that it cannot be considered in isolation of skin perfusion. 
 
The presence of factors promoting or inhibiting the hyperaemic response does not fully 
explain the different types of THR traces which can be identified. The pulsatile nature of 
capillary blood flow can be identified in flowflux traces but contributes only a very small 
component of baseline flowflux (in this study of the order of 5% of variation above and 
below baseline mean). Overlaid on this is the fluctuation caused by regular contractions 
which occur in metarterioles and pre-capillary sphincters at a rate of 5-10 
contractions/minute (Bliss M, 1998). Within these studies fluctuations could sometimes be 
identified overlying the baseline flow, but they were not very marked. It can be 
hypothesized that fluctuations became more pronounced after ischaemia and became 
superimposed on the THR trace. If this is the case it might further add to the inherent 
variability of the THRR. 
 
Age and gender 
Previous studies have suggested that resting skin flowflux, and resting vasomotor tone 
are not substantially different between young and older healthy volunteers, but that 
UHVSRQVLYHQHVV WR FXWDQHRXV KHDWLQJ DW VRPH VLWHV Į-adrenergic vasoconstrictor 
stimulus, and vasodilatory stimulus (using nitroprusside or acetylcholine) may be blunted 
(Evans E et al, 1993; Algottson A et al, 1995; Dinenno FA et al, 2002). 
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Within the aggregate dataset there was no clear relationship between age and the 
flowflux or the THR response. A previous study by Abaza KT et al, 2004, comparing 33 
young (21-25 years old) and 33 older (65-85 years old) volunteers, identified a significant 
decrease in flowflux in the older subjects (10.6 versus 15.2) but also identified no 
difference in THRR.  
 
The data relating to the effect of gender on skin perfusion and vascular reactivity are 
mixed. Algotsson et al, 1995, found that resting skin perfusion measured by LDPI was 
lower in women than in men and exhibited a greater response to vasodilators. Other 
research suggests that the hyperaemic response to prolonged ischaemia was affected by 
the phase of the menstrual cycle, being reduced in the luteal phase (Bungum L et al, 
1996) or increased in the follicular and luteal phases (Hashimoto M, et al, 1995). Another 
study found no gender difference or menstrual phase difference, but did identify a 
difference between post-menopausal women and older men as well as younger women 
and men (Gooding KM et al, 2001). 
 
Within the aggregate dataset presented here there were no gender differences in flowflux 
or THRR.  
 







Manipulation of the THR test in volunteers 
 
Introduction 
A series of exploratory studies were designed in order to better understand the response 
of the THR test to aspects of therapy associated with the management of critical illness.  
 
In the first experiment healthy volunteers were asked to breathe using a respiratory circuit 
in which there was expiratory resistance (positive-end-expiratory pressure, PEEP). The 
effects of external respiratory support on the transient hyperaemic response have not 
previously been investigated, although the effects of hyperventilation, hyper- and 
hypocapnia and hypoxia have. Previous studies have demonstrated that moderate 
decreases in expired air carbon dioxide tension (1 kPa below baseline values) result in 
decreased flowflux and THRR measurements, but only compared with moderate 
hypercapnia (1 kPa above baseline values). Hyperventilation without hypo- or 
hypercapnia did not affect the response (Richardson JR et al, 2004). Moderate hypoxia 
(oxygen saturations of 80-85%) has also been shown not to affect either flowflux or THRR 
measurements (Marval PD et al, 2004). 
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Respiratory support is commonly required in the management of critically ill patients either 
via an endotracheal tube or non-invasive respiratory support using a face-mask. The 
mode of this support can vary but mostly consists of PEEP which can be combined with 
an inspiratory pressure in order to drive or assist ventilation. The addition of external 
pressure will raise the mean intra-thoracic pressure. Where continuous pressure is 
applied, for instance using continuous positive-airways pressure (CPAP), the intra-
thoracic pressure is likely to remain positive even when the patient is breathing 
spontaneously. Where PEEP alone is applied intra-thoracic pressures are likely to 
oscillate between negative and higher-than-normal positive pressures. 
 
CPAP has been shown to decrease cardiac stroke volume in healthy volunteers and 
deplete intra-thoracic blood volume, shifting towards intra-abdominal organs. It might be 
predicted that such a change in large central vascular beds might trigger changes 
elsewhere in the body. A study by Fournell A et al, 2003, on gastric mucosal oxygenation 
demonstrated that it was decreased in proportion to the level of CPAP applied, suggesting 
a redistribution of blood away from the gastric mucosa. Changes in limb volume, which 
were ventilation related and occurred after the application of PEEP, have also been 
identified using strain gauge plethysmography (Christ F et al, 1995). In the latter study it 
was shown that cyclical changes occurred within the microvasculature, termed 
vasomotion, which were in phase with the changes in central venous pressure (CVP) 
caused by ventilation. 
 
In the study outlined below (termed protocol one) PEEP was used instead of CPAP for 
two reasons. Firstly this would allow for moderate average rises in intra-thoracic pressure 
to be evaluated; and secondly in order to reproduce the cyclical changes previously 
mentioned and measure the changes in flowflux they generated whilst attempting to 
perform THR measurements. 
 




In the second study (protocol 2) various agents were iontophoresed into forearm skin in 
order to measure their effects on cutaneous vascular reactivity. All of the agents chosen 
are commonly used within critical care, propofol and midazolam as sedatives, and in the 
case of hypertonic saline (HTS) and mannitol as resuscitation fluids predominantly used 
in patients with traumatic brain injury. 
 
Mannitol and hypertonic saline have previously been promoted as diluents, specifically 
because they are not well iontophoresed (Asberg A et al, 1999; Abou-Elenin K et al, 
2002), and in theory should not cause vasodilatation even though they, and the other 
agents chosen, are known to have vasodilatory effects in vivo when delivered 
intravenously.  
 
There is very limited data concerning the iontophoresis of lipid soluble agents such as 
propofol and it seemed unlikely that propofol would cause any vasodilatation, so in 
essence this was an exploratory study to examine whether or not these agents could be 
used to trigger vasodilatory responses. 
 
The effects of the iontophoresis of vasodilatory agents, such as acetylcholine and sodium 
nitroprusside, on vascular reactivity have been extensively investigated and two studies 
have even demonstrated the ablation of THRR after their administration (Webster VL, et 
al, 2002; Brown H et al, 2003). The iontophoresis of constrictive agents, such as 
norepinephrine, epinephrine and phenylephrine is less well investigated with regard to 
changes in vascular reactivity. The study by Brown H et al, 2003, showed a decrease in 
flowflux with epinephrine, but not phenylephrine, and did not demonstrate a change in 
THRR with either agent. It was hypothesised that vasoconstriction would be unlikely to 
manifest changes in the vascular reactivity of healthy skin because low nutritive 
requirements resulted in an already low resting flowflux. In contrast studies measuring 
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changes in forearm vascular plethysmography have demonstrated a response to 
phenylephrine in healthy volunteers and, to a lesser extent, in patients with septic shock. 
 
In the third experiment, protocol 3, iontophoresis of a different vasoconstrictor, 
norepinephrine, took place in healthy volunteers. In case norepinephrine was ineffective 
at vasoconstricting unstressed skin, a non-pharmacological method of vasodilating skin, 
localized heating, took place concurrently. Localised heating has previously been shown 
to increase skin flowflux and decrease THRR. A peak temperature of 42°C was chosen 
because it has been shown to be well tolerated and is the temperature at which the 
vasodilatory response plateaus, at least in volunteers in whom core body temperature 
ZDVZLWKLQWKHQRUPDOUDQJH2¶&RQQRU0%HWDO7D\ORU:)HWDO 





Three separate but linked protocols were used to manipulate the cutaneous THR in 
healthy volunteers in an attempt to replicate some of the conditions and circumstances to 
which critically ill patients might be subjected. Protocol one involved the application of 
positive-end-expiratory pressure (PEEP) to spontaneously breathing volunteers; protocol 
two involved the iontophoresis of pharmacological agents commonly administered to 
critically ill patients; and protocol three used localized cutaneous heating probes to mimic 
the vasodilatation seen in sepsis and systemic inflammatory states, combined with the co-
administration of iontophoresed vasopressor agents. Optimal experimental conditions 
were obtained as previously described in chapter 2. The equipment used, along with the 
techniques for flowflux, THR measurement, iontophoresis and localised skin heating have 
also been previously described in chapter 2. 
 
Protocol one: the effect of PEEP on THR 
Baseline flowflux and THR measurements were performed on fifteen healthy volunteers. 
Each volunteer was then asked to breathe through a tight-fitting face mask which was 
attached via a T-piece to a breathing circuit. The breathing circuit had fresh gas (medical 
air) flowing into a reservoir bag attached to the inspiratory limb at 15 l/min and a PEEP 
valve attached to the expiratory limb (figure 4.1). The PEEP valve was set to apply 10 
cmH2O of resistance to expiratory flow. After the volunteer had been breathing through 
the circuit for five minutes flow flux and THR were once again measured. During all 
periods of flow-flux and THR measurement cutaneous pulse oximetry (SpO2) and end-
tidal capnography (ETCO2) were used to measured blood oxygen saturation and the end-
expiratory partial pressure of exhaled carbon dioxide. 
 
Protocol two: the effect of iontophoresed chemicals on THR 
Two separate groups of 15 healthy volunteers were recruited. Each individual underwent 
two separate episodes of baseline flowflux and THR measurements followed by 
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measurements taken after cutaneous iontophoresis of one of four chemicals, such that 
there were 15 sets of paired before and after data for each chemical. The chemicals used 
were: hypertonic (2.7%) saline solution, mannitol 10% solution, propofol 1% solution 
(emulsified in 10% soybean oil, 1.2% purified egg phospholipid, and 2.25% glycerol, 
marketed as Diprivan®), and midazolam diluted in 0.9% saline solution to a concentration 
of 1mg/ml. Flowflux and THR measurements were simultaneously made from both the 
active (iontophoresed) sites and control sites on the same forearm. 
 
Midazolam was iontophoresed using a cathodal current due to the degree of positive 
ionization its water soluble state. Propofol, 2.7% saline and mannitol were all 
iontophoresed using an anodal current. In the case of 2.7% saline this was based upon 
the fact that although previous studies using hypertonic saline demonstrated only minimal 
hyperaemic effects after iontophoresis, these effects appeared to be larger when using 
anodal currents (Asberg et al, 1999; Brandrivskyy et al, 2004). Mannitol, a sugar alcohol, 
does not readily ionise in solution, but has previously been iontophoresed using anodal 
currents (Kirjavainen MH et al, Kim et al, 1993). Propofol iontophoresis was performed 
using an anodal current, even though it is not water-soluble and only ionizes at very high 
pH. Although attempts have been made to encourage the transdermal transmission of 
propofol, these have not utilized iontophoresis (Yamato K et al, 2009). 
 
As propofol is an opaque white solution of oil droplets it would be impossible to use LDF 
whilst propofol was present within the iontophoresis chamber. For this reason the 
chamber was filled with 0.9% saline prior to baseline laser Doppler flowmetry, after which 
the chamber was washed out and then filled with propofol prior to iontophoresis. After 
iontophoresis the chamber was again washed out with saline and LDF measurements 
recorded. propofol  
 
 




Protocol three: the effect heat of localized cutaneous heating and the co-
administration of iontophoresed vasopressors on THR 
Serial measurements of forearm flowflux and THR were taken before and after localised 
cutaneous heating (i.e. heating of skin directly under the LDF probe) using three groups of 
healthy volunteers. In first group 0.1% norepinephrine in 0.9% saline solution was 
iontophoresed prior to skin being heated to 35°C and then 45°C. Details of the study 
design for each group can be found in table 4.1. Simultaneous flowflux and THR 
measurements were also taken from control sites. In the other two groups skin was 
heated to either 35°C or 45°C prior to the iontophoresis of norepinephrine. The time taken 
to heat skin to the predetermined temperature varied between individuals, but was always 
less than two minutes. 
 
Norepinephrine was iontophoresed using a cathodal current (i.e. the iontophoresis 
chamber was the cathode), and followed the iontophoresis protocol outlined in chapter 
two. 














Group Phase 1 Phase 2 Phase 3 Phase 4 
1 Unheated skin Iontophoresis Heated to 35°C Heated to 42°C 
2 Unheated skin Heated to 35°C Iontophoresis at 35°C  
3 Unheated skin Heated to 42°C Iontophoresis at 42°C  
 
Table 4.1 The order in which localized cutaneous heating and norepinephrine 
iontophoresis occurred in each group within Protocol 3. Flowflux and THR 
measurements of both active and control sites occurred at each phase. There was no 
fourth phase in groups 2 and 3. 










Protocol one: the effect of PEEP on THR 
Of the 15 volunteers, 11 were male and 4 were female. The median age was 34 years old 
(range 25 to 48). Resting heart rate, mean-arterial pressure (MAP), end-tidal CO2, SpO2 
and skin temperature were not significantly altered by the application of PEEP (table 4.2). 
 
Baseline flowflux, LnTHRR measurements and duration of THR were not significantly 
altered after the application of PEEP (table 4.3 and figure 4.2), even though flow-flux 
measurements showed marked fluctuations once PEEP was applied, which occurred in 
time with respiration (figure 4.3). 
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Variable  Baseline, n=15 With PEEP, n=15 P-value 
 Values are means (SD)  
Heart Rate, beats/min 71 (12.6) 74 (11.9) 0.09 
Mean arterial pressure, mmHg 84 (11) 82 (8.3) 0.46 
End-tidal CO2, kPa 4.9 (0.5) 4.8 (0.5) 0.35 
SpO2, % 96 (1.4) 96 (1.5) 0.49 
Skin temperature, °C 29.7 (1.5) 29.9 (1.6) 0.22 
Flowflux 15.75 (11.01) 15.47 (12.43) 0.949 
LnTHRR 1.30 (0.45) 1.37 (0.59) 0.687 
THR time, seconds 15.0 (5.0) 12.6 (4.9) 0.196 
 
Table 4.2 Skin temperature, cardio-respiratory variables, flowflux, LnTHRR, and 
THR time of volunteers before and during application of PEEP. Samples compared using 
paired t-test except for flowflux, LnTHRR and THR time which are compared using 
independent t-test with equal variance not assumed. 
 









Figure 4.2 Mean flowflux and LnTHRR values in volunteers before and after the 
application of 10cmH2O PEEP. Error bars represent 95% confidence intervals. 





Figure 4.3 A sample flowflux and THR trace demonstrating the effect of PEEP on 
flow-flux in some volunteers. A: flowflux variation during baseline measurements; B: 
flowflux variation during THR 




Protocol two: the effect of iontophoresed chemicals on THR 
In each group there were 7 female and 8 male volunteers aged between 18 and 33 
(median age 21 in both groups). Resting skin temperature in all subjects was within the 
guidelines set out in chapter 3. Only resting mean arterial pressure was measured and in 
each group this was within what could be considered normal acceptable limits (overall 
mean 81mmHg, SD 12) 
 
Skin temperature, flowflux measurements, LnTHRR measurements and the duration of 
the THR response did not significantly change throughout the course of the experiments 
at any of the control sites (table 4.3). 
 
Although there was no change in skin temperature after the iontophoresis of propofol or 
mannitol, both midazolam and 2.7% saline were associated with a statistically significant 
rise. In both cases the absolute rise was very small (0.7ºC and 1.1ºC respectively). 
 
All of the drugs involved caused an increase in flowflux after iontophoresis and in each 
case there was an associated fall in LnTHRR (table 4.3, figure 4.4, and figure 4.5). 
Propofol and mannitol were associated with the highest rise in flowflux and the greatest 
fall in LnTHRR (in both cases the THR response was nearly ablated). Despite the 
decreases in LnTHRR with all drugs statistically significant decreases in THR time were 
only seen with midazolam and propofol. 
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 Chemical Probe Iontophoresis P-value Before After 
Skin temperature, 
°C Mean (SD) 
Midazolam Control 30.0 (1.3) 30.0 (1.3) 0.970 Active 29.1 (0.8) 29.8 (0.6) 0.018 
Propofol Control 30.3 (1.2) 30.1 (1.0) 0.654 Active 29.1 (1.0) 28.5 (0.9) 0.071 
2.7% Saline Control 29.9 (0.6) 29.9 (1.3) 0.799 Active 29.1 (0.7) 30.2 (0.6) <0.001 
Mannitol Control 30.4 (1.9) 30.3 (1.8) 0.812 Active 29.5 (1.8) 30.4 (1.6) 0.179 
Flowflux 
Mean (SD) 
Midazolam Control 20.36 (7.82) 17.44 (7.80) 0.316 Active 7.35 (2.89) 37.4 (29.57) 0.001 
Propofol Control 23.11 (9.85) 18.17 (8.02) 0.144 Active 7.90 (3.67) 57.94 (14.83) <0.001* 
2.7% Saline Control 20.29 (8.24) 16.94 (6.18) 0.235 Active 9.97 (4.97) 33.72 (25.93) 0.003 
Mannitol Control 21.01 (8.93) 20.16 (9.35) 0.799 Active 6.07 (2.16) 50.16 (20.41) <0.001 
LnTHRR 
Mean (SD) 
Midazolam Control 1.12 (0.30) 1.21 (0.33) 0.428 Active 1.21 (0.43) 0.52 (0.75) 0.005 
Propofol Control 1.19 (0.43) 1.18 (0.35) 0.928 Active 1.23 (0.39) 0.09 (0.10) <0.001 
2.7% Saline Control 1.02 (0.22) 1.13 (0.28) 0.260 Active 1.06 (0.38) 0.36 (0.40) <0.001 




Midazolam Control 16.1 (6.9) 14.8 (4.0) 0.528 Active 16.2 (6.4) 9.8 (6.5) 0.013 
Propofol Control 15.0 (4.7) 15.5 (4.0) 0.757 Active 15.6 (5.4) 11.8 (4.6) 0.050 
2.7% Saline Control 19.3 (10.7) 19.3 (10.1) 0.986 Active 15.6 (5.5) 20.8 (7.1) 0.482 
Mannitol Control 22.0 (7.7) 19.4 (5.7) 0.319 
Active 21.7 (8.0) 17.2 (6.5) 0.106 
 
 
Table 4.3 Skin temperature, flowflux, LnTHRR and THR time before and after the 
iontophoresis of midazolam, propofol, 2.7% saline or mannitol (designated active), 
compared with a control site with no iontophoresis (designated control). P-values 
represent the statistical significance comparing before and after values using an 
independent samples t-test where equal variances are not assumed







Figure 4.4 Graph of mean flowflux before and after the iontophoresis of midazolam, 
propofol, 2.7% saline or mannitol (designated active), compared with mean flowflux at 
control site where no iontophoresis took place (designated control). Error bars represent 
95% confidence intervals. 
 




Figure 4.5 Graph of mean LnTHRR before and after the iontophoresis of midazolam, 
propofol, 2.7% saline or mannitol (designated active), compared with mean LnTHRR at 
control site where no iontophoresis took place (designated control). Error bars represent 
95% confidence intervals. 




Protocol three: the effect of localized cutaneous heating and the co-administration 
of iontophoresed vasopressors on THR 
The age range and gender breakdown of volunteers within each group of the Protocol 3 
can be found in table 4.4, along with the average resting mean arterial pressure and 
resting skin temperature. 
 
Within the first group, where the iontophoresis of norepinephrine occurred prior to 
cutaneous heating to 35°C and then 42°C, skin flowflux decreased after the iontophoresis 
and did not increase after heating to 35°C but did increase after heating to 42°C back to 
levels which were statistically unchanged from levels before the introduction of 
norepinephrine (table 4.5). Skin temperature increased slightly after the iontophoresis of 
norepinephrine (mean increase 1.5°C). LnTHRR and the duration of the THR response 
both decreased after iontophoresis and remained at low levels even after heating to 42°C 
(table 4.5 and figure 4.6). 
 
Within the second group, the iontophoresis of norepinephrine after cutaneous heating to 
35°C, there was a rise in flowflux accompanying heating and a decrease after 
norepinephrine, but this was not statistically significant (table 4.6 and figure 4.7). LnTHRR 
decreased only after norepinephrine which was statistically significant when compared 
with heated skin, but not with unheated skin. The duration of THR also decreased after 
norepinephrine compared with both heated and unheated skin. 
 
Within the third group, the iontophoresis of norepinephrine after cutaneous heating to 
42°C, flowflux increased dramatically after heating, but after norepinephrine returned to 
values approximating baseline levels (table 4.7 and figure 4.8). LnTHRR also decreased 
GUDPDWLFDOO\ DIWHU KHDWLQJ DQG LQ PDQ\ FDVHV D ³QHJDWLYH K\SHUDHPLF UHVSRQVH´ ZDV
seen (figure 4.9). Norepinephrine increased the magnitude of LnTHRR but not back up to 
baseline levels. The duration of THR decreased after heating and this decrease was not 
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reversed by the iontophoresis of norepinephrine, although it should be noted that the THR 
WLPHDIWHUKHDWLQJUHIHUVWRDVLJQLILFDQWQXPEHURI³QHJDWLYHK\SHUDHPLF´HSLVRGHVZKLOVW
the THR time after norepinephrine only refers to positive, or true, hyperaemic responses. 





 Median age 
years (range) 
Gender Blood pressure 
MAP: mmHg (SD) 
Skin temperature 
°C (SD) 
     
Group 1 
(iontophoresis followed 
by skin heating) 
31 (26-44) 7 female 
8 male 
82 (14) 30 (1.6) 
 
    
Group 2 
(iontophoresis at 35°C) 33 (25±51) 
7 female 
8 male 
87 (10) 31 (1.2) 
 
    
Group 3 
(iontophoresis at 42°C) 34 (20±51) 
9 female 
6 male 
85 (14) 30 (0.9) 
 
Table 4.4 Baseline characteristics of volunteers prior to cutaneous heating or 
iontophoresis in all three groups within Protocol 3, including median age, gender, resting 
blood pressure (recorded as mean arterial pressure, MAP, in mmHg) and resting skin 
temperature. 
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Group 1: the iontophoresis of norepinephrine followed by cutaneous heating 
 Phase 1 Phase 2 Phase 3 Phase 4  
 Iontophoresis of 
norepinephrine 
Cutaneous heating  
 Before  After  35°C 42°C P-value 
   
  
 
Temperature °C, (SD) 28.0 (1.5) 29.5 (1.6) 35.0 42.0 0.013* 
Flowflux (SD) 12.83 (5.00) 6.55 (1.55) 6.21 (1.08) 9.55 (2.58) <0.001** 
LnTHRR (SD) 1.04 (0.39) 0.65 (0.32) 0.72 (0.41) 0.59 (0.37) 0.009 
THR time (SD) 18.2 (9.1) 8.3 (4.0) 8.7 (3.3) 6.1 (2.8) <0.001Á 
 
Table 4.5 Forearm skin temperature, flowflux, LnTHRR, and THR time values in 
volunteers from Group 1 where iontophoresis of norepinephrine was followed by 
cutaneous heating to 35°C and then 42°C 
 
* Independent sample t-test comparing skin temperature before and after iontophoresis, 
but before skin heating 
$129$WHVWVWDWLVWLFZLWK7DPKDQH¶V7WHVWDSSOLHGShase 1 vs. phase 2 (p = 0.001); 
phase 2 vs. phase 3 (p = 0.983); phase 3 vs. phase 4 (p = 0.001); phase 1 vs. phase 4 (p 
= 0.188); phase 1 vs. phase 3(p = 0.001); phase 2 vs. phase 4 (p = 0.005). 
 $129$WHVWVWDWLVWLFZLWK7DPKDQH¶V7WHVWDSSOLHGSKDVH 1 vs. phase 2 (p = 0.036); 
phase 2 vs. phase 3 (p = 0.997); phase 3 vs. phase 4 (p = 0.941); phase 1 vs. phase 4 (p 
= 0.019); phase 1 vs. phase 3(p = 0.209); phase 2 vs. phase 4 (p = 0.998). 
Á $129$WHVWVWDWLVWLFZLWK7DPKDQH¶V7WHVWDSSOLHGSKDVHYs. phase 2 (p = 0.006); 
phase 2 vs. phase 3 (p = 1.00); phase 3 vs. phase 4 (p = 0.145); phase 1 vs. phase 4 (p = 
0.001); phase 1 vs. phase 3(p = 0.008); phase 2 vs. phase 4 (p = 0.442). 








Figure 4.6 Mean flowflux, LnTHRR and THR time in volunteers after iontophoresis of 
norepinephrine followed by skin heating to 35°C and then 42°C; control sites had no 
heating or iontophoresis. Error bars represent 95% confidence intervals.
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Group 2: cutaneous heating to 35°C followed by iontophoresis of norepinephrine  
 Phase 1 Phase 2 Phase 3  
 Cutaneous heating  Norepinephrine 
iontophoresis at 35°C 
 




Temperature, °C (SD) 28.4 (1.1) 35 35  
Flowflux (SD) 15.52 (5.27) 19.76 (11.17) 13.69 (15.75) 0.346* 
LnTHRR (SD) 0.89 (0.30) 0.96 (0.24) 0.57 (0.49) 0.012** 
THR time (SD) 15.5 (7.3) 12.9 (4.9) 8.2 (4.8) 0.005 
 
Table 4.6 Forearm skin temperature, flowflux, LnTHRR, and THR time values in 




phase 2 vs. phase 3 (p = 0.552); phase 1 vs. phase 3 (p = 0.966). 
$129$WHVWVWDWLVWLFZLWK7DPKDQH¶V7WHVWDSSOLHGSKDVHYVSKDVHp = 0.868); 
phase 2 vs. phase 3 (p = 0.038); phase 1 vs. phase 3 (p = 0.125). 
 $129$WHVWVWDWLVWLFZLWK7DPKDQH¶V7WHVWDSSOLHGSKDVHYVSKDVHp = 0.612); 
phase 2 vs. phase 3 (p = 0.039); phase 1 vs. phase 3 (p = 0.011). 








Figure 4.7 Mean flowflux, LnTHRR and THR time in volunteers after skin heating to 
35°C followed by iontophoresis of norepinephrine; control sites had no heating or 
iontophoresis. Error bars represent 95% confidence intervals
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Group 3: cutaneous heating to 42°C followed by iontophoresis of norepinephrine  
 Phase 1 Phase 2 Phase 3  
 Cutaneous heating  Norepinephrine 
iontophoresis at 42°C 
 




Temperature, °C (SD) 28.2 (1.0) 42 42  
Flowflux (SD) 14.93 (7.83) 124.63 (61.40) 16.11 (8.14) <0.001* 
LnTHRR (SD) 1.08 (0.44) - 0.53 (0.35) 0.49 (0.34) <0.001** 
THR time (SD) 15.7 (6.0) 4.7 (2.4) 8.9 (6.5) <0.001 
 
Table 4.7 Forearm skin temperature, flowflux, LnTHRR, and THR time values in 
volunteers from Group 3 where cutaneous heating to 42°C was followed by iontophoresis 
of norepinephrine 
 
$129$WHVWVWDWLVWLFZLWK7DPKDQH¶V7WHVWDSSOLHGSKDVHYVSKDVHp < 0.001); 
phase 2 vs. phase 3 (p < 0.001); phase 1 vs. phase 3 (p= 0.970). 
$129$WHVWVWDWLVWLFZLWK7DPKDQH¶V7WHVWDSSOLHGSKDVHYVSKDVH2 (p< 0.001); 
phase 2 vs. phase 3 (p< 0.001); phase 1 vs. phase 3 (p= 0.001). 
 $129$WHVWVWDWLVWLFZLWK7DPKDQH¶V7WHVWDSSOLHGSKDVHYVSKDVHp< 0.001); 
phase 2 vs. phase 3 (p= 0.931); phase 1 vs. phase 3 (p< 0.001). 
 







Figure 4.8 Mean flowflux, LnTHRR and THR time in volunteers after skin heating to 
42°C followed by iontophoresis of norepinephrine; control sites had no heating or 
iontophoresis. Error bars represent 95% confidence intervals





Figure 4.9 Sample trace of THR in skin heated to 42°C. A: flowflux before heating; 
B: flowflux during and after heating; C: biological zero during arterial compression; D: 
QHJDWLYH³K\SHUDHPLD´GXULQJ7+5 





The effect of PEEP on THR 
The application of 10 cmH2O PEEP in volunteers induced a fluctuating flowflux in time 
with respiration in most, but not all, subjects (figure 4.3). These fluctuations may have 
been the same as those described in chapter 3, but in this case they were obviously 
present at all times and did not change in magnitude following a transient hyperaemic 
episode. Despite these fluctuations there was no identifiable difference in mean flow flux 
or the THR measurements before and after the application of PEEP.  
 
Fluctuations in flowflux associated with PEEP alter the variability of THR measurements, 
such that in subjects with raised mean intra-thoracic pressures they would be less 
reliable. 
 
Using plethysmography limb circumference has been shown to change in phase with 
PEEP-induced changes in central venous pressure, and to a lesser extent arterial 
pressure (Christ F et al, 1995; Peters JK et al, 1997). It has been suggested that changes 
in vascular tone associated with PEEP are arteriolar in origin and are part of a 
mobilization of skin blood volume occurring at maximal right atrial transmural pressure 
reduction (Peters JK et al, 1997). Christ et al, 1997, also demonstrated that further 
vascular reactivity occurred, specifically in the form of slow-wave vasomotion (i.e. with a 
periodicity less than that of breathing), in hypovolaemic patients; and that this did not 
diminish with the removal of PEEP-related CVP changes. This would indicate that 
mechanisms of vascular reactivity remain intact after the application of PEEP and might 
explain why the transient hyperaemic response was not diminished. 
 
The effects of iontophoresed chemicals on THR 
All of the chemicals iontophoresed caused an increase in microcirculatory blood flow 
which was exhibited as an increase in flowflux. One of the disadvantages of iontophoresis 
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is that although there were differences between chemicals in terms of the degree of 
change in flowflux it is impossible to know whether these were dose related. All of the 
drugs chosen were known, or suspected, to have vasodilatory effects or effects on skin 
perfusion.  
 
Hypertonic saline (HTS) is typically used clinically in the treatment of hypovolaemic states 
and is known to result in increased capillary blood flow measured by skin Doppler 
flowmetry, which is thought to be associated with the increased systemic perfusion due to 
volume resuscitation (Boldt et al, 1991). This cannot be the mechanism of action in this 
instance. Likewise the reversal of venule endothelial oedema by HTS is unlikely to play a 
significant role in causing the increased flow seen within this experiment, as post-capillary 
endothelial oedema is associated with shocked states which were not present in the 
volunteers studied (Oliviera RP et al, 2002). HTS, and other hyperosmolar solutions, have 
been shown to decrease peripheral vascular resistance in uninjured animals in a manner 
consistent with either the dilatation of vascular beds or the opening up of new channels 
(Read et al, 1960). One method by which this may occur is by the release of vasodilators, 
in particular the release of prostacyclin (PGI2) combined with a decrease in thromboxane 
B2, which is associated with HTS infusion (Oliviera RP et al, 2002). Evidence exists that 
hyperosmolality of lymph may cause arteriolar vasodilatation, at least in intestinal vessels, 
via the release of endothelial-derived relaxing factor (EDRF), and therefore may be 
related to nitric oxide (NO) or prostacyclin release (Steenbergen JM et al, 1993). 
 
Although the effects of mannitol on the renal vasculature are thought to also be mediated 
by prostaglandins (Johnstone PA et al, 1981), previous experiments using 3% mannitol 
have failed to demonstrate an increase in flowflux (Morris SJ et al, 1995), and the effects 
of mannitol on the skin microcirculation are largely unknown. 
 




Midazolam is thought to exhibit a vasodilatory effect via the release of NO and the 
inhibition of Ca2+ channels (Chang KSK et al, 1994). Although propofol might exhibit direct 
vasodilatory effects, possibly also via the inhibition of Ca2+ channels, other studies 
suggest that sympathetic inhibition is the most likely cause at therapeutic doses (which 
cannot be assumed here) (Robinson BJ et al, 1997; Chang KS et al, 1993; Nakamura K 
et al, 1992).  
 
As previously noted, in chapter 2, the iontophoresis of de-ionized water or saline have 
been associated with vasodilatation, and this has been termed the galvanic effect (i.e. 
related to current or potential difference, rather than a chemical effect per se) causing 
hyperpolarisation of cell membranes and smooth muscle relaxation. The protocol for 
current delivery used within this study was designed to reduce the likelihood of this 
occurring, particularly as it has been most associated with cathodal iontophoresis (Droog 
EJ et al, 2003; Abou-Elenin K et al, 2002); all the chemicals here were iontophoresed 
using anodal iontophoresis except midazolam. In fact the anodal iontophoresis of 
hypertonic saline solutions is not strongly associated with vasodilatation at all (Asberg A 
et al, 1999; Abou-Elenin K et al, 2002). The iontophoresis of de-ionized water, however, is 
associated with significant vasodilatation and it may be that the tonicities of carrier 
solutions (or HTS itself) used within this experiment were low enough to replicate this 
effect. The vasodilatation associated with both anodal and cathodal iontophoresis of de-
ionized water and tap water has previously been shown to be attenuated by prostaglandin 
inhibition (Abou-Elenin K et al, 2002; Durand S, 2002; Berliner M, 1997). The solution of 
mannitol used was an aqueous solution, and although propofol is an oil-based solution it 
does contain water, as well as sodium hydroxide, and it is impossible to know whether or 
not the carrier solution, or any other chemicals it contained, might have caused the 
vasodilatation seen. If it is the carrier solutions which are responsible for the degree of 
vasodilatation seen it is surprising that this occurred despite different carrier solutions and 
iontophoresis polarity. This would not be in keeping with the aforementioned studies or 
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the study by Brown et al, 2003, which found insignificant vasodilatation after 
iontophoresed saline.  
 
In each case the increase in flowflux was accompanied by a decrease in the THRR with 
increased levels of vasodilatation probably being associated with greater attenuation of 
the hyperaemic response. Iontophoresis of endothelium-dependent (sodium 
nitroprusside) and endothelium-independent (acetylcholine) vasodilators have been 
shown in previous studies to abolish the transient hyperaemic response (Webster VL et 
al, 2002; Brown H et al, 2003). In this study only propofol and mannitol nearly abolished 
the response. Regardless of the mechanism of vasodilatation this study proves that the 
THR can be partially depressed by the iontophoresis of exogenous chemicals.  
 
The duration of THR was only decreased after the iontophoresis of midazolam and 
propofol. Given the wide range of variability associated with these measurements a 
degree of caution must be taken when interpreting these results. Nevertheless if these 
results are accurate it would suggest that the effect of chemicals on the amplitude of the 
THR may be decoupled from the ability to sustain the response, which has not been 
previously described.   
 
The effect of localized cutaneous heating and the co-administration of 
iontophoresed vasopressors on THR 
Local heating of skin produced a vasodilatory response and abolished THRR at 42°C 
FRQVLVWHQWZLWKSUHYLRXVVWXGLHV2¶&RQQRUHWDO3UHYLRXVVWXGLHVKDYHVKRZQWKDW
hyperaemia associated with prolonged ischaemia may be increased by local warming 
(Johnson JM et al, 1986), and that this is in part mediated by the abolition of sympathetic 
adrenergic vasoconstriction, a process which can be mimicked by the iontophoresis of 
bretylium (Kellogg DL et al, 1989; Pergola PE et al, 1993).  
 




Adrenergic inhibition is not the only mechanism by which vasodilatation occurs with 
cutaneous heating; denervated skin, either by sympathectomy or contained within a skin 
graft, still demonstrates the ability to vasodilate (Bliss M, 1998; Freund PR et al, 1981). 
Despite this it would seem that the predominant mode of vasodilatation is adrenergic 
inhibition, as although hyperaemia associated with prolonged ischaemia may be 
increased by local warming the reverse is not true (i.e. hyperaemia associated with local 
warming is not increased after an additional period of ischaemia - Johnson JM et al, 
1986). This would explain why exogenous norepinephrine partially restored the transient 
hyperaemic response in skin heated to 42°C. It is harder to explain why the reverse was 
not true, in that heating skin already exposed to norepinephrine did not increase the THR. 
Unlike heating norepinephrine did not, however, abolish the hyperaemic response, only 
attenuate it. The decrease in the transient hyperaemic response seen after 
norepinephrine appeared to suggest a scenario in which the microcirculation became 
resistant, but not impervious to, hyperaemic vasodilatation. The duration of hyperaemia 
remained decreased after the iontophoresis of norepinephrine. 
 
Apart from in heated skin the application of norepinephrine diminished vasodilatation and 
hyperaemia. It is unclear why norepinephrine affected the microcirculation in this 
experiment whilst epinephrine and phenylephrine failed to affect the THR in previous 
experiments (Brown H et al, 2003). Changing the agent or iontophoresis protocol may 
have resulted in better drug delivery. 
 
7KH³QHJDWLYH´K\SHUDHPLFUHVSRQVHs seen with skin heating, (figure 4.9), indicate either 
new vasoconstriction or diminished vasodilatory effect occurring following transient 
ischaemia which was unexpected and was not present in previous studies where 
vasodilatation was chemically induced (Webster VL et al, 2002; Brown H et al, 2003).  
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Conclusion 
The preceding studies have demonstrated that the application of PEEP alters flowflux 
measurements in a manner consistent with the vasomotion associated with changes in 
intra-thoracic pressure seen in earlier studies. It does not appear to alter the transient 
hyperaemic response, but the aforementioned changes in flowflux will increase the 
degree of variability seen within the technique. 
 
The effects of the iontophoresis of novel chemicals on THR are difficult to interpret. At the 
most basic level it has been demonstrated that moderate vasodilatation through chemical 
iontophoresis is possible and affects THR. It has been also conclusively demonstrated 
that hypertonic solutions can cause vasodilatation after iontophoresis. It is highly likely 
that many of the drugs caused vasodilatation in their own right, otherwise these results 
would contradict findings found in earlier studies and results demonstrated later in this 
thesis (where the same diluents were used but no, or minimal, vasodilatation occurred)7-
7-=83339, but proving this is not possible using the current results. In future all 
iontophoresis of vasodilators should be performed alongside a control(s) consisting of the 
diluents used. 
 
The iontophoresis of norepinephrine was shown to provoke vasoconstriction, both in 
heated and unheated skin, and in heated skin this resulted in a partial return of THR. The 
logical next step would be to identify whether or not norepinephrine can restore the THR 
in other vasodilated states where adrenoceptor resistance is thought to be at least 
partially responsible, for example in systemic inflammation. 
 
7KH³QHJDWLYH´K\SHUDHPLFUHVSRQVHVHHQDIWHUORFDOL]HGKHDWLQJWR&LVXQH[SODLQHG
at this time, but further investigation may yield information regarding the vasodilator 
response which occurs with temperature. 
 







The THR test in patients with evidence of a 
systemic inflammatory response: a pilot study 
 
Introduction 
The systemic inflammatory response syndrome (SIRS) is a clinically-orientated definition 
of inflammation which can occur in critically ill patients after a range of insults including 
trauma, pancreatitis, poisoning and, most commonly within the intensive care 
environment, sepsis (Bone RC et al, 1992).Sepsis with evidence of organ failure is known 
to be common, with a surprisingly high population incidence in the United States of 
approximately 3 cases per 1000; and an approximate mortality of 28.6% (Angus DC et al, 
2001). Although the incidence of SIRS is not known, in a study of the natural history of 
SIRS 26% of patients developed sepsis, 18% developed sepsis with associated organ 
failure and 4% developed septic shock; and the mortality associated with each definition 
increased in a stepwise manner with 7% of SIRS patients dying compared with 16% of 
septic patients and 46% of patients with septic shock (Rangel-Frausto MS et al, 1995). 
Whilst the criteria for SIRS have been criticized as being over-sensitive and non-specific, 
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no alternative clinical definitions or biomarkers have yet been identified (Vincent J-L, 
1997; Levy MM et al, 2003).  
 
Microcirculatory changes present in the tongue in patients with septic shock have 
previously been identified, and it has been demonstrated that perfusion increased rapidly 
in patients who went on to survive, but did not improve in non-survivors. Lack of 
improvement in non-survivors appeared to occur even after the shocked state was 
corrected (Sakr et al, 2004). 
 
Reactive hyperaemia has previously been investigated in critically ill patients, although 
not using the transient hyperaemic response. Young JD et al, 1995, identified an increase 
in skin perfusion in patients with sepsis which was accompanied by a decrease in the 
hyperaemic response to post-occlusive ischaemia. Reactive hyperaemia has also been 
shown to become diminished in patients with other inflammatory conditions as well as 
sepsis and, but that diminution does not universally occur in either state. The reduction in 
hyperaemic response was associated with increased mortality, but was not predictive of it 
(Hartl et al, 1988). 
 
In a study by Haisjackl et al, 1990, the reactive hyperaemic response of skin in critically ill 
patients was diminished, as was carbon dioxide elimination, when compared with healthy 
subjects. The finding of a diminished hyperaemic response was associated with the 
degree of physiologic derangement measured by the Acute Physiology and Chronic 
Health Evaluation score (APACHE II). 
 
Kienbaum P et al, 2008, have previously demonstrated that forearm vascular resistance is 
reduced in patients with septic shock, and can be reduced still further by the introduction 
of sodium nitroprusside, similar to that seen in healthy volunteers. They also 




demonstrated and that the normally vasoconstrictive response to phenylephrine was 
impaired in septic shock, although the response to vasopressin was not. 
 
This study was designed as a pilot in order to examine whether the transient hyperaemic 
response could be successfully measured in critically ill patients within the intensive care 
unit (ICU). As decreased vascular reactivity has been shown to be present in patients with 
inflammatory responses other than sepsis, and also has been shown to occur before 
clinically identifiable evidence of vascular derangement in patients with sepsis, it was 
decided to examine the vascular reactivity in patients who presented with evidence of 
SIRS regardless of the cause (Hartl WH et al, 1988). 
 
In order to evaluate the effects of exogenous vasoconstrictors and vasodilators a 
secondary aspect of the investigation was to examine the effects on the transient 
hyperaemic response of iontophoresed norepinephrine and acetylcholine.  
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Methods 
All patients admitted to the ICU at Nottingham City Hospital over a 6 month period 
between February and July 2004 were screened for the presence of systemic 
inflammatory response syndrome criteria (SIRS). Where patients were found to have 
evidence of SIRS they were further screened to ensure suitability for admission into the 
trial. Where patients were found to be suitable they were asked for their consent to take 
part. Where patients were unable to give consent, for example where they were 
unconscious or sedated, the informed assent of their relatives was sought instead. 
 
The presence of SIRS criteria was defined using the guidelines suggested by the 
American College of Chest Physicians/ Society of Critical Care Medicine Consensus 
Conference 1992 (Bone et al, 1992), with patients defined as having SIRS where 2 or 
more of the following are present: 
x Core temperature > 38oC or < 36oC 
x Heart rate > 90 beats/min 
x Respiratory rate > 20 breaths/min or PaCO2 < 4.3 kPa * 
x White blood cell count > 12,000 cells/mm3, < 4000 cells/mm3, or > 10% immature 
(band) forms 
* For the purposes of this study the presence of mandatory mechanical ventilation via an 
endotracheal tube or tracheostomy tube was also used as a surrogate marker of impaired 
ventilation, except where short-term ventilation was required in the immediate post-
operative period. 
 
These same criteria were also used to identify patients with sepsis (SIRS plus the 
presence of bacteraemia or an infected body cavity) or septic shock (sepsis associated 
with a systolic blood pressure of <90mmHg or the requirement for inotropes to maintain 
blood pressure) (Bone et al, 1992). 
 




Patients were excluded where consent / assent could not be obtained. Other exclusion 
criteria were those defined in chapter 2. Patients in whom further ICU treatment was 
deemed to be futile and / or was in the process of being withdrawn were also excluded 
prior to enrolment. 
 
Demographic and clinical data, both retrospective and prospective was collected on 
patients during their ICU and hospital admission. Patients were visited once every three 
days after enrolment resulting in a minimum of three visits during their stay. On the first 
and second visits LDF was performed with three flowflux and THR measurements being 
recorded. The third and any subsequent visits consisted of routine follow-up visits which 
ZHUHSHUIRUPHGLQRUGHUWRPRQLWRUWKHSDWLHQW¶VFOLQLFDOFRQGLWLRQDQGWRHQVXUHWKDWWKHUH
were no adverse events which occurred as a result of the study. No attempt was made to 
DOWHURULQWHUIHUHZLWKWKHSDWLHQW¶VFOLQLFDOPDQDJHPHQWGXULQJWKHSHULRGRIREVHUYDWLRQ  
 
Except where it was specifically refused during consent/assent iontophoresis of either 
norepinephrine or acetylcholine was performed on each visit after baseline flowflux and 
THR measurements had already been taken. Acetylcholine was chosen as one of the 
iontophoresed agents as its effects on the oropharyngeal mucosal microcirculation have 
previously been investigated in critically ill patients. Norepinephrine was chosen as a 
vasoconstricting agent as its effects had previously been investigated in healthy 
volunteers (see chapter 4). 
 
The order in which agents were iontophorsed into patients was done according to a 
predefined randomization template. Iontophoresis was performed according to the 
protocol laid out in chapter two and was followed by a further three flowflux and THR 
measurements. Skin temperature measurements were made using the LDF probes during 
each period of LDF recording. 
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Acetylcholine was iontophoresed using an anodal current (i.e. the iontophoresis chamber 
contained the anode), whilst norepinephrine was iontophoresed using a cathodal current. 
 
The following clinical data was collated regarding each patient: 
x Pre-morbid illnesses and medication use 
x Age and gender 
x Presumed diagnosis on ICU admission 
x ICU and hospital outcome 
x Clinical and laboratory data associated with each patient visit 
o The presence of SIRS criteria (including absolute white cell count) 
o APACHE II* and SOFA scores** 
o Cardiovascular status and level of inotropic support 
o Respiratory support 
o Renal support (either haemodialysis or continuous veno-venous 
haemofiltration, CVVH) 
o White cell count (WCC), and serum C-reactive protein (CRP) and lactate 
levels (from arterial blood samples) 
o Use of steroids or intravenous insulin 
 
*Acute physiology and chronic health evaluation score. An ICU severity of illness scoring 
system usually performed within the first 24 hours of admission (Knaus W et al, 1985). ± 
see appendix ii 
**Sequential organ failure assessment score. Previously known as: sepsis organ failure 









Of 42 patients who were identified as suitable for inclusion within the study, only 14 
patients or their relatives consented to take part. Of those who did not choose to take 
part, the majority either refused consent /assent, or were unable to give consent and had 
no relative available to provide assent. 2 patients agreed to take part but were not 
prepared to undergo iontophoresis of chemicals into the skin. Two patients who agreed to 
take part were unable to remain still for sufficiently long periods to allow flowflux and THR 
measurements to take place. 
 
Twelve patients had flowflux and THR measurements recorded, and nine patients went 
on to have a second set of flowflux and THR measurements. Of the remaining three 
patients two died prior to the second visit, and one patient withdrew from the study. Out of 
the twelve patients six were male, and the median age was 62 (range 23-70). The details 
of the gender, age, past medical history and pre-morbid drug history of all the patients can 
be found in table 5.1.  
 
All of the patients demonstrated evidence of SIRS at the time of the first set of flowflux 
and THR measurements. During the second set of measurements only patient 2 did not 
exhibit two or more symptoms of inflammation that define SIRS. Seven patients had 
evidence of positive microbiological samples at one or both visit, suggesting that the 
commonest cause of inflammation was sepsis. Six patients required inotropes, of which 
four also had confirmed bacteraemia, suggesting septic shock. The details of the 
presence or absence of the criteria for SIRS, sepsis and septic shock can be found in 
table 5.2. 
 
APACHE II scores ranged from 6 to 29 (first visit: median 12, mean 12.8; second visit: 
median 15, mean 15.7). SOFA scores ranged from 2 to 16 (first visit: median 5.5, mean 
6.5; second visit: median 5, mean 5.8). Serum CRP values were raised (>10 mg/L) in all 
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patients indicating the presence of inflammation; and serum lactate levels were raised (>2 
mmol/L) in four patients at each visit, suggesting organ hypoperfusion. The majority of 
patients had demonstrable evidence of pitting oedema to a greater or lesser degree 
suggesting an increased level of vascular permeability and/or fluid overload. Table 5.3 
contains details of individual APACHE II scores, SOFA scores, serum CRP and lactate 
levels, the presence of oedema, and whether or not patients were receiving renal 
replacement therapy, steroids or intravenous insulin. 
 





   Pre-morbid history Intensive Care  
Patient Sex Age Medical history Drug history Admission 
diagnosis 
Outcome 






Cardiac arrest Died in 
hospital 
2 F 68 Thyrotoxicosis 
Lymphoma 
Celecoxib Pneumonia Died in 
ICU 

















5 M 25 Smoking  Pneumonia Died in 
ICU 
6 F 54   Pneumonia Survived to 
discharge 







Pneumonia Survived to 
discharge 








Meningitis Died in 
hospital 
9 M 57   Pneumonia Survived to 
discharge 
10 M 23 Smoking  Pneumonia Survived to 
discharge 









12 M 67   Pneumonia Survived to 
discharge 
 
Table 5.1 Age, gender, past medical history and prior medication usage of patients 
*Chronic obstructive pulmonary disease (COPD) 
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 Visit 1 
 HR WCC Pyrexia Respiration Blood pressure  




1 110 10.0 * 32  140/85   
2 100 5.0 Yes  Yes 100/50 Dobutamine 
Norepinephrine 
Yes 
3 150 26.8 Yes  Yes 130/75   
4 168 25.9  16  90/70 Vasopressin  
5 120 24.4   Yes 120/80  Yes 
6 105 9.4 * 44  140/99 Dopamine  
7 80 20.1 Yes  Yes 150/60 Norepinephrine Yes 
8 115 11.2 Yes  Yes 150/75  Yes 
9 120 9.7  27  165/85   
10 100 23.1   Yes 120/55   
11 80 20.8 Yes  Yes 115/50 Norepinephrine Yes 
12 95 25.9 Yes  Yes 105/58 Norepinephrine  
 Visit 2 
1 110 9.2 Yes 20  160/90  Yes 
2 115 4.2  17  100/50 Dobutamine  
3 135 17.1 Yes  Yes 140/65  Yes 
4 110 35.4  15  100/60   
6 95 19.2 Yes  Yes 120/70  Yes 
7 100 17.6 Yes  Yes 110/55  Yes 
8 120 14.2 Yes 19  160/75  Yes 
10 120 26.0 Yes  Yes 125/54   
12 91 25.4 Yes 22  125/70   
 
Table 5.2 Evidence of SIRS, sepsis, or septic shock in patients on whom THR was 
measured; including during a second visit where appropriate. 
HR: heart rate, beats / minute; WCC: white cell count, cells x109/L; Pyrexia: temperature > 
38°C (*pyrexia not present at the time of THR measurement, but occurring within the 
preceding 24 hours); RR: respiratory rate, breaths / minute, in spontaneously breathing 
patients without assisted support other than PEEP; IPPV: intermittent positive pressure 
ventilation, including all forms or mandatory or assisted ventilation via an endotracheal or 
tracheostomy tube; BP: blood pressure, systolic / diastolic in mmHg; Positive cultures: 
microbial samples grown from blood or peritoneal fluid within the 24 hours prior to 
measurement of THR. 





 Visit 1 
 Organ failure 
scores 
   Patient receiving 
Patient APACHE II SOFA CRP Lactate Oedema RRT Steroids Insulin 
1 26 9 26 1.57 Present Yes   
2 11 16 52 4.90 Present Yes Yes Yes 
3 18 5 315 1.56 Present  Yes  
4 20 6 249 1.55 Present Yes Yes  
5 6 4  0.77     
6 13 6 221  Present    
7 16 10 391 4.89  Yes Yes Yes 
8 14 4 87 0.98 Present  Yes  
9 10 2 225 0.89   Yes  
10 6 5 66 4.55  Yes Yes Yes 
11 7 6  3.42 Present   Yes 
12 7 5 360 2.00 Present    
    Visit 2     
1 29 8 288 1.00 Present Yes   
2 18 13 38 3.65 Present  Yes  
3 16 5  1.49 Present  Yes  
4 15 5   Present Yes   
6 14 3 153 2.9 Present    
7 20 8 234 0.60  Yes Yes Yes 
8 12 3 36 3.12 Present  Yes  
10 10 5 35 3.24  Yes Yes Yes 
12 7 2  1.17 Present    
 
Table 5.3 Patient organ failure assessment scores, serum C-reactive protein (CRP) 
and lactate levels, the presence or absence of pitting oedema, and whether or not the 
patient was receiving renal replacement therapy (RRT), steroids or insulin at the time 
THR was measured; including during a second visit where appropriate. CRP is recorded 
in mg/L and serum lactate in mmol/L. 
Plasma CRP or lactate unavailable 
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Flowflux and THRR measurements 
Flowflux and THR measurements proved difficult to perform in some patients. Patients 
were sometimes unable to remain still for sufficiently long periods requiring multiple THR 
attempts to be made to achieve a recording in which there was no background 
interference from movement. Also the presence of a significant degree of tissue oedema 
meant that multiple THR manoeuvres had to be performed in order to ensure a biological 
zero with no demonstrable distal pulsatile blood flow (confirmed using pulse oximetry). In 
one patient flowflux measurements had to be abandoned after the iontophoresis of 
acetylcholine because of the onset of seizure activity. 
 
Skin temperature flowflux, LnTHRR and THR time measurements for each patient can be 
found in table 5.4. Only one patient had a skin temperature significantly outside the range 
accepted for laboratory studies of THR (patient 6 during the first visit: 24.4°C). Compared 
with the aggregate values from healthy volunteers measured using the standard LDF 
probe (see chapter 3) the mean values from patients in visits 1 and 2 demonstrated raised 
flowflux values and decreased LnTHRR values with a trend towards a decreased time 
over which the hyperaemic response was present (Figures 5.1 and 5.2). 
 
On closer examination only patients 6 and 12 during the first visit and patients 8 and 10 
during the second visit had flowflux values which were not significantly different from that 
of healthy volunteers. Patient 10 had values which were significantly lower than that of 
healthy volunteers during the first visit.  
 
Despite this, half of all LnTHRR measurements (10 of 21) were not significantly lower 
than those of the aggregate standard LDF probe group (discussed in chapter 3) when 
compared with ; with the same being true of THR time (12 of 21). Interestingly a 
decreased THR response was not always associated with a shortened THR time; and 




shortened THR times also occurred in patients with apparently normal THR 
measurements. 
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 Temperature Flowflux LnTHRR THR time 
 °C, (SD) (SD) P-value (SD) P-value Secs., (SD) P-value 
 
 
 Volunteers combined aggregate group (from chapter 3) 
 30.7 (0.9) 20.4 (11.8)  1.15 (0.44)  16.1 (0.72)  
 Combined means from patients during each visit 
Visit 1 30.6 (2.2) 78.87 (92.55) 0.05 0.78 (0.52) 0.028 12.4 (8.5) 0.180 
Visit 2 31.1 (1.2) 80.50 (78.70) 0.05 0.73 (0.48) 0.030 9.5 (6.7) 0.026 
Patient Individual patient values during visit 1 
1 28.9 (0.3) 38.25 (3.12) <0.001 1.65 (0.92) 0.245 23.0 (2.5) 0.523 
2 30.7 (0.2) 26.70 (2.19) <0.001 0.95 (0.28) 0.132 15.2 (5.8) 0.762 
3 31.9 (0.1) 320.22 (11.77) <0.001 0.00 (0.08) <0.001 4.4 (3.9) 0.001 
4 30.9 (0.1) 115.62 (15.82) <0.001 0.92 (0.23) 0.058 2.3 (0.5) <0.001 
5 30.1 (0.3) 202.80 (20.97) <0.001 0.21 (0.10) <0.001 2.80 (0.8) 0.014 
6 24.4 (1.6) 21.55 (14.07) 0.849 0.58 (0.39) 0.016 3.2 (2.4) <0.001 
7 30.9 (0.2) 56.35 (11.00) <0.001 0.65 (0.71) 0.148 3.7 (2.3) <0.001 
8 32.7 (0.1) 49.45 (0.49) <0.001 0.42 (0.26) 0.001 6.5 (0.9) 0.046 
9 30.5 (1.5) 38.05 (8.59) 0.004 1.36 (0.76) 0.535 14.6 (1.0) 0.757 
10 32.6 (0.2) 15.60 (0.33) <0.001 1.51 (0.52) 0.158 20.1 (3.9) 0.047 
11 31.7 (0.8) 27.75 (9.54) 0.038 0.49 (0.16) <0.001 12.8 (4.3) 0.049 
12 31.8 (0.4) 34.30 (20.66) 0.062 0.57 (0.18) <0.001 15.0 (6.0) 0.655 
 Individual patient values during visit 2 
1 29.7 (0.1) 45.40 (0.15) <0.001 1.12 (0.24) 0.835 18.7 (4.5) 0.389 
2 31.3 (0.1) 53.01 (2.57) <0.001 1.04 (0.47) 0.716 15.1 (3.6) 0.725 
3 32.7 (0.1) 230.56 (17.82) <0.001 0.05 (0.01) <0.001 7.9 (2.1) 0.020 
4 30.3 (0.1) 191.42 (13.46) <0.001 0.22 (0.37) 0.050 2.2 (0.9) <0.001 
6 29.3 (0.0) 48.88 (1.99) <0.001 1.21 (0.43) 0.828 2.7 (0.8) <0.001 
7 31.9 (0.0) 97.76 (5.16) <0.001 0.56 (0.23) 0.014 10.1 (0.9) 0.305 
8 30.8 (0.1) 17.50 (1.30) 0.080 0.29 (0.16) <0.001 0.8 (0.7) <0.001 
10 31.3 (0.0) 13.18 (3.69) 0.074 1.38 (0.44) 0.462 16.2 (0.9) 0.959 
12 32.3 (0.9) 28.82 (0.21) 0.004 0.69 (0.14) <0.001 14.5 (5.2) 0.425 
 
Table 5.4 Patient temperature, flowflux, LnTHRR, and THR times during both visits, 
as well as combined mean values from all patients at both visits. P-values refer to 
independent samples t-test when compared with Aggregate standard LDF probe group 
(discussed in chapter 3), with equal variance not assumed 






Figure 5.1 Graph of mean LnTHRR of all patients during visit 1 and visit 2 compared 
with mean LnTHRR value derived from the Aggregate standard LDF probe group 




Figure 5.2 Graph of mean THR time of all patients during visit 1 and visit 2 
compared with mean THR time value derived from the Aggregate standard LDF probe 
group (discussed in chapter 3). Error bars represent 95% confidence intervals. 
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Flowflux and THR measurements after iontophoresis 
The values for flowflux, LnTHRR and duration of THR in patients before and after the 
iontophoresis of both norepinephrine and acetylcholine can be found in table 5.5. The 
mean overall changes associated with iontophoresis of both drugs compared with the 
means from the aggregate group of healthy volunteers using LDF needle-probes can be 
seen in figure 5.3. 
 
In those patients in whom iontophoresis of norepinephrine was performed there was no 
statistically significant decrease in flowflux, LnTHRR or duration of THR (respective P-
values 0.627, 0.282, 0.334; independent t-test with equal variances not assumed). Only 
patients 1, 3 and 10 showed a reduction of flowflux from baseline of more than 30%. 
 
Whilst it was not statistically significant overall the iontophoresis of norepinephrine 
appeared to be associated with an increase in LnTHRR in most patients, though not all, 
and there was no clear association between the degree of change in flowflux and the 
changes in LnTHRR. 
 
Although the iontophoresis of acetylcholine appeared to be associated with an increase in 
flowflux and a decrease in LnTHRR and duration of THR the mean changes overall were 
not statistically significant (respective P-values 0.159, 0.278, 0.394; independent t-test 
with equal variances not assumed). 
 
In patients who already appeared to have raised flowflux the iontophoresis of 
acetylcholine still appeared to induce further vasodilatation. Both the LnTHRR and the 
THR time appeared to decrease in patients where it had been normal beforehand 
(patients 1, 2, 9 and 10), but remained relatively unchanged in cases where it had already 
been low prior to iontophoresis (patients patients 3,4,5 and 7). 
 




In one case, patient 6, flowflux, LnTHRR and duration of THR all appeared to change in 
the opposite direction to what would normally be expected. 
 
The individual changes in mean flowflux and LnTHRR before and after the iontophoresis 
of acetylcholine and norepinephrine can be seen in Figure 5.4. 
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Healthy volunteers 10.35 (6.64) 1.06 (0.46) 16.1 (12.15) 
  Patients undergoing norepinephrine iontophoresis 
Patient Before After Before After Before After 
        
1 Visit 2 10.00 6.70 1.12 (0.24) 0.98 (0.39) 18.7 (4.5) 3.2 (3.1) 
2 Visit 2 12.29 9.8 1.04 (0.47) 1.35 (0.41) 15.1 (3.6) 17.6 (1.1) 
3 Visit 1 100.63 54.7 0.05 (0.06) 0.41 (0.29) 6.0 (5.1) 6.1 (1.2) 
4 Visit 1 21.91 26.5 0.84 (0.12) 0.84 (0.58) 2.1 (0.5) 2.8 (1.9) 
6 Visit 2 8.48 7.3 1.21 (0.43) 2.40 (0.62) 2.7 (0.8) 2.8 (0.9) 
7 Visit 1 9.80 9.0 1.24 (0.48) 1.81 (1.25) 5.7 (1.1) 3.2 (1.7) 
8 Visit 1 10.10 12.8 0.41 (0.23) 1.34 (0.83) 1.6 (0.2) 3.8 (2.4) 
10 Visit 1 8.22 3.3 1.64 (0.77) 0.95 (0.55) 20.7 (5.7) 6.6 (2.2) 




0.94 (0.50) 1.26 (0.62) 9.1 (7.8) 5.8 (5.0) 
  
 
  Patients undergoing acetylcholine iontophoresis 
Patient Before After Before After Before After 
        
1 Visit 1 10.0 6.7 2.93 (0.56) 1.20 (0.58) 7.1 (26.1) 10.9 (8.0) 
2 Visit 1 6.66 68.7 1.09 (0.02) 0.24 (0.03) 12.8 (3.8) 8.0 (7.9) 
3 Visit 2 76.4 103.6 0.05 (0.01) 0.08 (0.01) 7.9 (2.1) 1.7 (3.0) 
4 Visit 2 19.1 28.1 0.37 (0.22) 0.31 (0.43) 2.2 (0.9) 1.8 (1.9) 
5 Visit 1 7.3 84.1 0.15 (0.09) 0.10 (0.01) 0.3 (0.1) 0 
6 Visit 1 28.7 26.2 0.38 (0.36) 1.32 (0.48) 2.0 (1.7) 5.7 (3.5) 
7 Visit 2 21.3 35.9 0.56 (0.23) 0.41 (0.12) 10.1 (9.4) 10.1 (7.5) 
9 Visit 1 16.0 10.9 1.52 (0.81) 0.84 (0.66) 23.1 (3.9) 8.6 (9.7) 
10 Visit 2 6.0 12.6 1.38 (0.44) 0.43 (0.22) 16.2 (9.7) 12.1 (11.3) 




0.94 (0.91) 0.55 (0.46) 9.0 (7.4) 6.5 (4.4) 
 
Table 5.5 Patient, flowflux, LnTHRR, and THR times before and after the 
iontophoresis of norepinephrine and acetylcholine combined mean values from all 
patients before and after iontophoresis. Results from the Aggregate group of healthy 
volunteers performed using a needle-probe LDF (see chapter 3) are included for 
comparison.







Figure 5.3 Graphs of mean flowflux, LnTHRR and THR time in patients before and 
after iontophoresis of norepinephrine or acetylcholine. Means from the Aggregate group 
of healthy volunteers using LDF needle-probes (see chapter 3) included for comparison. 
Error bars represent 95% confidence intervals. 
SIRS Group One denotes all those patients who were exposed to noepinephrine and 
SIRS Group Two denotes all those patients exposed to acetylcholine.







Figure 5.4 Individual changes in mean flowflux and LnTHRR before and after the 
iontophoresis of acetylcholine and norepinephrine 




Vascular reactivity and outcome 
 
Although eleven out of the twelve patients presented here were suspected of having 
sepsis on admission to the ICU (the remaining patient having been admitted following a 
cardiac arrest), only 7 patients were proven to have sepsis. In total 6 patients died, of 
whom 5 were proven to have had sepsis during their ICU stay. Those patients with sepsis 
all had raised flowflux measurements except one in whom flowflux was abnormally low. 
 
There was no obvious relationship in this small study between the transient hyperaemic 
response and the presence of sepsis or eventual survival (table 5.6). Nor was there any 
clear relationship between organ failure scores, or CRP, and flowflux or THR 
measurements.  
 
The responses to norepinephrine and acetylcholine were mixed and appeared unrelated 
to outcome (table 5.6). Overall the introduction of norepinephrine and acetylcholine did 
not alter flowflux, THR, or THR time.  
 
Iontophoresis only produced a dramatic decrease in flowflux in one individual, in whom 
flowflux was high before-hand and in this individual the hyperaemic response was partially 
restored. Acetylcholine failed to cause a vasodilatory effect on flowflux in 3 patients. 
Where the hyperaemic response was low beforehand the introduction of acetylcholine 
made no difference; where it was normal beforehand acetylcholine resulted in a reduction 
in THR. 





Visit 1 Visit 2 Outcome 
 Flowflux LnTHRR Flowflux LnTHRR  
1 Yes Increased Normal Increased Normal Died 
2 Yes Increased Normal Increased Normal Died 
3 Yes Increased* Decreased* Increased* Decreased* Survived 
4 No Increased* Normal Increased* Decreased* Died 
5 Yes Increased* Decreased*   Died 
6 No Normal Decreased Increased Normal Survived 
7 Yes Increased Normal Increased* Decreased Survived 
8 Yes Increased Decreased Normal Decreased Died 
9 No Increased Normal   Survived 
10 No Normal Normal Normal Normal Survived 
11 Yes Decreased Decreased   Died 
12 No Normal Decreased Increased Decreased Survived 
       
  LnTHRR response to 
norepinephrine 
LnTHRR response to 
acetylcholine 
 
1 Yes Unchanged Decreased Died 
2 Yes Unchanged Decreased Died 
3 Yes Increased Unchanged Survived 
4 No Unchanged Unchanged Died 
5 Yes  Unchanged Died 
6 No Unchanged Unchanged Survived 
7 Yes Unchanged Unchanged Survived 
8 Yes Unchanged  Died 
9 No  Unchanged Survived 
10 No Unchanged Decreased Survived 
 
Table 5.6  Flowflux and LnTHRR measurements when compared with healthy 
volunteers tabulated alongside proven evidence of sepsis and survival status at the time 
of hospital discharge; and statistically significant changes in LnTHRR response to 
iontophoresed norepinephrine and acetylcholine 
*Indicates a greater increase or decrease from normal: flowflux >75 or LnTHRR <0.25 





Flowmetry measurements proved difficult to obtain during this study. Laser Doppler 
flowmetry is not well suited for use in critically ill patients because of the requirement for 
patients to avoid voluntary movements even for relatively short periods. This is clearly 
less of an issue for heavily sedated or paralysed patients, but even in such cases the 
presence of tissue oedema, where it occurs, is likely to make the THR measurements 
more difficult and potentially less reliable. The potential advantages of LDF, that it only 
requires access to skin, is portable and relatively non-invasive, are offset by these factors. 
 
Despite these limitations this study demonstrated that overall skin flowflux measurements 
were raised in patients with evidence of SIRS compared with healthy volunteers. The 
transient hyperaemic response was also diminished in these patients as a whole.  
 
A previous study performed in septic patients found that reactive hyperaemia provoked by 
prolonged ischaemia was not diminished in the early stages but only decreased when 
multiple organ failure ensued, even though adequate oxygenation and blood pressure 
were sustained through interventions (Hartl WH et al, 1988). In the study by Hartl 7 of the 
9 patients with diminished vascular reactivity died. Within this study 8 patients 
demonstrated decreased transient hyperaemic responses, of whom half survived. Two 
patients in whom flowflux was raised but who had normal hyperaemic responses also 
died; and in these patients (and one other with a normal THR response) SOFA scores 
were relatively high (>8) indicating at least dual organ dysfunction. 
 
Near-infrared spectroscopy has previously demonstrated that thenar muscle 
deoxygenation is significantly slower in patients with septic shock, and that the rate of 
decrease is closely related to organ failure as determined by the sequential organ failure 
assessment (SOFA) score. (Pareånik R et al, 2006). In contrast, in sepsis without shock a 
more rapid decline in deoxygenation was found. This has been interpreted as 
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mitochondrial respiration becoming dormant in the presence of septic shock (Singer M et 
al, 2004).  
 
It is clear that SIRS is an imprecise definition and that sepsis is a complex entity, with 
different patterns of infection and inflammation being associated with different outcomes 
(Vincent J-L, 1997; Bossink AWJ et al, 1998; Knaus WA et al, 1992). It is probable that 
wide variations in vascular reactivity also occur, even amongst haemodynamically stable 
patients. Small studies such as this, and previous studies which have examined the 
microcirculation in critically ill patients, might be expected to identify a variety of 
responses. 
 
Whilst the intention of this study was to recruit patients with evidence of SIRS, only seven 
patients had evidence of sepsis; and only three could be classified as having septic shock 
(albeit treated with vasopressors). With this in mind one of the most surprising results 
from this study was that the iontophoresis of acetylcholine did not result in an increase in 
flowflux caused by vasodilatation. Previous studies involving the effects of acetylcholine 
on the sublingual vessels of septic patients have demonstrated a preserved response 
(Rennie M, 2007; De Backer D, Creteur J et al, 2002). In another study by Kubli et al, 
2003, the cutaneous responses to iontophoresed acetylcholine and sodium nitroprusside 
were preserved, but greatly diminished compared to healthy controls and a second 
control group of non-septic ICU patients. The effects of acetylcholine were also 
diminished, but to a lesser extent, in non-septic controls. 
 
The iontophoresis protocol used by Kubli et al was different from that used in this study; in 
this study an iontophoresis pattern specifically designed to minimize current-induced 
vasodilatatioQZDVXVHGZKLOVWLQ.XEOLHWDO¶VVWXG\WRSLFDOORFDODQDHVWKHVLDZDVDSSOLHG
to achieve the same effect. It is possible that our iontophoresis protocol was simply less 
effective in septic patients, or, less likely, that the topical anaesthesia did not have the 




GHVLUHG HIIHFW RQ VHSWLF SDWLHQWV LQ .XEOL HW DO¶V VWXG\ 6RPH ORFDO DQDHVWKHWLF FUHDPV
have previously been shown to increase flowflux and decrease THRR measurements 
(Wiles MD et al, 2008). 
 
The tissue oedema commonly present in treated critically ill patients might be expected to 
reduce the efficacy of drug iontophoresis. Although there was no obvious association 
between the subjective assessment that tissue oedema was present and changes in 
flowflux associated with acetylcholine, this remains a possibility. Oedema has also been 
reported as increasing the biological zero seen using laser Doppler flowmetry (Wahlberg 
E et al, 1992). Since THRR is calculated after the removal of biological zero this effect is 
unlikely to have altered the results found within this study. 
 
Within this study there was no clear relationship between the need for inotropic infusions 
and vascular reactivity as assessed by the THRR. Iontophoresed norepinephrine only 
caused a statistically significant increase in the transient hyperaemic response in one 
patient. In a study by Keinbaum et al, 2008, forearm vascular resistance was increased by 
phenylephrine in patients with septic shock, but to a much lesser extent than in healthy 
volunteers. This would be consistent with the findings in our study and would suggest that 
patients were either already exposed to a sufficiently large dose of systemic or 
endogenous catecholamines, or had already developed a degree of resistance to 
norepinephrine, such that the dose of iontophoresed norepinephrine was insufficient to 
cause further vasoconstriction. 
 
In conclusion it would appear that the transient hyperaemic response is much harder to 
perform and interpret when used within the ICU environment than was anticipated. An 
overall increase in flowflux was demonstrated, as had been predicted in other similar 
studies, and THRR was found to be reduced. No overall change in THRR could be 
demonstrated after the iontophoresis of norepinephrine or acetylcholine. 











The effects of the prior administration of statins and 
cardiovascular medications in critically ill patients 
 
Introduction 
Previous studies within the thesis have concentrated on the application of the transient 
hyperaemic response in volunteers and patients with a view to further understanding its 
potential to investigate the microcirculatory changes associated with critical illness and 
sepsis. In the last study the difficulties in applying the THR to patients with evidence of 
SIRS were exposed. With this in mind it was decided to attempt to identify other agents 
with known cardiovascular actions, or speculated to have cardiovascular actions, which 
may alter vascular reactivity in sepsis; in particular agents which can be, in the first 
instance, administered safely, via ingestion, to volunteers in whom vascular reactivity can 
be measured. NSAIDs have previously been investigated in this regard (Moppett IK, 
Davies JA et al, 2003), but their effects in critical illness are far from certain (Bernard GR, 
Wheeler AP et al, 1997; Winning J et al, 2010; Mahajan RP et al, 2010). 
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Statins (HMG CoA reductase inhibitors) are currently being investigated to evaluate their 
effects in a wide range of illnesses. They are widely-used well tolerated drugs which are 
taken orally. Although side-effects with statins are rare, their safety record is such that 
changing their status from a prescription-only medication to an over-the-counter 
medication has even been considered (MHRA 2004;Strom BL, 2005). For these reasons 
this study attempts to better define the effects of prior statin usage on the outcomes of 
critically ill patients within intensive care, including survival and cardiovascular status 
immediately after admission to the ICU. 
 
Statins are widely used in the treatment of hypercholesterolaemia and the prevention of 
ischaemic heart disease, but are suspected of having clinically useful therapeutic effects 
independent of their accepted lipid-lowering effects. These "pleiotropic" actions may 
include immunomodulatory, anti-inflammatory, and antithrombotic properties, as well as 
vascular endothelial effects (Almog Y, 2003; Mekntso-Dessap A, 2006). The effects of 
statins on a wide range of disease processes are currently being investigated (Bonovas S 
et al, 2006; Marti-Fàbregas J, 2004; Glynn RJ, 2009). 
 
Two groups of patients of particular interest to intensive care practitioners are those with 
infections and those patients undergoing major surgery. Previous studies have suggested 
that statins may improve survival in patients with bacteraemia and may decrease the 
likelihood of their progression to develop sepsis or need intensive care unit (ICU) 
treatment (Liappis AP et al, 2001; Almog Y et al, 2004; Kruger P et al, 2006; Falagas ME 
et al, 2008). Studies have also suggested that statins may also reduce the morbidity and 
mortality associated with major cardiac and non-cardiac elective surgery (Clark LL et al, 
2006; 3ROGHUPDQV ' HW DO  2¶1HLO-Callahan K et al, 2005; Lindenauer PK et al, 
2004). 
 




Few studies have specifically examined the effects of prior statin use on critically ill 
patients already requiring ICU, and from those that have there have been mixed results 
(Fernandez R et al, 2006; Schmidt H et al, 2006). By collecting data on patients admitted 
to ICU with a presumed diagnosis of sepsis, or as a planned admission following major 
elective surgery, and retrospectively identifying those who had been taking statins prior to 
their admission to hospital, we aimed to examine in a pragmatic manner whether or not 
statins had been responsible for any measurable differences in outcome. 
 
As statin use is strongly associated with the presence of patient co-morbidities other than 
hypercholesterolaemia, and with concomitant use of other medications with 
cardiovascular effects, we attempted to control for the presence of these factors. We also 
attempted to examine individual statins to ensure that any effect seen was a class-effect 
true of all statins. 
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Methods 
After obtaining approval from the local ethics committee we retrospectively identified all 
adult patients admitted to one of two teaching hospital intensive care units (City Hospital 
or Queens Medical Centre, Nottingham, UK) with either a presumed diagnosis of sepsis, 
or as a planned admission following major elective surgery. Patients were identified 
between January 2000 and September 2005 using a combination of four continually 
maintained databases. The first two databases were local APACHE II databases 
supported run in conjunction with the Intensive Care National Audit and Research Centre 
(ICNARC) with data input by the data-clerks on both ICUs; the other two databases were 
internally designed Microsoft Access databases, one designed to capture ICU data input 
by nursing staff for the Critical Care Minimum Dataset (CCMDS), and the other designed 
and maintained by the local microbiology departments as a means of recording positive 
microbiology results. The ICNARC data contains information about all ICU admissions 
including the basic demographics, admission and discharge dates, and admitting 
diagnosis, as well as the information regarding the status of the patient during the first 24 
hours of ICU admission required to calculate APACHE II scores (see appendix ii). The 
CCMDS data (DoH DSCN 02, 2005) was used to identify all planned and unplanned 
admissions to the ICU as well as the source of those admissions (i.e. theatre recovery, 
ward, etc), the level of care required once admitted to the ICU, and length of stay. 
CCMDS data was used to cross-check and ensure that no admissions were missed. 
Critically CCMDS data does not carry any information about admission diagnoses and so 
where there was any doubt as to whether the patient had either a presumed diagnosis of 
sepsis, or was a planned admission following major elective surgery, WKHSDWLHQW¶VQRWHs 
were analysed. The microbiology database only contained details about positive 
microbiology results and was used to ensure that no patients with a presumed diagnosis 
of sepsis were missed. In all cases where it was felt that patients were likely to fulfil the 
inclusion criteria a retrospective casenote analysis was performed. 
 




Of the post-operative cohort only patients where ICU admission was planned prior to 
surgery were included. Patients whose admission was a result of surgical or anaesthetic 
complications, or where surgery was performed semi-electively or as an emergency (for 
example, surgery for abscess drainage or perforated viscus) were specifically excluded. 
 
Where patients with sepsis were re-admitted to intensive care within thirty days of 
discharge, only the first admission was counted. Patients who had no evidence of sepsis 
on admission but who developed sepsis during their ICU stay were not included. Patients 
were also excluded where casenotes were unavailable or incomplete. 
 
Casenotes were reviewed in order to confirm the cause of admission, and identify any 
evidence of pre-existing chronic disease and prescribed medication usage prior to 
hospital admission. Statin usage was recorded along with other cardiovascularly active 
medications, including angiotensin converting enzyme inhibitors (ACEi), angiotensin 
receptor antagonists (ARAs), long-acting nitrates, beta-blockers, and calcium channel 
antagonists. It was not possible to identify the indication, dosing, length of use, or 
compliance associated with any individual medication; nor was it possible to determine 
the efficacy of pre-admission medication usage, and where statins were prescribed recent 
lipid levels were only rarely available. 
 
Patients were defined as having a significant co-morbidity if it was recorded in the notes 
as being part of the patients past medical history on admission to hospital or on admission 
to intensive care. Those co-morbidities recorded included ischaemic heart disease (any 
history of angina, heart failure, previous myocardial infarctions or ischaemic heart 
disease), other vascular disease (including cerebrovascular disease and peripheral 
vascular disease), diabetes (both non-insulin dependent and insulin-dependent diabetes), 
and chronic renal insufficiency (including all patients with a history of chronic kidney 
disease of stage 3 or worse). 
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The primary outcome measured was survival to hospital discharge. Secondary outcomes 
included survival to ICU discharge, length of ICU stay, presence of 3 or more systemic 
inflammatory response syndrome (SIRS) criteria, and evidence of cardiovascular 
instability within the first 24 hours of admission. 
 
Univariate analysis was used to compare the two groups of prior statin usage and no-prior 
statin usage. After testing for multi-collinearity, multivariate logistic regression was also 
performed to calculate odds ratios adjusted for age, gender, APACHE II score at 
presentation, presence of pre-morbid diabetes or cardiovascular illness, and pre-morbid 
use of other cardiovascularly active medications (as defined above). Logistic regression 
was performed for: any statin usage, simvastatin usage, atorvastatin usage, and other 
statin usage (i.e. not simvastatin or atorvastatin). All analyses were carried out using 
SPSS version 14. 
 
Logistic regression was also applied to four pre-defined subgroups: patients with 
presumed sepsis and proven bacteraemia at the time of admission, patients with 
presumed sepsis and shock at the time of admission (defined as a systolic blood pressure 
< 90 mmHg or already on inotropes), elective patients having undergone an 
oesophagectomy, and elective patients prescribed inotropes within 24 hours of admission 
to ICU. 





Over 1100 patients were identified, of whom only 15 had casenotes which were 
incomplete or unavailable for review. 414 patients had a presumed diagnosis of sepsis 
and 672 were planned admissions following elective major surgery. The overall mean age 
was 62 years old; and in total 138 patients (12.7%) were prescribed statins prior to their 
admission to hospital. The most commonly prescribed statins were simvastatin (43% of all 
statins prescribed), atorvastatin (38%), pravastatin (10%), and fluvastatin (7%). Only two 
patients were prescribed rosuvastatin and one was prescribed cerivastatin (prior to the 
drug being withdrawn by the manufacturers). The relative distribution of statins was the 
same in both post-operative patients and those presumed to have sepsis. Only one 
patient was identified as having been prescribed a non-statin cholesterol lowering drug 
(bezafibrate).  
 
For both elective and emergency admissions statins were discontinued at least during the 
first part of any ICU stay, and often for the duration of stay. This probably reflects the 
difficulty of administering statin therapy to patients who are kept nil-by-mouth, or who are 
fed enterally using naso-gastric tubes. 
 
In both cohorts those patients taking statins were on average 6-10 years older, had 
marginally higher APACHE II scores, and were more likely to have a history of ischaemic 
heart disease, vascular disease, or diabetes (tables 6.1 and 6.2). Statins users were also 
more likely to have been prescribed other cardiovascularly active medications. There 
were proportionally more male patients prescribed statins within the post-operative group, 
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Patients presumed to have sepsis 
The two most common sources of presumed sepsis were peritonitis and pneumonia. 
There were no statistically significant differences in the proportion of statin prescribing in 
patients presenting to ICU with peritonitis or pneumonia, or where patients were shocked 
or found to have a proven bacteraemia at the time of admission (table 6.1). 
 
Univariate analyses revealed no outcome differences associated with prior statin use in 
terms of ICU mortality, hospital mortality, or length of ICU stay (table 6.3). Statin usage 
was also not associated with an increased likelihood of presenting to ICU in shock, with 
any increased prescription of inotropes within the first 24 hours of admission, or with an 
increased likelihood of three or more SIRS criteria being present at admission. 
 
Where individual types of statin were analysed simvastatin was associated with a higher 
ICU mortality (p = 0.018) and hospital mortality (p = 0.030). This association was not true 
of atorvastatin or other statins, although the absolute number of patients prescribed other 
statins was very small. Comparing outcome over time using composite endpoint of 
survival or discharge from hospital at 160 days demonstrates a trend for simvastatin to be 
associated with worse outcomes whilst atovastatin is associated with better outcomes 
(figure 6.1).  
 
Using multivariate binomial regression, no medication use, including statins, was 
independently associated with increased mortality (table 6.5). This was also true when 
multivariate analysis was applied to ICU mortality, with the exception of simvastatin (odds 
ratio 3.15; confidence intervals 1.03-9.65; p =0.044). As expected, a significant 
association existed between hospital mortality and age or APACHE II score at 
presentation. 
 




No association between hospital mortality and statin usage of any type was identified 
when multivariate analysis was applied to the subset of patients with proven bacteraemia 
at the time of admission, although the small numbers of patients resulted in very large 
confidence intervals (table 6.6). In the subgroup of patients presenting with shock, 
simvastatin usage, but not usage of other statins, was again associated with increased 
mortality (p =0.039). 
 
Post-operative patients 
The most common procedures requiring elective ICU admission were oesophageal 
resection, hepato-biliary / pancreatic, vascular, and neurosurgical operations. A 
statistically significant number of patients undergoing vascular surgery were prescribed 
statins prior to their surgery; this was not true of other procedures (table 6.2). 
 
Univariate analysis revealed statistically significant associations between prior statin 
usage and the likelihood of dying whilst on ICU (though not whilst in hospital), and also 
receiving inotropes within the first 24 hours of ICU admission (table 6.4). Where statins 
were examined individually only simvastatin had a statistically significant association with 
ICU mortality (p =0.048); and a graph of outcome over time using composite endpoint of 
survival or discharge from hospital at 160 days demonstrates a trend for simvastatin to be 
associated with worse outcomes (figure 6.2) This association was not statistically 
significant when multivariate analysis was used (odds ratio 1.51; confidence intervals 
0.30-7.68; p =0.618). 
 
Multivariate analysis of hospital survival identified the significance of age and APACHE II 
score; neurosurgical procedures were also strongly associated with hospital mortality 
(table 6.5). Pre-existing co-morbidities and prior medication use, including statin usage, 
were not associated with altered mortality. This was also true when multivariate analyses 
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were applied to the subgroups of patients who had undergone oesophageal resection or 
who had received inotropes within the first 24 hours of ICU admission (table 6.6). 





 Patients with presumed sepsis, n=414 





Age, mean (SD)  60.0 (16.8)  69.6 (8.1) <0.005 
Male gender, n (%)  199 (54.7)  28 (56.0) 0.881 
APACHE II score, mean (SD)  21.6 (8.1)  23.3 (8.6) 0.168 
Other co-morbidities and medication usage   
Ischaemic heart disease, n (%)  44 (12.1)  24 (48.0) <0.005 
Other vascular disease, n (%)  26 (7.1)  15 (30.0) <0.005 
Diabetes, n (%)  26 (7.1)  20 (40.0) <0.005 
Chronic kidney disease, n (%)  20 (5.5)  6 (12) 0.11 
ACE inhibitors / ARAs, n (%)  38 (10.4)  22 (44.0) <0.005 
Ca2+ channel antagonists, n (%)  23 (6.3)  16 (32) <0.005 
Beta-blockers, n (%)  32 (8.8)  13 (26) 0.001 
Nitrates, n (%)  5 (1.4)  6 (12.0) 0.001 
Suspected site of sepsis & presenting features   
Pneumonia, n (%)  106 (29.1)  12 (24.0) 0.508 
Peritonitis, n (%)  128 (35.2)  22 (44.0) 0.272 
Bacteraemia, n (%)  100 (27.5)  14 (28.0) 1.000 
Shock, n (%)  326 (89.6)  43 (86.0) 0.466 
Type of statin    
Simvastatin, n (%)   23 (46.0)  
Atorvastatin, n (%)   22 (44.0)  
Other statin, n (%)   5 (10.0)  
 
Table 6.1 Characteristics of patients admitted with a presumed diagnosis of sepsis 
stratified by prior statin usage. *P-values are for independent t-test results for means, or 
chi-squared tests for categorical data. 




 Post-operative patients, n=672 





Age, mean (SD)  61.6 (15.6)  67.7 (13.1) 0.001 
Male gender, n (%)  366 (62.7)  66 (75.0) 0.024 
APACHE II score, mean (SD)  13.2 (5.1)  14.5 (6.4) 0.029 
Other co-morbidities and medication usage   
Ischaemic heart disease, n (%)  56 (9.6)  53 (60.2) <0.005 
Other vascular disease, n (%)  65 (11.1)  33 (37.5) <0.005 
Diabetes, n (%)  33 (5.7)  22 (25) <0.005 
Chronic kidney disease, n (%)  11 (2.8)**  1 (1.8)** 1.000 
ACE inhibitors / ARAs, n (%)  57 (9.8)  41 (46.6) <0.005 
Ca2+ channel antagonists, n (%)  58 (9.9)  17 (19.3) 0.017 
Beta-blockers, n (%)  72 (12.3)  31.8) <0.005 
Nitrates, n (%)  10 (1.7)  10 (11.4) <0.005 
Type of surgery    
Oesophagectomy, n (%)  210 (36.0)  28 (31.8) 0.476 
Hepato-biliary/pancreatic, n (%)  66 (11.3)  6 (6.8) 0.267 
Vascular  44 (7.5)  24 (27.3) <0.005 
Neurosurgery  33 (5.7)  2 (2.3) 0.299 
Type of statin     
Simvastatin, n (%)   37 (42.0)  
Atorvastatin, n (%)   30 (34.1)  
Other statin, n (%)   21 (23.9)  
 
Table 6.2 Characteristics of patients having planned ICU admission after major 
elective surgery stratified by prior statin usage. *P-values are for independent t-test 
results for means, or chi-squared tests for categorical data.  
**Incomplete dataset, denominator changed: no prior statin usage, n=392; prior statin 
usage, n=55 





 Patients with presumed sepsis, n=414 






Died in ICU, n (%)  159 (43.7)  24 (48) 0.649 
Died in hospital, n (%)  197 (54.6)  29 (58.0) 0.762 
Median ICU stay, days (range)  4 (1-31)  3 (1-31) 0.203 
Presenting in shock, n (%)  326 (89.6)  43 (86.0) 0.466 
Inotropes prescribed within 
24hours of admission, n (%) 
 293 (80.9)  40 (80.0) 0.849 
Presence of SIRS criteria**, n (%)  321 (90.7)  44 (89.8) 0.503 
 
Table 6.3 Crude outcome data for patients presumed to have sepsis, stratified by 
prior statin usage. *P-values are for chi-squared tests except length of ICU stay where 
Mann-Whitney U-test was used 
0RGLILHG6,56FULWHULDYDULDEOHVZDVXVHG 
 
 Post-operative patients, n=672 






Died in ICU, n (%)  20 (3.4)  8 (9.1) 0.021 
Died in hospital, n (%)  53 (9.1)  13 (14.8) 0.121 
Median ICU stay, days (range)  2 (0-30)  2 (1-20) 0.517 
Inotropes prescribed within 
24hours of admission, n (%) 
 221 (37.9)  47 (53.4) 0.007Á 
Presence of SIRS criteria**, n (%)  276 (49.2)  40 (45.5) 0.567 
 
Table 6.4 Crude outcome data for patients having planned ICU admission after 
major elective surgery, stratified by prior statin usage. *P-values are for chi-squared tests 
except length of ICU stay where Mann-Whitney U-test was used 
0RGLILHG6,56FULWHULDYDULDEOHVZDVXVHG 
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Hospital mortality for all patients 











Age 1.03 (1.01-1.04) <0.005 1.05 (1.02-1.08) 0.001 
Male gender 1.04 (0.67-1.61) 0.877 1.29 (0.70-2.41) 0.415 
APACHE II score 1.09 (1.06-1.13) <0.005 1.16 (1.10-1.08) <0.005 
Other co-morbidities and medication usage    
Ischaemic heart disease 1.37 (0.68-2.75) 0.379 0.93 (0.39-2.24) 0.877 
Other vascular disease 0.92 (0.43-1.95) 0.818 1.16 (0.52-2.57) 0.719 
Diabetes 0.55 (0.25-1.21) 0.138 0.93 (0.39-2.24) 0.876 
Chronic kidney disease 2.59 (0.94-7.08) 0.064 *  
ACE inhibitors / ARAs 0.73 (0.37-1.46) 0.375 1.32 (0.61-2.87) 0.482 
Ca2+ channel antagonists 0.91 (0.41-2.02) 0.816 0.73 (0.31-1.70) 0.467 
Beta-blockers 1.02 (0.49-2.11) 0.957 0.60 (0.27-1.35) 0.218 
Nitrates 2.23 (0.39-12.90) 0.371 1.90 (0.48-7.52) 0.359 
Type of surgery     
Oesophagectomy   1.18 (0.57-2.43) 0.658 
Hepato-biliary / pancreatic   1.66 (0.64-4.27) 0.296 
Vascular   0.64 (0.22-1.84) 0.403 
Neurosurgery   6.95 (2.29-
21.15) 
0.001 
Statin usage     
Any statin 0.88 (0.40-1.94) 0.755 1.28 (0.53-3.11) 0.579 
Simvastatin 2.29 (0.71-7.40) 0.167 1.88 (0.63-5.67) 0.261 
Atorvastatin 0.43 (0.15-1.30) 0.135 0.97 (0.24-4.01) 0.966 
Other statins 0.38 (0.05-2.90) 0.352 0.82 (0.17-3.90) 0.807 
 
Table 6.5 Adjusted odds ratio for patients presumed to have sepsis and post-
operative patients 
*Chronic kidney disease patients excluded due to incomplete dataset. Calculated crude 
odds ratio for chronic kidney disease was: OR 2.03, CI0.43-9.60, p=0.371 
All variables were tested to ensure tolerance of any multicollinearity





Hospital mortality for patients prescribed inotropes within 24 hours of admission 
 Patients with presumed sepsis, 
n=369 
Post-operative patients,  
n=268 
Simvastatin 4.49 (1.08-18.70); n=20 0.039 0.59 (0.12-2.90); n=22 0.518 
Atorvastatin 0.36 (0.10-1.28); n=19 0.116 0.82 (0.16-4.23); n=14 0.808 
Other statins 0.51 (0.06-4.41); n=4 0.537 0.36 (0.04-3.03); n=11 0.348 
     
Hospital mortality for patients with proven bacteraemia 
 Patients with presumed sepsis, n=144  
Simvastatin 4.16 (0.15-113.04); n=6 0.397   
Atorvastatin 5.06 (0.36-70.88); n=6 0.229   
Other statins 1.70 (0.00-1371.87); n=2 0.876   
 
Table 6.6 Adjusted odds ratio data for type of statin in patients presumed to have 
sepsis and in post-operative patients; within the subgroups of patients who required 
inotropes within 24 hours of admission, or who had proven bacteraemia. All variables 
were tested to ensure tolerance of any multicollinearity  
*Chronic kidney disease patients excluded due to incomplete dataset. Calculated crude 
odds ratio for chronic kidney disease was: OR 2.03, CI0.43-9.60, p=0.371 



































Figure 6.1 Crude 160 day survival curves for all patients with presumed sepsis, 
stratified by statin usage 





































Figure 6.2 Crude 160 day survival curves for all post-operative patients, stratified by 
statin usage 
P a g e  | 160        Chapter six 
 
Discussion 
Previous studies have suggested potentially beneficial effects of statins in patients with 
bacteraemia or who have undergone major surgery. In patients with bacteraemia several 
studies have suggested that prior statin therapy protects against progression to severe 
sepsis and the need for admission to ICU; as well as decreasing overall mortality (Liappis 
AP et al, 2001; Almog Y et al, 2004; Kruger P et al, 2006). Other studies have suggested 
that statin usage confers long-term rather than short-term benefits amongst patients 
admitted with bacteraemia with Thomsen et al reporting unchanged mortality at 30 days, 
though improved mortality at 180 days (Thomsen RW, Hundborg HH et al, 2006). 
 
When individual patient groups are selectively analysed there is also mixed evidence for 
any benefit from statins with regard to the development of sepsis. In the context of 
community-acquired pneumonia Majumdar et al found that statins were not associated 
with reduced mortality or reduced need for ICU admission, although Mortensen et al 
found did find an associated decrease in mortality at 30 days (Majumdar SR et al, 2006; 
Mortensen SR et al, 2005). Other studies have found a reduced incidence of sepsis in 
patients taking statins who had chronic kidney disease or prior cardiovascular disease 
(Gupta R et al, 2007; Hackam DG et al, 2006; Almog Y et al, 2007). 
 
Several theories have been put forward to explain any potential benefit in terms of 
pleiotropic effects of statins, unrelated to their cholesterol-lowering abilities. Such 
pleiotropic effects include immunomodulation, reduction in blood thrombogenesis, and 
improved endothelial function and vascular reactivity (Almog Y, 2003; Mekontso-Dessap 
A et al, 2006). 
 
Given this evidence it is reasonable to hypothesise that any protective effect of prior statin 
usage in bacteraemic patients might extend to those already admitted to the ICU. Our 
study found no survival benefit associated with prior statin-usage in patients admitted to 




the ICU with presumed sepsis with or without a proven bacteraemia. Previous studies 
have suggested mixed findings amongst those admitted to ICU, with prior statin usage 
associated with increased mortality in patients who develop ICU-acquired infections, and 
decreased mortality in patients with multiple-organ dysfunction syndrome (Fernandez R et 
al, 2006; Schmidt H et al, 2006). Where statins have been found to be associated with 
worse outcome it has been suggested that this is because their use is associated with 
increasing age and the presence of pre-existing diseases, both of which are clearly 
evident in our study, and which were taken into account during the multivariate analyses. 
 
The fact that statins users are more likely to be older with more co-morbidities may be 
offset by the fact that they may be a group who are more likely to receive other 
preventative therapies, the so-FDOOHG ³KHDOWK\XVHUHIIHFW´ ,Q WKHLUVWXG\RIVWDWLQV-users 
with community-acquired pneumonia Majumdar et al found that statins decreased the 
crude relative risk, but that the relative risk increased once the healthy user effect was 
factored in (including walking unaided, quitting smoking, and up to date immunisations) 
(Majumdar SR et al, 2006; Thomsen RW, 2006)  The strength of any healthy user effect is 
difficult to quantify, with one study indicating that it might even extend to statins users 
being at less risk of being involved in accidents (Dormuth CR et al, 2009). 
 
There are a number of possible reasons why the design of our trial might fail to detect any 
beneficial effect exerted by statins in the presence of sepsis. Firstly our cohort involved 
patients presumed to have sepsis, rather than having proven sepsis. It is possible that 
any beneficial effect does not extend beyond those patients with sepsis, although we also 
failed to detect any benefit in patients with proven bacteraemia around the time of 
admission. Secondly we were unable to confirm what dose of statin patients had been 
taking, or for how long prior to admission. Nor could we confirm how compliant patients 
were with their statin medication. Lastly it was evident that statins were rapidly 
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discontinued following ICU admission, and it has been suggested that any benefit from 
statins may rapidly dissipate (Almog Y et al, 2007). 
 
The same reasons might also explain why our study failed to find any association 
between statin usage and decreased mortality following major surgery. Several studies 
have identified an association between prior statin usage and improved morbidity and 
mortality after cardiac surgery, non-cardiac vascular surgery, and other non-cardiac 
VXUJHU\ &ODUN//HWDO3ROGHUPDQV'HWDO2¶1HLO-Callahan K et al, 2005; 
Lindenauer PK et al, 2004). The only association found by our study between statins and 
survival was that of an increased ICU mortality using univariate analysis, which was not 
present using multivariate analysis. 
 
Where statins have been found to be beneficial it has been assumed that their pleiotropic 
effects, and particularly their immunomodulatory effects, have been protective; and 
indeed there is some in-vivo evidence that prospectively administering simvastatin 
reduces cytokine levels (specifically TNF-alpha and interleukin-6) amongst patients with 
acute bacterial infection and patients with severe sepsis (Novack V et al, 2009).  It is 
possible that in the cohort of patients with presumed sepsis presentation to ICU meant 
that patients had already progressed beyond the point at which statins (either by their 
pleiotropic effects or by any healthy-user effect) could exert a beneficial effect. Those 
patients in the post-operative cohort might be considered to have too small an 
inflammatory response to be affected by statins. Statin usage in either cohort was 
associated with small, but statistically significant, increases in APACHE II scores which 
might indicate that any protective effect had already been lost. There was no difference in 
the frequency with which patients fulfilled the modified SIRS criteria, although this is 
admittedly a crude clinical measure of inflammation open to much criticism (Vincent J-L, 
1997). 
 




Alternatively any beneficial pleiotropic effect of statins in either group might be mediated 
by microvascular or antithrombotic mechanisms (Glynn RJ et al, 2009; McGown CC et al, 
2007). Using the number of potentially septic patients presenting with shock, and the early 
requirement for inotropes in all patients, as crude measures of vascular reactivity we 
identified no differences between statins and non-statins users, with the exception that 
early inotrope use appeared more frequent amongst post-operative statins users. This 
association was no longer statistically significant using multivariate analysis, although a 
trend was still apparent (odds ratio 1.70, confidence intervals 0.95-3.05, p =0.074). 
Predictably beta-blockers (odds ratio 2.01, confidence intervals 1.03-3.26, p =0.005) and 
ACE inhibitor / ARAs (odds ratio 1.74, confidence intervals 1.04-2.91, p =0.035) were 
both significantly associated with inotrope requirement, as was oesophageal resection 
(odds ratio 2.94, confidence intervals 1.95-4.45, p <0.005) which always involved post-
operative epidural analgesia combined with a fluid restrictive policy.  
 
There is evidence that the sudden discontinuation of statins can result in a loss of 
endothelial benefit, and rebound cardiovascular effects that might even adversely affect 
outcome (Taneva E et al, 2006; Puccetti L et al, 2003; Laufs U et al, 2000; Tristano AG et 
al, 2007). Le Manach Y et al, 2007, found evidence of increased risk of cardiac 
myonecrosis when statins were discontinued after major vascular surgery. It is possible, 
but would seem unlikely, that any benefit from statins was offset by an equally powerful 
detrimental effect resulting from abrupt withdrawal. Although statins users were more 
likely to die on ICU following major surgery, this finding was no longer present after 
multivariate analysis (odds ratio 1.27, confidence intervals 0.37-4.32, p =0.704), and was 
not present when considering hospital mortality. It seems unlikely that this provides any 
support for abrupt withdrawal masking a beneficial effect, at least in the post-operative 
cohort. Furthermore patients undergoing oesophageal resection had prolonged 
withdrawal of their statins when compared with other post-operative patients and we could 
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identify no differences in their outcomes with regard to statins when compared with other 
groups. 
 
Previous retrospective studies have mostly chosen to consider the pleiotropic effects of 
statins to be a class-effect and have grouped statins together. Simvastatin and 
pravastatin are closely related to the fungal metabolite lovastatin, whilst atorvastatin, 
rosuvastatin and fluvastatin are synthetic. Some statins (simvastatin, lovastatin) are pro-
drug lactones, whilst others are in the active acid form (McCarey DW et al, 2005). It is 
unclear what influence these differences might have on poorly understood pleiotropic 
effects. It is also unclear how much differences in drug metabolism, particularly in critically 
ill patients, may affect the degree with which pleiotropic effects are present. Atorvastatin 
metabolism has been shown to be impaired in critically ill patients, even in the absence of 
known metabolic pathway inhibitors, resulting in higher than expected levels (Kruger PS 
et al, 2009). The degree to which other statins may be affected is unclear. 
 
In this study we have attempted to examine statins separately, however only patients 
prescribed simvastatin and atorvastatin represented moderately large subgroups. Crude 
outcome data did identify some differences between simvastatin and atorvastatin, with 
simvastatin being associated with worse outcomes in the cohort with presumed sepsis. 
Although these findings were no longer statistically significant using multivariate analysis 
(except in the subgroup of patients presenting with presumed sepsis and shock) it is 
perhaps worth noting that the overall trend in sepsis was for simvastatin to be detrimental 
and atorvastatin to be protective; whilst in post-operative patients the trend was for 
simvastatin to be more strongly associated with worse outcome than other agents. It is 
unclear whether or not this represents random variation, or the variability with which 
different statins are prescribed for different indications, or even evidence of a subtle 
difference between agents in patients with altered vascular reactivity.  
 




In conclusion it is surprising that many other retrospective studies have identified strong 
associations between statin usage and improved outcome, which this study has been 
unable to find.  We are aware of several prospective trials which are underway involving 
patients with sepsis or critical illness. We would strongly suggest that any findings, 
positive or negative, are interpreted with caution and with regard to timing of intervention, 
underlying disease and vascular lability, and type of statin used. We would also suggest 
that where any findings are negative there is scope for a prospective study examining the 
effects of statin discontinuation in critically ill patients. 












Conclusion and future proposals 
 
In this thesis I have attempted to further explore the nature of the transient hyperaemic 
response, with a view to its use as an investigative tool in critically ill patients. In chapter 3 
the intra- and inter-individual variability of the test was further clarified and a large dataset 
of results from healthy volunteers compiled. This dataset also appeared to corroborate 
data from earlier studies suggesting that age and gender do not cause large changes in 
THR. Due to the intrinsic properties of the transient hyperaemic response it is suggested 
that equal variances are not assumed when analyzing data, and that it may be of benefit 
to analyze the log-transformed THRR rather than the ratio as it stands in order to apply 
parametric tests. 
 
Increased baseline flowflux fluctuations, such as was generated using PEEP in 
volunteers, cause an increase in variability but do not necessarily invalidate measurement 
of THR. 
 
Within the context of critically ill ICU patients the transient hyperaemic response proved 
harder to measure and analyze than expected (chapter 5). Other techniques described in 
the literature do not appear to have highlighted such difficulties. The experiences of the 
P a g e  | 168       Chapter seven 
 
pilot study presented within this thesis would suggest that its use in clinical settings is 
restricted to highly cooperative individuals, or patients who are sedated and immobile.  
 
Although those critical care patients known to have evidence of SIRS were found, as a 
group, to have altered vascular reactivity, a surprising finding within this study was the 
lack of effect of iontophoresed norepinephrine and acetylcholine. This would suggest that 
the effects described in previous studies are not clear cut, although it must be stressed 
that previous studies involved patients with sepsis rather than SIRS. Due to the 
heterogeneous nature of ICU patients it is hard to conceive a scenario in which a more 
homogenous group of patients could be investigated using this technique at this time. 
Attempts to better classify sepsis are underway, and any future attempts at investigating 
vascular reactivity in the clinical setting may become simpler as these develop (Levy MM 
et al, 2003; Lisboa T et al, 2008). 
 
The transient hyperaemic response may still be a valuable tool for investigating models of 
sepsis in otherwise healthy human volunteers. Iontophoresis of chemicals into the 
forearm in order to induce a very localised inflammatory response is an attractive 
proposition, and would seem intuitively safer than triggering systemic or regional 
responses, such as those achieved by infusing inflammatory mediators into the brachial 
artery (Patel JN et al, 2002). Unfortunately the effects of iontophoresis appear to be less 
predictable than previously thought, and it cannot be assumed that carrier mediums are 
inert, despite previous evidence to the contrary. There is also evidence that prior 
iontophoresis of saline can enhance the effect of later vasoconstrictor iontophoresis 
(Drummond P, 2002). Any model involving the iontophoresis of chemicals to induce 
inflammation is likely to require carefully chosen control agents and/or a non-
iontophoresed component. 
 




The effects of iontophoresed norepinephrine on the THR had not been previously 
demonstrated prior to the investigations presented here. The finding that norepinephrine 
partially reversed the vasodilatation induced by localized heating may be of interest in 
future research involving other vasodilator mechanisms, observing the caveats already 
PHQWLRQHG7KH³QHJDWLYH´K\SHUDHPLFUHVSRQVHWRKHDW LV LQLWVHOIDQLQWHUHVWLQJILQGLQJ
and a future study combining localized heating with iontophoresed adrenoceptor 
antagonists (with appropriate controls) is already being planned. 
 
The effects of prior use of statins on the outcomes of critically ill patients was investigated 
in chapter 6 in response to a number of recent studies which have suggested a beneficial 
pleiotropic effect of statins in this scenario. A beneficial effect on mortality was not seen in 
the retrospective analysis performed within this study. There are many reasons why this 
FRXOGKDYHRFFXUUHGHYHQ LQ WKHSUHVHQFHRID ³WUXH´EHQHILFLDOHIIHFWDQGUDQGRPLVHG
controlled trials into the beneficial effects of statins in sepsis and other conditions affecting 
critically ill patients are currently underway which may better analyse any effect. 
 
As a hypothesis-generating exercise the retrospective analysis performed within this 
thesis suggests two important areas for future research. Firstly that the effects of the 
discontinuation of statins in critically ill patients is worthy of further investigation in its own 
right, regardless of whether or not statins are shown to be of benefit when given to ICU 
patients de novo; secondly that a class-effect of statins cannot be assumed. Although the 
margins of error within the research presented here are such that differences seen may 
be purely artefactual, there is sufficient evidence within the literature to suggest that the 
effects of different statins are not equal, at least as regards non-pleiotropic effects. 
 
It was hoped that the research presented in chapter six would be complemented by 
further research investigating the effects of different statins on the vascular reactivity of 
healthy volunteers. A study measuring the effects (if any) of simvastatin usage on the 
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transient hyperaemic response of the cutaneous microcirculation is planned and has 
ethical approval Unfortunately at the time of writing this thesis that study has yet to be 
started. Nevertheless it is hoped that future studies looking at the effects of different 
statins on vascular reactivity, measured by the THR, will shed further light on the question 
of whether or not the pleiotropic cardiovascular effects of statins are measurable within 
the cutaneous microcirculation, and whether or not such effects, if they are found, 
represent a class-effect true of all statins. 
 
 





Appendix i  Abbreviations 
 
°C   Temperature in degrees Celsius 
2D   Two-dimensional (an ultrasound imaging mode) 
ACF   Ante-cubital fossa 
AIDS   Acquired immune deficiency syndrome 
APACHE II  Acute physiology and chronic health evaluation score (version II) 
ARF   Acute renal failure 
AU   Arbitrary units 
BP   Blood pressure 
CCMDS  Critical care minimum data set 
CKD   Chronic kidney disease 
CNS   Central nervous system 
COPD   Chronic obstructive pulmonary disease 
CPAP   Continuous positive-airways pressure 
CRP   C-reactive protein 
CVP   Central venous pressure 
CVS   Cardiovascular system 
CVVH   Continuous veno-venous haemofiltration 
DRT4   A laser Doppler flow controller (Moor Instruments) 
EDRF   Endothelial-derived relaxing factor(s) 
EMLA   Eutectic mixture of local anaesthetics 
F0   Flowflux biological zero (during THR) 
F1   Baseline flowflux (prior to THR) 
F2   Peak flowflux during hyperaemic response 
FiO2   Fraction of inspired oxygen 
GCS   Glasgow coma score 
GI   Gastro-intestinal 
Hct   Haematocrit 
HR   Heart rate (beats per minute) 
HTS   Hypertonic saline 
IABP   Intra-aortic balloon pump 
ICNARC  Intensive Care National Audit and Research Centre 
ICP   Intra-cranial pressure 
ICU   Intensive care unit 
IPPV   Intermittent positive pressure ventilation 
P a g e  | 172        Appendices 
 
K   Potassium 
LDF   Laser Doppler flowmetry 
LDPI   Laser Doppler perfusion imaging 
LDPM   Laser Doppler perfusion monitoring 
MAP   Mean arterial pressure 
MARS   Molecular adsorption recirculation system 
MIC1-e   An iontophoresis current controller (Moor Instruments) 
mmHg   Millimetres of mercury 
Na   Sodium 
NIDDM   Non-insulin dependent diabetes 
NIRS   Near-infrared spectroscopy 
NSAIDs  Non-steroidal anti-inflammatory drugs 
NYHA   New York heart association 
NO   Nitric oxide 
PaO2   Partial pressure of arterial oxygen 
PDI   Phosphodiesterase inhibitor 
PEEP   Positive end-expiratory pressure 
PGI2   Prostacyclin 
RBC   Red blood cell 
RR   Respiratory rate 
RRT   Renal replacement therapy 
RS   Respiratory system 
SD   Standard deviation 
SH02   A heating control unit (Moor Instruments) 
SHP2   A cutaneous heating probe (Moor Instruments) 
SIRS   Systemic inflammatory response syndrome 
SOFA   6HTXHQWLDOSUHYLRXVO\³VHSVLV´RUJDQIDLOXUHDVVHVVPHQW 
SpO2   Cutaneous pulse oximetry saturations 
STROBE guidelines Strengthening the Reporting of OBservational studies in   
   Epidemiology guidelines 
TCD   Trans-cranial Doppler 
THR   Transient hyperaemic response 
THRR   Transient hyperaemic response ratio 
THR time  The length of time (in seconds) a THR persists 
UOP   Urine output 






































APACHE II scoring system 






















Score equals 15 minus GCS 
Chronic ill health is defined as follows 
x Liver: Biopsy proven cirrhosis / portal hypertension / GI bleed secondary to portal hypertension / encephalopathy 
x CVS: NYHA class 4 
x RS: Domiciliary oxygen / pulmonary hypertension >40mmHg / fails stairs / documented hypoxia or hypercapnia / secondary polycythaemia 
x Renal: Chronic dialysis 












































































































































































Oxygenation if FiO2 > 0.5 (FiO2 / 

































































































































University of Nottingham  
Faculty of Medicine and Health Sciences 
Division of Anaesthesia and Intensive Care 
University Hospital 
Queens Medical Centre 
Nottingham NG7 2UH 
 
 
Title of Project:   
 
³7KHHIIHFWRIFRQWLQXRXVSRVLWLYHDLUZD\VSUHVVXUHRQ
forearm skin vascular reactivity in spontaneously breathing 
volunteers assessed by laser Doppler flowmetry.´ 
 
A study of how the blood flow in the skin responds when breathing 




 Dr Martin J Beed   FRCA,  Research Fellow in Anaesthesia 
 Dr Iain Moppett   MRCP, FRCA Lecturer in Anaesthesia 







You have been invited to take part in a research study.  Before you decide whether to take part it is 
important for you to understand why the research is being done and what it will involve.  Please 
take time to read the following information carefully and discuss it with friends and relatives if you 
wish to.   Ask us if there is anything that is not clear or if you would like more information.  Take 
the time to decide whether you wish to take part or not.  If you decide to take part you may keep 




In health blood vessels contract and relax in response to various stimuli, including the blood 
pressure within them.  This is so that tissues receive the right amount of oxygen for their needs.  
This response, known as autoregulation, can be altered in various conditions, such as under 
anaesthesia, on the intensive care unit and with diseases such as high blood pressure and diabetes.  
We are developing a no-needles test to look at how skin blood vessels react in normal people, with 
the aim of eventually using it on patients.  The test involves a technique called laser Doppler 
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flowmetry.  This involves shining a very weak laser at your forearm skin and measuring the 
amount of light that comes back.  From this we can get an estimate of the blood flow in your skin.  
In order to be sure that any changes in blood vessel autoregulation are due to a disease or illness it 
is important that we know whether anything else might interfere with the test. One possible 
SURFHGXUHWKDWFRPPRQO\RFFXUVRQLQWHQVLYHFDUHXQLWVLVYHQWLODWLRQZKHUHDSDWLHQW¶VEUHDWKLQJ
is taken over by a ventilator, and it is possible that this might interfere with blood vessel 
autoregulation. Since being on a ventilator can sometimes be quite uncomfortable, with patients 
needing sedation, we intend to mimic ventilation with something called Continuous Positive 
Airways Pressure or CPAP which is much more comfortable and involves blowing air through a 
tight fitting mask into the mouth and nose, rather like breathing whilst facing a very strong wind. 
This has the effect of raising the pressure inside the chest slightly which is similar to the overall 
effect of being on a ventilator. CPAP is often used on fully awake patients in many of the hospital 
wards and is known to be very safe and well tolerated. 
 
We hope to run this study over a period of nine months. 
 
What does the study involve? 
. 
We will ask you to come to the study area and spend at least 15 minutes there before the study is to 
start, so that you can relax and get used to the surroundings.  You will be asked to lie down on a 
couch with one arm comfortably outstretched on a table and pillow. A blood pressure cuff will be 
placed around your other arm to check your blood pressure before and during the experiment.  We 
will then attach a special probe to the surface of your outstretched forearm with a small adhesive 
sticker. On the first occasion, when the blood flow measurements are steady we will perform 3 
identical tests on you at 2-minute intervals.  One of the investigators will feel for the artery at your 
upper arm and when they have found it, they will press on it firmly for 20 seconds and then release. 
The increase in blood flow will be recorded by the probe and the test repeated twice more. 
 
After these initial tests we will fit a breathing mask to your face using a special harness that fits 
around your head and holds the mask tight. It is important that the mask is tight fitting with very 
little air leaking around the edges and this can mean that the mask is sometimes slightly 
uncomfortable as it may press slightly on the bridge of the nose. Once this is done we will then use 
a machine to blow air into the mask at a fixed pressure. This will make it feel as if there is a slight 
resistance when you are breathing out and air blowing at you when you are breathing in. Whilst it is 
very safe this can feel a little strange and sometimes uncomfortable. After we are sure there are no 
leaks we will ask you to continue breathing through the mask for 5 minutes before repeating the 
measurements of skin blood flow by pressing the artery in the upper arm 3 more times. During the 
time you are breathing through the mask we will be monitoring the gases you breathe out and the 
level of oxygen in your blood, this will require a monitor rather like a clothes peg being placed on a 
finger. 
 
The whole process should take less than 30 minutes. 
 
We do not expect any pain or side effects to occur as a result of this study apart from mild 
discomfort resulting from compression of the artery, perhaps some discomfort where the mask 
presses against the face and bridge of the nose, and breathing may feel uncomfortable whilst the 
mask is on. Occasionally people find they swallow some air with the mask on and may belch 
afterwards. 
 
If you do feel uncomfortable the study will be terminated.  You may withdraw from the study at 
any time without having to give a reason. 
 
There is no requirement for blood tests or questionnaires either at the time of the study or in the 
future. 
 




Why have you been chosen? 
 
We need 15 healthy volunteers to complete the study. 
 
Do you have to take part? 
 
It is up to you to decide or not to take part.  If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form.  If you decide to take part you are 
still free to withdraw at any time and without giving a reason. 
 
What do I have to do? 
 
We need you to avoid strenuous exercise before the study.  Caffeine-containing substances (coffee, 
tea, and cola) or food should not be consumed for at least 2 hours before the study.  
 
What is the drug or procedure that is being tested? 
 
Laser Doppler flowmetry is a safe, painless method of measuring blood flow.  It involves shining a 
weak laser light at the skin and measuring the light that is reflected back.  It does not involve 
needles and does not cause any damage to the skin.  
 
What are the side effects of any treatment or procedures received when 
taking part? 
 
Pressing on the artery in your upper arm is not usually a problem, but can occasionally be a little 
uncomfortable.  
Using the special mask which delivers continuous positive airways pressure (CPAP) can make 
breathing feel uncomfortable, and can occasionally lead to redness where the mask presses against 
the bridge of the nose, but it is not known to cause any serious side effects. Occasionally people 
breathing through a CPAP mask can find that they swallow more air than normal which can lead to 
mild stomach discomfort relieved by belching, but this normally happens after long periods of time 
breathing through the mask and is unlikely to occur in the short period of time which we will be 
using. 
 
What are the possible disadvantages and risks of taking part? 
 
We do not anticipate any risk to you from taking part, apart from the discomfort mentioned above.   
 
Even so we will not include you in the study if: 
 
a) You are allergic to any of the drugs or adhesives used to secure the probe 
b) You have damaged skin on your arm 
c) <RXKDYHDQ\FLUFXODWRU\GLVRUGHUVVXFKDV5D\QDXG¶VGLVHDVHV\VWHPLFVFOHURVLV
diabetes or have high blood pressure which requires medication 
d) You are a smoker 
e) You have recently injured your chest or have a history of collapsed lung, poorly 
controlled asthma or other chest disease which limits your ability to breath. 
 
What if something goes wrong? 
 
If taking part in this research project harms you, there are no special compensation arrangements.  
,I\RXDUHKDUPHGGXHWRVRPHRQH¶VQHJOLJHQFHWKHQ\RXPD\KDYHJURXQGVIRUDOHJDODFWLRQEXW
you may have to pay for it.  Regardless of this, if you wish to complain about any aspect of the 
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way you have been approached or treated during the course of this study you may complain to 
Professor A. Aitkenhead, Head of University Department of Anaesthesia in the first instance, or 
the Dean of the Medical School. 
 
Will my taking part in this study be kept confidential? 
 
All information collected about you during the course of the research will be kept strictly 
confidential.  Any information about you that leaves the research unit will have your name and 
address removed so that you cannot be recognised from it. 
 
What will happen to the results of the research study? 
 
Once the study is completed the results will be submitted for publication to a scientific journal and 
will probably be published by the end of 2004.  You will not be identified in any publication or 
report.  If you wish to obtain a copy of the published results then please contact the investigators. 
 
Who is organising and funding the research? 
 
The investigators are all members of the University Department of Anaesthesia or medical students 
attached to the University Department of Anaesthesia.  
 
Who has reviewed the study? 
 
This study has been reviewed and approved by the University of Nottingham Medical School 
Ethics Committee 
 
Contact for Further Information 
 
You may contact any of the investigators: Dr Martin Beed or Iain Moppett. 
 
By phone: 0115 924 9924 Ext. 42855 
 
By email:  martin.beed@nottingham.ac.uk 
  iain.moppett@nottingham.ac.uk 
                
By post:  University Department of Anaesthesia 
  C Floor, East Block 
  4XHHQ¶V0HGLFDO&HQWUH 
  Derby Road 
  Nottingham 
  NG7 2UH 
 
Thank you for taking the time to read this information sheet and agreeing to take part in this study.  
You will be given a copy of this information sheet and a signed consent form to keep. 




University of Nottingham 
Faculty of Medicine and Health Sciences 
Division of Anaesthesia and Intensive Care 
University Hospital 
Queens Medical Centre 




Title of Project:   
 
³7KHHIIHFWRILRQWRSKRUHVHGPDQQLWROSURSRIRODQG
midazolam on vascular reactivity in skin vessels 
using laser Doppler flowmetry of forearm skin.´ 
 
A study of how the blood flow in skin responds to drugs 




 Dr Martin J Beed   FRCA,  Research Fellow in Anaesthesia 








You have been invited to take part in a research study.  Before you decide whether to take part it is 
important for you to understand why the research is being done and what it will involve.  Please 
take time to read the following information carefully and discuss it with friends and relatives if you 
wish to.   Ask us if there is anything that is not clear or if you would like more information.  Take 
the time to decide whether you wish to take part or not.  If you decide to take part you may keep 




In health blood vessels contract and relax in response to various stimuli, including the blood 
pressure within them.  This is so that tissues receive the right amount of oxygen for their needs.  
This response, known as autoregulation, can be altered in various conditions, such as under 
anaesthesia, on the intensive care unit and with diseases such as high blood pressure and diabetes.  
We are developing a no-needles test to look at how skin blood vessels react in normal people, with 
the aim of eventually using it on patients in Intensive Care.  The test involves a technique called 
laser Doppler flowmetry.  This involves shining a very weak laser at your forearm skin and 
measuring the amount of light that comes back.  From this we can get an estimate of the blood flow 
in your skin.  We want to know whether our test will be affected by any of the drugs commonly 
used on Intensive Care. There are three drugs we are hoping to test two of which are commonly 
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used to sedate patients on intensive care; the third one is often used in the treatment of patients with 
head injuries. The drugs are going to be given directly to the skin by a process called iontophoresis 
which uses a tiny electrical current to drive a small amount of the drug into the surface of the skin. 
It is very safe and gives a much smaller amount of drug than any tablet or injection would, affecting 
only a small area of forearm skin. Given this way the drugs will have no sedative effect. 
 We hope to run this study over a period of nine months. 
 
What does the study involve? 
 
We will ask you to come to the study area and spend at least 15 minutes there before the study is to 
start, so that you can relax and get used to the surroundings.  You will be asked to lie down on a 
couch with one arm comfortably outstretched on a table and pillow. A blood pressure cuff will be 
placed around your other arm to check your blood pressure before and during the experiment.  We 
will then attach a special probe to the surface of your outstretched forearm with a small adhesive 
sticker. On the first occasion, when the blood flow measurements are steady we will perform 3 
identical tests on you at 2-minute intervals.  One of the investigators will feel for the artery at your 
upper arm and when they have found it, they will press on it firmly for 20 seconds and then release. 
The increase in blood flow will be recorded by the probe and the test repeated twice more. 
Another probe will be attached to another part of the same forearm and the process of iontophoresis 
will take place with one of the drugs we are testing. Most people feel a slight tingling sensation. 
Once this has been completed the measurements of skin blood flow will be repeated by pressing the 
artery in the upper arm 3 more times. There are three drugs to test and so the process of giving a 
drug by iontophoresis and pressing the artery will be done on three different areas of forearm skin. 
The whole process should take about 45 minutes. 
 
We do not expect any pain or side effects to occur as a result of this study apart from mild 
discomfort resulting from compression of the artery, a tingling sensation as previously described 
and a small area of redness where the drug is applied. 
 If you do feel uncomfortable the study will be terminated.  You may withdraw from the study at 
any time without having to give a reason. 
 
 There is no requirement for blood tests or questionnaires either at the time of the study or in the 
future. 
 
Why have you been chosen? 
 
We need 15 healthy volunteers to complete the study with no special requirements. 
 
Do you have to take part? 
 
It is up to you to decide or not to take part.  If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form.  If you decide to take part you are 
still free to withdraw at any time and without giving a reason. 
 
What do I have to do? 
 
We need you to avoid strenuous exercise before the study.  Caffeine-containing substances (coffee, 
tea, and cola) or food should not be consumed for at least 2 hours before the study.  
What is the drug or procedure that is being tested? 
 
Laser Doppler flowmetry is a safe, painless method of measuring blood flow.  It involves shining a 
weak laser light at the skin and measuring the light that is reflected back.  It does not involve 




needles and does not cause any damage to the skin. The drugs which we wish to investigate are 
ones currently used within intensive care and anaesthesia for sedation or the treatment of head 
injuries. 
 
What are the side effects of any treatment or procedures received when 
taking part? 
 
Pressing on the artery in your upper arm is not usually a problem, but can occasionally be a little 
uncomfortable. The application of the two drugs to the skin may cause a little itching or redness, 
which may last up to 24 hours. The quantity used is too small to produce any other effects.  
 
What are the possible disadvantages and risks of taking part? 
 
We do not anticipate any risk to you from taking part, apart from the discomfort mentioned above.   
 
We will not include you in the study if: 
 
a) You are allergic to any of the drugs or adhesives used to secure the probe 
b) You have damaged skin on your arm 
c) You have any circuODWRU\GLVRUGHUVVXFKDV5D\QDXG¶VGLVHDVHV\VWHPLFVFOHURVLV
diabetes or high blood pressure 
d) You are a smoker 
 
 
What if something goes wrong? 
 
If taking part in this research project harms you, there are no special compensation arrangements.  
If you are KDUPHGGXHWRVRPHRQH¶VQHJOLJHQFHWKHQ\RXPD\KDYHJURXQGVIRUDOHJDODFWLRQEXW
you may have to pay for it.  Regardless of this, if you wish to complain about any aspect of the 
way you have been approached or treated during the course of this study you may complain to 
Professor A. Aitkenhead, Head of University Department of Anaesthesia in the first instance, or 
the Dean of the Medical School. 
 
 
Will my taking part in this study be kept confidential? 
 
All information collected about you during the course of the research will be kept strictly 
confidential.  Any information about you that leaves the research unit will have your name and 
address removed so that you cannot be recognised from it. 
 
 
What will happen to the results of the research study? 
 
Once the study is completed the results will be submitted for publication to a scientific journal and 
will probably be published by the end of 2005.  You will not be identified in any publication or 
report.  If you wish to obtain a copy of the published results then please contact the investigators. 
Who is organising and funding the research? 
 
The investigators are all members of the University Department of Anaesthesia or medical students 
attached to the University Department of Anaesthesia.  
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Who has reviewed the study? 
 
This study has been reviewed and approved by the University of Nottingham Medical School 
Ethics Committee 
 
Contact for Further Information 
 
You may contact any of the investigators: Dr Martin Beed or Dr Iain Moppett,  
 
By phone: 0115 924 9924 Ext. 42855 
 
By email:  martin.beed@nottingham.ac.uk 
  iain.moppett@nottingham.ac.uk 
                
By post:  University Department of Anaesthesia 
  C Floor, East Block 
  4XHHQ¶V0HGLFDO&HQWUH 
  Derby Road 
  Nottingham 
  NG7 2UH 
 
Thank you for taking the time to read this information sheet and agreeing to take part in this study.  
You will be given a copy of this information sheet and a signed consent form to keep. 





University of Nottingham 
Faculty of Medicine and Health Sciences 
Division of Anaesthesia and Intensive Care 
University Hospital 
Queens Medical Centre 




Title of Project:   
 
³The effect of iontophoresed norepinephrine, vasopressin and endothelin 
on vascular reactivity in skin vessels dilated by heat assessed using laser 
DoSSOHUIORZPHWU\RIIRUHDUPVNLQ´ 
 
A study of how the blood flow in skin that is warm responds 




 Dr Martin J Beed   FRCA,  Research Fellow in Anaesthesia 
 Dr Iain Moppett   MRCP, FRCA Lecturer in Anaesthesia 







You have been invited to take part in a research study.  Before you decide whether to take part it is 
important for you to understand why the research is being done and what it will involve.  Please 
take time to read the following information carefully and discuss it with friends and relatives if you 
wish to.   Ask us if there is anything that is not clear or if you would like more information.  Take 
the time to decide whether you wish to take part or not.  If you decide to take part you may keep 




In health blood vessels contract and relax in response to various stimuli, including the blood 
pressure within them.  This is so that tissues receive the right amount of oxygen for their needs.  
This response, known as autoregulation, can be altered in various conditions, such as under 
anaesthesia, on the intensive care unit and with diseases such as high blood pressure and diabetes.  
We are developing a no-needles test to look at how skin blood vessels react in normal people, with 
the aim of eventually using it on patients.  The test involves a technique called laser Doppler 
flowmetry.  This involves shining a very weak laser at your forearm skin and measuring the amount 
of light that comes back.  From this we can get an estimate of the blood flow in your skin.  We want 
to know whether our test can be used to look at the effect of various drugs that we use to raise 
SHRSOH¶VEORRGSUHVVXUHZKHQWKH\DUHXQZHOO6RIDUWHVWLQJWKHVHGUXJVKDVEHHQGLIILFXOWWRGRVR
we are going to try testing them on skin that has already been warmed up to make the blood vessels 
expand. The drugs are going to be given directly to the skin by a process called iontophoresis which 
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uses a tiny electrical current to drive a small amount of the drug into the surface of the skin. It is 
very safe and gives a much smaller amount of drug than any tablet or injection would, affecting 
only a small area of forearm skin. 
 We hope to run this study over a period of six months. 
 
What does the study involve? 
 
We will ask you to come to the study area and spend at least 15 minutes there before the study is to 
start, so that you can relax and get used to the surroundings.  You will be asked to lie down on a 
couch with one arm comfortably outstretched on a table and pillow. A blood pressure cuff will be 
placed around your other arm to check your blood pressure before and during the experiment.  We 
will then attach a special probe to the surface of your outstretched forearm with a small adhesive 
sticker. On the first occasion, when the blood flow measurements are steady we will perform 3 
identical tests on you at 2-minute intervals.  One of the investigators will feel for the artery at your 
upper arm and when they have found it, they will press on it firmly for 20 seconds and then release. 
The increase in blood flow will be recorded by the probe and the test repeated twice more. 
Another probe will be attached to another part of the same forearm and this one will gently heat a 
small area of skin underneath to a temperature of 38 degrees Celsius. Once the skin is warmed the 
process of iontophoresis will take place with one of the drugs we are testing. Most people feel a 
slight tingling sensation. Once this has been completed the measurements of skin blood flow will be 
repeated by pressing the artery in the upper arm 3 more times. There are three drugs to test and so 
the process of heating an area of skin, giving a drug by iontophoresis and pressing the artery will be 
done on three different areas of forearm skin. 
The whole process should take about 45 minutes. 
 
We do not expect any pain or side effects to occur as a result of this study apart from mild 
discomfort resulting from compression of the artery, a tingling sensation as previously described 
and a small area of redness where the drug is applied. 
 If you do feel uncomfortable the study will be terminated.  You may withdraw from the study at 
any time without having to give a reason. 
 
 There is no requirement for blood tests or questionnaires either at the time of the study or in the 
future. 
 
Why have you been chosen? 
 
We need 15 healthy volunteers to complete the study with no special requirements. 
 
Do you have to take part? 
 
It is up to you to decide or not to take part.  If you do decide to take part you will be given this 
information sheet to keep and be asked to sign a consent form.  If you decide to take part you are 
still free to withdraw at any time and without giving a reason. 
 
What do I have to do? 
 
We need you to avoid strenuous exercise before the study.  Caffeine-containing substances (coffee, 
tea, and cola) or food should not be consumed for at least 2 hours before the study.  
 
What is the drug or procedure that is being tested? 
 
Laser Doppler flowmetry is a safe, painless method of measuring blood flow.  It involves shining a 
weak laser light at the skin and measuring the light that is reflected back.  It does not involve 
needles and does not cause any damage to the skin. The drugs which we wish to investigate are 




ones currently used within intensive care and anaesthesia in order to raise the blood pressure of 
critically ill patients. 
 
What are the side effects of any treatment or procedures received when 
taking part? 
 
Pressing on the artery in your upper arm is not usually a problem, but can occasionally be a little 
uncomfortable. The application of the two drugs to the skin may cause a little itching or redness, 
which may last up to 24 hours. The quantity used is too small to produce any other effects.  
 
What are the possible disadvantages and risks of taking part? 
 
We do not anticipate any risk to you from taking part, apart from the discomfort mentioned above.   
 
We will not include you in the study if: 
 
a) You are allergic to any of the drugs or adhesives used to secure the probe 
b) You have damaged skin on your arm 
c) <RXKDYHDQ\FLUFXODWRU\GLVRUGHUVVXFKDV5D\QDXG¶VGLVHDVHV\VWHPLFVFOHURVLV
diabetes or high blood pressure 
d) You are a smoker 
 
What if something goes wrong? 
 
If taking part in this research project harms you, there are no special compensation arrangements.  
,I\RXDUHKDUPHGGXHWRVRPHRQH¶VQHJOLJHQFHWKHQ\RXPD\KDYHJURXQGVIRUDOHJDODFWLRQEXW
you may have to pay for it.  Regardless of this, if you wish to complain about any aspect of the 
way you have been approached or treated during the course of this study you may complain to 
Professor A. Aitkenhead, Head of University Department of Anaesthesia in the first instance, or 
the Dean of the Medical School. 
 
Will my taking part in this study be kept confidential? 
 
All information collected about you during the course of the research will be kept strictly 
confidential.  Any information about you that leaves the research unit will have your name and 
address removed so that you cannot be recognised from it. 
 
What will happen to the results of the research study? 
 
Once the study is completed the results will be submitted for publication to a scientific journal and 
will probably be published by the end of 2004.  You will not be identified in any publication or 
report.  If you wish to obtain a copy of the published results then please contact the investigators. 
 
Who is organising and funding the research? 
 
The investigators are all members of the University Department of Anaesthesia or medical students 
attached to the University Department of Anaesthesia.  
 
Who has reviewed the study? 
 
This study has been reviewed and approved by the University of Nottingham Medical School 
Ethics Committee 
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Contact for Further Information 
 
You may contact any of the investigators: Dr Martin Beed or Dr Iain Moppett,  
 
By phone: 0115 924 9924 Ext. 42855 
 
By email:  martin.beed@nottingham.ac.uk 
  iain.moppett@nottingham.ac.uk 
                
By post:  University Department of Anaesthesia 
  C Floor, East Block 
  4XHHQ¶V0HGLFDO&HQWUH 
  Derby Road 
  Nottingham 
  NG7 2UH 
 
Thank you for taking the time to read this information sheet and agreeing to take part in this study.  
You will be given a copy of this information sheet and a signed consent form to keep. 
 




The same consent form was used for all three studies, with altered titles as 
 
 
Title of Project: 
³7KHHIIHFWRIFRQWLQXRXVSRVLWLYHDLUZD\VSUHVVXUHRQIRUHDUPVNLQYDVFXODU
reactivity in spontaneously breathing volunteers assessed by laser Doppler 
IORZPHWU\´ 
 





University of Nottingham 
Faculty of Medicine and Health Sciences 
Division of Anaesthesia and Intensive Care 
University Hospital 
Queens Medical Centre 
Nottingham, NG7 2UH 
 
 
Title of Project: 
³The effect of iontophoresed norepinephrine, vasopressin and endothelin 




Name of Investigators: 
 Dr Martin J Beed   FRCA,  Research Fellow in Anaesthesia 
 Dr Iain Moppett   MRCP FRCA Lecturer in Anaesthesia 








Please read this form and sign it once the above named or their designated representative, has 
explained fully the aims and procedures of the study to you 
 
x I voluntarily agree to take part in this study. 
 
x I confirm that I have been given a full explanation by the above named and that I have read 
and understand the information sheet given to me which is attached. 
 
x I have been given the opportunity to ask questions and discuss the study with one of the above 
investigators or their deputies on all aspects of the study and have understood the advice and 
information given as a result. 
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x I agree to the above investigators contacting my general practitioner [and teaching or 
university authority if appropriate] to make known my participation in the study where 
relevant. 
 
x I agree to comply with the reasonable instructions of the supervising investigator and will 
notify him immediately of any unexpected unusual symptoms or deterioration of health. 
 
x I authorise the investigators to disclose the results of my participation in the study but not my 
name. 
 
x I understand that information about me recorded during the study will be kept in a secure 
database.  If data is transferred to others it will be made anonymous.  Data will be kept for 7 
years after the results of this study have been published. 
 
x I understand that I can ask for further instructions or explanations at any time. 
x I understand that I am free to withdraw from the study at any time, without having to 
give a reason for withdrawing. 
 
x I confirm that I have disclosed relevant medical information before the study. 
 
x I have not been a subject in any other research study in the last three months which involved: 
taking a drug; being paid a disturbance allowance; having an invasive procedure (e.g. 













Signature:  ««««««««««««««««Date:  «««««««««««« 
 
 




I have given the above named a copy of this form together with the information sheet. 
 
 
Investigators Signature:  «««««««««Name«««««««««««« 
 
 
Study Volunteer Number:   
««««««««««««««««««««««««« 
 




Appendix v  Patient and relatives information sheets 
and consent / assent forms 
 
Similar but adapted forms was used for relatives who were approached to provide 









Title of Project:   
 
³7RGHWHUPLQHDVVRFLDWLRQEHWZHHQDOWHUHGVNLQYDVFXODUUHDFWLYLW\DQG









Investigators:  Dr Martin Beed  Research Fellow 
   Dr Iain Moppett   Clinical Lecturer 
   Dr Sally Hancock   Clinical Lecturer 
   Dr Ravi Mahajan  Reader and Consultant 
 
 




You are being invited to take part in a research study.  Before you decide it is important for you to 
understand why the research is being done and what it will involve.  Please take time to read the 
following information carefully and discuss it with others if you wish.  Ask us if there is anything 
that is not clear or if you would like more information.  Take time to decide whether or not you 
wish to take part. 
 
Thank you for reading this. 
 
 
What is the purpose of the study? 
 
In health blood vessels contract and relax in response to many things so that tissues receive the 
right amount of oxygen for their needs.  This response is known as autoregulation and can be 
altered by many illnesses including infections or inflammation.  We are developing a no-needles 
test to look at how skin blood vessels react in patients who are unwell, particularly with infections 
or inflammation.  Our test uses a technique called laser Doppler flowmetry which involves shining 
a very weak laser at forearm skin and measuring the amount of light that comes back.  From this 
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we can get an estimate of the skin blood flow.  We want to know whether our test will show how 
well any treatment is working. 
 
The study will last for about two years and involve 160 people. 
Why have I been chosen? 
 
You have been chosen because you have an infection or another condition, such as a burn or an 
injury to your bowel, causing inflammation, particularly to the blood vessels. 
 
 
Do I have to take part? 
 
It is up to you to decide whether or not to take part.  If you do decide to take part you will be given 
this information sheet to keep and be asked to sign a consent form.  If you decide to take part you 
are still free to withdraw at any time and without giving a reason.  A decision to withdraw at any 
time, or a decision not to take part, will not affect the standard of care you receive. 
 
 
What will happen to me if I take part? 
 
We will visit you on the Intensive Care Unit or High Dependency Unit and ask you to lie with one 
arm comfortably outstretched on a table and pillow. A blood pressure machine will be placed on 
your other arm to check your blood pressure before and during the experiment. We will then attach 
a special probe to the surface of your outstretched forearm with a small adhesive sticker. At least 15 
minutes will be spent relaxing and getting used to this before any measurements are taken. After 15 
minutes we will perform 3 identical tests at 2-minute intervals. An investigator will feel for the 
artery at your elbow.  When they have found it, they will press on it firmly for 20 seconds and then 
release. The increase in blood flow will be recorded by the probe and the test repeated twice more. 
 
Once this has been completed a very small amount of a drug that alters the ability of blood vessels 
to dilate and expand will then be applied to the skin via the chamber holding the laser flow monitor. 
A tiny electric current will then be passed through the chamber for two minutes. This enables the 
drug to penetrate the outermost layer of skin to reach the superficial vessels underneath. The size of 
the current is too small to be felt other than as an itching sensation. The quantity of drug used is 
only able to produce effects locally in the skin. It produces no other effects in the body other than a 
slightly red area where it has been applied, lasting a few hours. The technique has been used for 
many years and been proven to be safe. Once this has been performed we will press firmly on the 
artery two more times. 
 
On a second day a baseline set of blood flow readings will again be taken. For the last part of the 
study a drug with slightly different effects on blood vessel reactivity will be applied in the same 
way as previously to the forearm.  
 
On both occasions a blood sample will be taken to test for markers of inflammation. In the vast 
majority of cases this can be done via intravenous drips that are already in place, and so will not 




We do not expect any pain or side effects to occur as a result of this study apart from mild 
discomfort resulting from compression of the artery, a tingling sensation as previously described 
and a small area of redness where the drug is applied. If you do feel uncomfortable the study will be 
terminated.   
 
YOU MAY WITHDRAW FROM THE STUDY AT ANY TIME WITHOUT HAVING TO GIVE 
A REASON. 
 




We anticipate that the study will take about 30 minutes to complete on each occasion.  We will 
not alter your medical or nursing care in any other way, however we would like to follow your 
care and monitor your progress whilst in the hospital.  
 
You will receive the same standard of care and medication for your illness whether you are part of 
the study or not. 
 
 
What do I have to do? 
 
If you are able to eat or drink please avoid caffeine-containing substances (coffee, tea, and cola) or 
food for at least 2 hours before the study. There are no other restrictions. 
 
 
What is the drug or procedure that is being tested? 
 
Laser Doppler flowmetry is a safe, painless method of measuring blood flow.  It involves shining a 
weak laser light at the skin and measuring the light that is reflected back.  It does not involve 
needles and does not cause any damage to the skin.  
A blood sample will be taken to test for markers of inflammation both times that the test takes 
place, but in most cases this too can be done without any needles. 
 
 
What are the alternatives for diagnosis or treatment? 
 
There are currently no tests that will predict how well patients respond to treatment for 
inflammation or sepsis, which is why we wish to develop one. The results of our research will not 
affect your treatment or management in any way. 
 
 
What are the side effects of taking part? 
 
Pressing on the artery at the elbow is not usually a problem, but can occasionally be a little 
uncomfortable. The application of the two drugs to the skin may cause a little itching or redness, 
which may last up to 24 hours. The quantity used is too small to produce any other effects.  
In the event of a problem a doctor will be present throughout the duration of the test. 
  
  
What are the possible disadvantages and risks of taking part? 
 
We do not anticipate any risk to you from taking part, apart from the discomfort mentioned above. 
We will not include you in the study if: 
 
a)  You are allergic to any of the adhesives used to secure the probe 
b)  You have damaged skin on your arm 
c)  <RXKDYHDQ\FLUFXODWRU\GLVRUGHUVVXFKDV5D\QDXG¶VGLVHDVHV\VWHPLFVFOHURVLV
or diabetes affecting the circulation.  
d) You are pregnant 
 
 
What are the possible benefits of taking part? 
 




What is something goes wrong? 
 
If you are harmed by taking part in this research project, there are no special compensation 
DUUDQJHPHQWV,I\RXDUHKDUPHGGXHWRVRPHRQH¶VQHJOLJHQFHWKHQ\RXPD\KDYHJURXQGVIRUD
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legal action but you may have to pay for it.  Regardless of this, if you wish to complain about any 
aspect of the way you have been approached or treated during the course of this study, the normal 
National Health Service complaints mechanisms should be available to you. 
 
 
Will my taking part in this study be kept confidential? 
 
All information collected about you during the course of the research will be kept strictly 
confidential.  Any information about you that leaves the research unit will have your name and 
address removed so that you cannot be recognised from it. Your GP will be informed that you have 
participated in this research study as a matter of course. 
 
 
What will happen to the results of the research study? 
 
Once the study is completed the results will be submitted for publication to a scientific journal and 
will probably be published by the end of 2005.  You will not be identified in any publication or 
report.  If you wish to obtain a copy of the published results then please contact the investigators. 
 
 
Who is organising and funding the research? 
 
The investigators are all members of Nottingham University Department of Anaesthesia.  The 
funding is from the Association of Anaesthetists of Great Britain and Ireland. 
Your doctor will NOT be paid for including you in this study. 
 
Who has reviewed the study? 
 
This study has been reviewed and approved by the Nottingham Research Ethics Committee. 
 
 
Contact for further information 
 
You may contact any of the investigators: Dr Martin Beed and Dr Iain Moppett  
 
By phone: 0115 9691169 Ext. 46837 
 
By email: martin.beed@nottingham.ac.uk 
               iain.moppett@nottingham.ac.uk 
 
By post:  University Department of Anaesthesia 
  C Floor, East Block 
  4XHHQ¶V0HGLFDO&HQWUH 
  Derby Road 
  Nottingham 




Thank you for taking the time to read this information sheet. 
 
If you agree to take part in this study you will be given a copy of this information sheet and a 
signed consent form to keep. 











To determine association between altered skin vascular reactivity and 
haemodynamic instability, level of inotropic support, morbidity and mortality in 
patients with systemic inflammatory response syndrome (SIRS). 
 
A study of how skin blood flow responds in people with sepsis or inflammation.  
 
 
Please ask the patient to complete the following:     Please 
cross out as necessary 
 
Have you read and understood the patient information sheet?     YES/NO 
 
Have you had an opportunity to ask questions and discuss this study?   YES/NO 
 
Have you received satisfactory answers to all your questions?    YES/NO 
 
Have you received enough information about the study?    YES/NO 
 
Do you understand that you are free to withdraw from the study at any time?  YES/NO  
 
- without giving a reason for withdrawing?    YES/NO 
 
- and without affecting your future medical care?   YES/NO 
 
 
Who explained tKHGHWDLOVRIWKLVVWXG\WR\RX"«««««««««««««««« 
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